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 The guaipyridines are a class of naturally occurring alkaloids isolated from plants 
native to the Pacific Islands and Southeast Asia.  One member of this family, cananodine, has 
displayed potent in vitro cytotoxic effects against two different types of hepatocellular 
carcinoma cell lines.  More recently discovered guaipyridne compounds, rupestines A-M, 
share structural similarities to cananodine and might possess similar anti-cancer properties.  
The potential medical benefits and the rare and interesting structure of the guaipyridines 
make them desirable and challenging synthetic targets.  Two distinct synthetic routes were 
developed to access the guaipyridine core, and in doing so the total synthesis of cananodine 
and its diastereomers was accomplished. 
 The initial route (epoxide-opening route) had previously been explored by the 
Vyvyan group (see Meyer, Ligon thesis; Yarbrough unpublished results) although room for 
improved efficiency and the final stereoselective hydrogenation reaction left significant work 
to be completed on this project.  The critical Suzuki-Miyaura cross-coupling step involving a 
dienyl boronate ester and pyridyl triflate produced lower than desired yields, thus numerous 
combinations of coupling partners and reaction conditions were explored to improve the 
performance of this reaction.  Once optimized conditions were developed, the sequence was 
continued and both enantiomers of the key 7-exo cyclization precursor was successfully 
isolated after base-promoted epoxide-opening.  Exhaustive hydrogenation and reduction 
efforts of the remaining 1,1-disubstituted alkene provided a ~1:1 diastereomeric mixture of 
cananodine and its C5 epimer. 
 The second route (intramolecular Heck cross-coupling route) to the guaipyridine 





picolyl bromide and tert-butyl hexenoate precursors, an alkylation reaction provided the 
carbon-backbone compound in satisfactory yields.  Subsequent phenol deprotection and 
functionalization allowed for intramolecular Heck coupling between the 1,1-disubstituted 
side-chain alkene and a newly formed pyridyl triflate group provided the cyclized 
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1.1. Hepatocellular carcinoma  
Hepatocellular carcinoma (HCC) is a malignant cancer of the liver and the third 
leading cause of cancer related deaths worldwide.1 The death tolls are estimated to be 
upwards of 700,000 people annually and the number of new cases per year is on the rise, now 
approximately 1.2 million.2 While this particular type of cancer has historically been most 
prevalent among developing countries in Africa and Southeast Asia, the number of HCC 
diagnoses has been steadily increasing in the United States and Europe for over two decades, 
with a noticeable shift in distribution to younger age groups.3 
HCC can arise through a number of different external and genetic factors.  The most 
common cause of liver dysfunction, and thus HCC development, is extensive scarring of the 
liver tissue, a condition called cirrhosis.  This scarring of the liver is most commonly brought 
about by alcohol abuse in addition to hepatitis B (HBV) and hepatitis C (HCV) viral 
infections.  These conditions promote inflammation, necrosis and regeneration processes in 
liver cells, leading to genetic alterations and ultimately cancer. The potential for an even 
larger number of annual HCC cases is present, as the combined number of people suffering 
from chronic HBV and HCV exceeds 500 million.4  Other HCC promoting factors include 
prolonged aflatoxin B exposure, steatosis (non-alcoholic fatty liver disease), 
hemochromatosis (over exposure of the liver to iron) and virtually all cirrhosis inducing 
afflictions. 
The outlook for patients with HCC is especially grim relative to other forms of cancer  
____________________________________________________ 
1 El-Serag, H.B.; Rudolph, K.L.; Gastroenterology, 2007, 132, 2557-2576. 
2 Thomas, M.B.; Zhi, A.X.; J. Clin. Oncol. 2005, 23, 2892-2899. 
3 El-Serag, H.B.; Mason, A.C.; N. Engl. J. Med. 1999, 340, 745-750. 





and the prognosis for treatment depends largely on what stage the cancer is in when it is 
identified.  Common forms of cancer treatment such as chemotherapy (both single and 
combination therapies) have proven generally ineffective, making HCC a notoriously 
difficult cancer to treat.5  If treated at an early stage when liver function remains mostly 
intact and the cancer has not yet metastasized, a 5-year survival rate as high as 70% is 
observed when the patient is treated with radiofrequency ablation of the tumor or ethanol 
injection.6,7 Despite the availability of effective HCC screening procedures and treatment 
modalities, just 40% of HCC patients within the United States are identified early enough for 
these treatments.8 Liver transplantation and resection have also found wide spread use in 
treating liver cancer, but again are limited to early HCC identification.  These treatments 
methods, however, are often less effective as only 25-50% of patients who receive a liver 
transplant live at least five years afterward, while a 75%-100% recurrence rate is observed in 
patients who undergo resection of the affected part of the liver.5 Despite the lack of 
consensus on treatment options, the advancement in our understanding of the cancer at a 
molecular level has led to the development of structure-based drug design and small 
molecule treatments of HCC. 
 
1.2. Sorafenib and small molecule treatment of HCC 
In the 1980’s, continued preserverence and advancements in the fields relating to 
chemical and molecular biology led researchers to unequivocally established that proteins 
known as kinases are intimately involved in cancer cell growth, proliferation and 
____________________________________________________ 
5 Ikeda, M.; Okusaka, T.; Ueno, H. et al; Cancer 2005, 103, 756-763. 
6 Clavien P.A.; Petrowsky H.; DeOliveira M.L. et al; N Engl. J. Med. 2007, 356, 1545–1559. 
7 Cho Y.K.; Kim J.K.; Kim M.Y. et al; Hepatology. 2009, 49, 453–459. 






regeneration pathways.  Kinases make up the largest family of proteins in the human body 
and are responsible for catalyzing the transfer of phosphate molecules from phosphate 
donors, such as ATP, to other proteins or substrates.  The importance of these proteins to the 
survival of cancer cells has made them primary targets for small molecule inhibitor 
development.  Most kinase inhibitors are discovered by a process known as high through-put 
screening (HTS) where thousands of candidate compounds are screened simultaneously for 
inhibition hits, and then synthetically modified to improve their efficacy and selectivity.  
Kinase inhibitors are further divided into two classes: type I and type II.  Type I kinase 
inhibitors bind to the active form of the kinase, occupying the purine pocket that would 
otherwise be occupied by an ATP molecule.  Type II inhibitors bind to the inactive form and 
do not allow the kinase to become active.9 
 Through HTS, some of the first commercially available small molecule protein kinase 
inhibitors were developed.10 A type II kinase inhibitor, imatinib [Novartis, Gleevec® (1.1)], 
which received FDA approval  in 2001, is among these pioneering small molecule cancer 
treatments.  Imatinib has found extensive use in inhibiting the BCR-ABL tyrosine kinase of 
chronic myeloid leukemia (CML) with a concentration required to inhibit 50% of kinase 





9 Zhang, J.; Gray, N.S.; Nature Reviews, 2009, 9, 28-39. 
10 Wilhelm, S.; Carter C.; Lynch, M. et al; Nature Reviews: Drug Discovery 2006, 5, 835-844. 





Other type II inhibitors include dasatinib [Bristol-Myers Squibb, Sprycel® (1.2)] and 
sunitinib [Pfizer, Sutent® (1.3)], which are more recent additions to the cancer treatment 
repertoire and aim to treat certain forms of cancer in imatinib-resistant patients.  Dasatinib 
was found to be a 300 times more effective inhibitor of the BCR-ABL kinase in CML, and 
no dose-limited side effects were observed at dosages which were clinically effective.12 
Sunitinib was the first drug to be simultaneously approved for treating multiple targets [renal 
cell carcinoma (RCC) and gastrointestinal stromal tumors (GIST)] and inhibits a variety of 
protein kinases within these cancer cells.13 Interestingly, all of the approved protein kinase 
inhibitors to date possess at least one nitrogen-containing heterocycle in their structure 
including pyridines, piperazines, pyrimidines, thiazole and oxindoles which indicates that 




Despite the advancements in small molecule treatment of many forms of cancer in the 
1990’s and early 2000’s, none of the first developed compounds were observed to 
significantly inhibit any of the prominent kinases in the mitogen activated protein kinase 
(MAPK)  pathway of HCC, largely responsible for tumor angiogenesis and proliferation.  
With FDA approval in 2007, a new drug called sorafenib [Bayer, Nexavar® (1.4)]  
____________________________________________________ 
12 Shah, P.; Drugs of Today, 2007, 43, 5-12. 







became the first commercial drug used to treat patients suffering from inoperable HCC. 
A type II kinase inhibitor, sorafenib has been found to inhibit the HepG2 HCC cell 
line with an IC50 value of 4.5 μM and specifically inhibits vascular endothelial growth factors 
(VEGF) 1-3 and the platelet derived growth factor β (PDGFβ) receptor proteins, as well as 
B-Raf and C-Raf protein kinases within the MAPK phosphorylation cascade.14 As expected, 
the structural features of sorafenib allow for specific interactions with the kinases that it 
inhibits.  Its amide-substituted nitrogen heterocycle and di-aryl urea functionality play 
important roles in the inhibition mechanism of the B-Raf kinase (Figure 1), a commonly 
mutated protein.  The backbone cysteine 531 residue of B-Raf, which normally binds ATP, 
has been shown to form strong hydrogen bond interactions with the amide and pyridine 
nitrogen atoms of sorafenib (3.2 Å and 3.0 Å respectively).  The urea nitrogens also form 
hydrogen bond interactions with backbone aspartate and glutamate residues of B-Raf while 
the trifluoromethyl benzene ring also fits into a hydrophobic ‘allosteric site’ within the 
protein (not shown).15 
While these drugs have certainly provided an alternative to treating many cancers, 
and in some cases the only option for treating HCC, they are by no means perfect.  Besides 
the prohibitive cost of many small molecules treatments, they are not without their adverse 
side effects and often only extend the life of their patient by several months.  Sorafenib for  
____________________________________________________ 
14 Keating, G.M.; Santoro, A.; Drugs, 2009, 69, 223-40. 






Figure 1. Hydrogen bond interactions between sorafenib and B-Raf 
 
instance is the most effective available drug for treating HCC, yet only extends the life of 
advanced liver cancer patients by an average of 3-6 months.14 Research towards the 
development of more effective small molecule kinase inhibitors are endeavors that could 
significantly benefit cancer patients. 
 
1.3. Natural products as cancer fighting agents 
 For thousands of years, mankind has utilized its surrounding environment to treat and 
cure many illnesses and ailments.  Natural sources, and the recipes derived from them, have 
been passed down with ever evolving refinement.  As our understanding of medicine has 
continued to expand, we have been able to slowly eliminate the number of diseases and 
sicknesses that were once thought to be incurable.  Due to the complex nature and 
uncontrollable growth of cancer, it remains one of the few conditions that cannot be reliably 
and consistently cured by any one treatment method.  In spite of the many forms of treatment 
options available (surgery, chemotherapy, radiation therapy etc.), none of them are 
guaranteed to work for everyone or all types of cancers, nor do they guarantee that the cancer 





will continue to be made in treating all forms of cancer.  We have already found use for 
many naturally derived compounds possessing anti-carcinogenic, anti-proliferative, and anti-
angiogenic qualities in pharmaceutical drugs or in current clinical trials. 
 One of the most well recognized, naturally derived, chemotherapeutic agents is 
paclitaxel [Bristol-Myers Squibb, Taxol® (1.5)].  Isolated from the bark of Taxus brevifolia 
(Pacific Yew) in 1967 by Wani et al, paclitaxel has been established as the most effective 
drug for treating breast, ovarian, certain types of lung cancer, as well as head and neck 
cancers.16,17 Various parts of the tree itself have been used in traditional Native American 
medicines for treating non-cancerous illnesses and conditions. 
 
 Unlike type I/II protein kinase inhibitors, paclitaxel exists in a class of 
chemotherapeutic compounds known as mitotic inhibitors, which prevent cell division by 
disrupting tubulin polymers known as microtubules, responsible for pulling the cell apart.  
Paclitaxel stabilizes microtubules and prevents depolymerization, leading to microtubule 
bundling, mitotic arrest and ultimately cell death.18  
The unsustainable environmental impact of harvesting paclitaxel from the relatively 
scarce Pacific Yew has necessitated alternate means of obtaining this precious compound.   
____________________________________________________ 
16 Wani, M.C. et al; J. Am. Chem. Soc., 1971, 93, 2325-2327. 
17 Cragg, G.M.; Newman, J.M.; J. Ethnopharmacology, 2005, 100, 72-79. 





The more abundant Taxus baccata (European Yew) provides 10-deacetylbaccatin III which 
is used in a semi-synthetic method for obtaining paclitaxel, and is currently meeting 
consumer demand.19 Another taxane compound, docetaxel (1.6), is a semi-synthetic analog to 
paclitaxel which is also used to treat a variety of cancers and works through a similar anti-
mitotic mechanism. 
 Curcuma longa (turmeric) is another plant that produces biologically useful 
compounds, notably the polyphenol diferuloylmethane [curcumin (1.7)].  Data from over 60 
years of research indicates that curcumin suppresses an astonishing amount of cancers and 
other conditions, and acts as both an anti-proliferative and anti-carcincogenic.20 Among 
them, curcumin is thought to suppress and prevent colon, breast and prostate cancers.  These 
conditions, which are comparatively common in the United States and Europe, are far less 
prevalent in India and surrounding countries where curcumin is frequently consumed in the 
spice that it originates from.21 Despite the medical potential of curcumin, extensive 
therapeutic research has been slow.  The wide spread natural occurrence and dietary usage 
prevents patenting of the molecule and thus has dissuaded pharmaceutical companies from 
performing extensive research on curcumin as a curative or preventative agent. Recent 
syntheses of curcumin analogs aim to uncover cancer inhibitors even more potent than the 
curcumin parent compound.22   
 
____________________________________________________ 
19 Rowinsky, E.K.; Annu. Rev. Med, 1997, 48, 353–374. 
20 Aggarwal, B.B.; Kumar, A.; Bharti, A.C.; Anticancer Research, 2003, 23, 363-398. 
21 Food, Nutrition and the Prevention of Cancer: A Global Perspective. Washington DC: World Cancer 





Medicinally useful naturally occurring compounds are not limited to plant material, 
but can also be found in a wide variety of sources throughout the animal kingdom.  One 
example is the mitotic inhibitor, discodermolide (1.8).  Isolated from the marine sponge 
Discodermia dissolute by Gunasekara et al in 1990, the limited quantities of the compound 
obtained from its natural source (7 mg/434 g) initially hindered complete biological 
evaluation.23 However, a number of recent total syntheses has allowed for larger scale 
production and has established (+)-discodermolide as a potential chemotherapeutic drug, 
which entered clinical trials in 2002.24  
 
Preliminary biological activity assays in hollow fiber murine and human xenograph 
models indicated substantial inhibition against multiple cancers including lung, breast and 
colon, some of which are paclitaxel-resistant.25 Discodermolide was originally shown to be a 
powerful immunosuppressant, leading to questions about its viability as a means for treating 
cancer.  Later research proved that this immunosuppressive activity was prominently due to 
anti-proliferative effects on lymphoid cells.26 
Another example of a lead anti-cancer compound obtained from marine animal 
____________________________________________________ 
22 (a) Chellakili, B.; Elavarasan, T.; Gopalakrishnan, M. et al; Spectrochimca Acta, 2012, 97, 717-721. 
   (b) Fuchs, J.R.; Pandit, B.; Bhasin, D. et al; Bioorg. Med. Chem. Lett., 2009, 19, 2065-2068. 
23 Gunasekera, S.P.; Gunasekera, M. et al; J. Org. Chem., 1990, 55, 4912. 
24 (a) Schreiber, S.L.; Chen, J.; Hung, D.T.; Chem. Biol., 1996, 287. 
   (b) Rawat, D.S. et al; Anti-cancer Agents in Med. Chem., 2008, 8, 603-617. 
25 Honore, S. et al; Mol. Cancer Therapeut., 2003, 2, 1303. 
26 (a) Longley, R.E.; Gunasekera, M.; Gunasekera, S.P. et al; Transplantation, 1991, 52, 650. 





species is the aminosterol, squalamine (1.9), isolated from the liver of Squalus acanthias 
(dogfish shark).  Occasionally confused with controversial shark cartilage dietary 
supplements, which are often marketed to claim anti-cancer properties with no scientific 
evidence from clinical trials, squalamine was in phase II clinical trials in 2008 for significant 
activity that it displayed against ovarian and non-small cell lung cancer.27 The limited natural 
availability (approximately 10-20 µg/g of liver and gall bladder tissue) and non-viable 
synthetic routes have, and continue to limit complete structure activity studies.28 
 
 Even with the vast amounts of therapeutically useful natural products at our disposal, 
there are still relatively few that can be used to treat HCC, and an even smaller number that 
significantly inhibit HCC proliferation.  This fact further demonstrates the need to search and 
examine our natural surroundings for biologically active compounds.  The growing 
importance of plant and animal derived natural products in medicinal and chemical fields 





27 (a) Moriarty, R.M.; Tuladhar, S.M.; Guo, L.; Wehrli, S. Tetrahedron Lett., 1994, 35, 8103. 
    (b) Pechulis, A.D.; Bellevue, F.H.; Cio, C.L.; Trapp, S.G. et al; J. Org. Chem., 1995, 60, 5121. 






1.4. Discovery of (-)-cananodine and the rupestine natural products 
 One family within the plant kingdom that has garnered significant attention for the 
exceptionally wide variety of natural products that it produces is the Annonaceae family.  
Colloquially known as the ‘custard apple’ family, Annonaceae are generally found in tropical 
and sub-tropical regions of the world and are further divided into over 130 genera and 2300 
species.29,30 A number of species within the family have been used in folk medicines to treat 
a wide range of symptoms and conditions.31 
 A particularly interesting species within the Annonaceae family is the tropical 
evergreen tree labeled Cananga odorata, also known as the ylang-ylang tree.  The tree, 
which grows up to 12 m in height, is native to the rainforests of Indonesia and the Philippines 
but has been purposely spread to many islands in the Pacific for its fragrant and attractive 
yellow flowers.  Its common name is derived from the ylang-ylang essential oil (comprised 
of 49 different compounds) that can be obtained through steam distillation of the leaves and 
flowers, which in turn finds many uses in floral perfumes and aromatherapy.32 Besides the 
desirable scent that it produces, C. odorata is an example of an Annonaceae family member 
that has long been used in folk medicine, specifically in Taiwanese tonics for alleviating 
malaria, fever, and tinea infections.33 
 From 1999-2001, Wu et al examined the extracts from the fruit of C. odorata in 
hopes of discovering interesting bioactive compounds that are often found in the alkaloid 
____________________________________________________ 
29 Alali, F.G.; McLaughlin, J.L.; Liu, X.X.; J. Nat. Prod., 1999, 62, 504-540. 
30 Cortes, D.; Figadère, B. et al; Nat. Prod. Rep., 2005, 22, 269-303. 
31 (a) Hartwell, J.L.; Plants Used Against Cancer; Quarterman: Lawrence, MA, 1982, 406. 
   (b) Farnsworth, N.R. et al; J. Ethnopharm., 2000, 73, 347-377. 
32 Olivero, J. et al; J. Pharm. Sci., 1997, 86, 625-630. 







and terpenoid rich Cananga genus.34 In their research, they isolated and characterized eight 
alkaloids and sesquiterpenes (Figure 2.)  The isolated compounds included the guaipyridine 
(-)-cananodine (1.10) , the eudesmanes cryptomeridiol 11-α-L-rhamnoside (1.11), γ-
eudesmol (1.12) and γ-eudesmol 11-α-rhamnoside (1.13), along with alkaloids 
cleistopholine, (1.14), N-trans-feruloyltyramine (1.15), (+)-ushinsunine-β-N-oxide (1.16) and 
lyscamine (1.17), all of which showed at least partial in vitro cytotoxicity in two different 
HCC cell lines.  Compounds 1.13 and 1.14 were also previously shown by Wu et al to 
possess activity against leukemia as well as lung and colon cancer.35 
 
Figure 2. Cytotoxic constituents of C. odorata fruit extract 
 
 Arguably the most stimulating of these compounds is the guaipyridine alkaloid, 
cananodine.  Its rarely seen guaipyridine structure consisting of a fused pyridine ring and 
seven-membered carbocycle, is the most potent among the cytotoxic constituents of the C.  
____________________________________________________ 
34 (a) Wu, Y.C. et al; J. Nat. Prod., 2001, 64, 616-618. 
(b) Wu, Y.C. et al; J. Chin. Chem. Soc., 1999, 46, 607-611. 





odorata extract in inhibitory concentration against HepG2 and HepG2,2,15 cell lines of 0.94 
μM and 16 μM respectively.34  The inhibition mechanism, although yet to be confirmed, is 
hypothesized to emulate that of sorafenib in that the pyridine nitrogen and hydroxyl 
hydrogen form strong hydrogen bond interactions with a backbone cysteine residue of B-Raf 
(Figure 3).  Because the in vitro IC50 of cananodine is nearly five times less than that 
displayed by sorafenib in the HepG2 inhibitory assay, it is also speculated that the large, 
aliphatic cycloheptane ring interacts with a hydrophobic site of B-Raf that is not filled by 
sorafenib. The extremely limited natural occurence (~3 mg/kg of fruit) of cananodine makes 
commercial extraction of the precious material unfeasible, but its potent cytotoxicity and rare 
structural motif makes it a worthy, challenging synthetic target. 
 
Figure 3. Hypothesized interactions between cananodine and B-Raf 
 
 The Artemisia genus is another collection of plant species known for its variety of 
secondary metabolites.  With over 260 known species, Artemisia is one of the largest genera 
from the Asteraceae family and is found primarily in northern temperate regions of the 
world.  The genus is comprised of widely recognized plant species including sagebrush (A. 
tridenta), wormwood (A. absinthum) and tarragon (A. dracunculus).  The last two decades 





selection of natural products contained within the plants, and also due to the abundance of 
plant material and usage in traditional folk remedies.36 Members of this genus have been 
utilized for centuries for everything from suppressing coughs to relieving pain.37  More 
modern investigations have revealed that many species possess bioactive compounds with 
antimalarial, anti-viral, anti-tumor, anti-pyretic, anti-oxidant, and anti-hepatitis properties, to 
list a few.36   
 Some of the most recently discovered compounds isolated from the Artemisia genus 
are the rupestines.  From 2010-2012, Aisa et al uncovered twelve new guaipyridine alkaloids, 
rupestines A-M [1.18-1.29 (Figure 4)].37 Curiously, no compound was designated as 
‘rupestine E’ as the molecules were being discovered.  These natural compounds were  
 
Figure 4. Rupestines A-D, F-M 
____________________________________________________ 
36 Tan, R.X. et al; Planta Medica, 1998, 64, 295-302. 
37 (a) Aisa, H.A. et al; Hel. Chim. Acta, 2010, 93, 33-38. 





isolated by high-speed counter current chromatography of the extract from Artemisia 
rupestris (rock wormwood), which is used in traditional Chinese medicines for detoxification 
as well as its anti-viral, anti-bacterial and anti-tumor qualities.38 
 The rupestines share the same guaipyridine bicyclic core with cananodine, and differ 
only in stereochemistry at the 5- and 8-postions and the substituent at the 8-position of the 
cycloheptane ring.  These structural similarities lead to postulation that the rupestines possess 
similar HCC cytotoxic activity and thus the potential benefits of developing a synthetic route 
to produce the guaipyridine core could establish these molecules as leads to new and more 
effective HCC treatments. 
 
1.5. Previous guaipyridine syntheses 
 Attempts to synthetically produce members of the guaipyridine family have been few 
and far between, likely because their medical potential was long unknown but also due to the 
synthetic challenge that they pose.  The first reported syntheses were in 1966 by Büchi et 
al.39  After isolating two guaipyridine compounds, patchoulipyridine (1.30) and 
epiguaipyridine (1.31), from the essential oil extract of Pogostemon patchouli (patchouli oil), 
Büchi sought further structural confirmation by producing their synthetic analogs.  From β-
patchoulene (1.32) starting material, a hydrazoic acid promoted nitrogen incorporation, 
followed by palladium catalyzed dehydrogenation produced a mixture of compounds which 
convincingly included 1.30, as the observed physical properties very closely correlated with 
those of the naturally occurring compound.  In their synthesis of 1.31, Büchi et al employed 
guaiol (1.33) as the starting material and first performed a reduction of the hydroxyl group. 
____________________________________________________ 
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The product was then treated with hydrazoic acid to incorporate the nitrogen atom of the 
resulting pyridine ring.  This reaction series provided dihydroepiguaipyridine (1.34) which 
was subsequently used to match physical properties with the dihydro-natural product 
derivative. 
 
Figure 5. Compounds from Büchi and Van der Gen isolations and syntheses 
 
 Several years later, Van der Gen et al noticed discrepancies in the absolute 
configuration that Büchi claimed for their synthetic 1.34 compound and that of the product 
that was isolated from the natural source.40 While starting material 1.33 has a well-
established stereochemistry of 7R, 10S (and thus should the product of his synthetic route), 
Büchi et al surprisingly attributed a 7R, 10R stereochemistry to the isolated natural product.  
Van der Gen therefore devised independent synthetic schemes from starting materials with 
known configurations to produce both C10 epimers of guaipyridine.   
 Guaiol was again chosen as the starting material to produce the 10S epimer.  A 
palladium catalyzed alkene isomerization, followed by ozonolysis produced diketone 
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intermediate 1.35.  Treatment with hydroxylamine hydrochloride in ethanol, and dehydration 
of the hydroxyl group, produced the desired epimer with spectral properties matching the 
natural product isolated by both sets of researchers.  The 10R epimer was synthesized from 
α-gurjunene (1.36) following a similar ozonolysis and hydroxylamine hydrochloride driven 
reaction sequence.  A mixture of products was obtained including the anticipated 10R epimer 
with clearly differing spectral properties. After producing both stereoisomers, Van der Gen 
concluded that Büchi had incorrectly assigned the configuration of the natural product and 
had synthetically produced the dihydro C10 epimer of 1.31, guaipyridine (1.37). 
In 1987, Okatani and Koyama et al reported two new synthetic methods to produce 
1.31 and 1.37 (Schemes 1, 2).  In the first route, they applied their recently developed Diels- 
Alder reaction of 1,2,3-triazine with enamines to the synthesis of natural products.41  From 3-   
isopropenyl-l,6-methylcycloheptanone (1.38), the enamine isomers 1.39 and 1.40 were 
synthesized, then immediately treated with triazine.  Through this hetero-Diels-Alder 
reaction, three products were isolated via HPLC, which included 1.31 and 1.37.  In the 
second publication, the group discovered that treatment of the same 1.38 starting material 














decomposition, a mixture of products was obtained which again included 1.31 and 1.37.42  
While these syntheses could likely be applied to more recently discovered members 
of the guaipyridine family, such as cananodine and the rupestines, several factors keep them 
from being commercially viable.  Despite the novelty of the routes developed by Büchi and 
Van Der Gen, they use precious, naturally occurring starting materials which are generally 
difficult to obtain.  Also, all of their syntheses are initiated from starting materials that 
already possess a seven-membered ring, one of the more synthetically interesting pieces of 
the guaipyridines.  Not only that but the all of previously mentioned sequences are neither 
regioselective nor stereoselective, which can often determine the functionality and toxicity of 
compounds used for medicinal purposes.  The noticeable flaws in the guaipyridine syntheses 
to date leave much to be desired, and an efficient and selective synthesis of these compounds 
may ultimately lead to a new class of cancer fighting drugs. 
 
1.6. Total synthesis of cananodine by Craig & Henry 
 With the isolation of cananodine by Wu et al in 2001, Craig and Henry decided to 
employ their recently developed microwave-assisted, decarboxylative Claisen rearrangement 
(dCr), to the synthesis of the guaipyridine.43 Their clever approach combined chiral pool and 
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chiral auxiliary methods for setting the two stereocenters of cananodine and can be thought 
of as possessing four key reaction steps, shown in their retrosynthetic analysis (Scheme 3).  
Simple methylation of the ester substituent using MeMgBr provided 1.10, but was preceded 
by ozonolysis of the 1,6-diene and ammonia based nitrogen incorporation on substrate 1.50 
to provide the bicyclic guaipyridine core.  Their microwave assisted dCr reaction on 
compound 1.49 proceeded with yields as high as 71% which confirmed that this in-house 
developed reaction could be used toward natural product synthesis.  Compound 1.49 was the 
product of oxazolidinone auxiliary elimination and esterification using 4-methyl-2-(4-
tolylsulfonyl)-4-pentenoic acid on substrate 1.48.  A ring-closing metathesis reaction (RCM) 
on compound 1.47 was used to create the seven-membered ring of intermediate 1.48.  Both 
stereocenters of the final molecule were locked in compound 1.47 as the result of a series of 
transformations, including addition of the oxazolidinone chiral auxiliary and nucleophilic 
addition between the starting materials 2-methylenepropane-1,3-diol (1.45) and enantiopure 









 In all, Craig and Henry’s reaction sequence is comprised of 17 steps with an overall 
yield of 4%.  It should be noted that the specific rotation measured by Craig and Henry for 
their synthetic cananodine ([α]21
𝐷
 = +17.4°, c = 1.34, l = 0.25 dm, CHCl3) significantly 
differed from that which was reported by Wu et al for the naturally occurring product ([α]24
𝐷
 = 
-76.2°, c = 0.06, l = 0.10 dm, CHCl3).  Of particular concern is the difference in the sign of 
the measured optical rotation.  However, Craig and Henry claim that a more concentrated 
sample solution and thus greater order of magnitude of the observed rotation makes their 
sample less susceptible to experimental error.  Regardless, a synthetic route that is designed 
to select for a particular desired stereoisomer should settle the discrepancy, while shortening 
the overall reaction sequence may lead to a method of producing the guaipyridine alkaloids 

















2. Total Synthesis of Cananodine via Epoxide-Opening Route 
2.1. Original synthetic routes 
 Our original plan for the synthesis of cananodine varied drastically from that 
published by Craig and Henry.  Not only did the projected synthetic routes shorten the 
overall number of reaction steps, but it was also anticipated that the sequence would allow 
for selection of specific configurations at both stereocenters in the target.  The Vyvyan 
group’s proposed plan for preparation of the bicyclic core of cananodine (1.10) was centered 
on an intramolecular sulfone-epoxide-opening under strongly basic conditions (Scheme 4).  
In general, preparation of carbocycles by base-promoted picolyl anion attack has historically 
been under-utilized.  Intermolecular reactions of this type are far more prevalent than the 
intramolecular variety that we propose as majority of the research involving intramolecular 
ring formation by this method has generally focused on construction of 3, 4 and 5 membered 







The sulfone-epoxide cyclization precursor (2.1) could be synthesized through two 
different routes.  In the first route (Scheme 4, Path A) a Suzuki-Miyaura cross-coupling 
reaction between functionalized pyridine derivative 2.2 with either a vinyl boronate ester 
(2.3) or triflate (2.4) side-chain was suggested to create the carbon-carbon bond that forms 
the backbone of the final product. Alternatively (Scheme 4, Path B), a Negishi-style cross-
coupling between the metalated pyridyl species 2.5 (derived from an appropriately 
disubstituted pyridine 2.6) and vinyl triflate 2.4 would also ultimately lead to the desired 
epoxide intermediate.   
Once synthesized, the sulfone-epoxide intermediate would be subjected to basic 
conditions thereby producing a picolyl anion.  This anion would be expected to attack the 
less-substituted epoxide carbon in the side-chain, opening the epoxide and forming the 
cycloheptane ring of the guaipyridine core.  The picolyl sulfone group shown in compound 
2.1 was expected to dramatically decrease the pka (increase the acidity) of the picolyl protons 
from ~34 to ~21, thus stabilizing the deprotonated intermediate and allowing cyclization to 
occur more readily.44 
Important to our reaction sequence is the ability to selectively set the configuration of 
the stereocenters at the 5- and 8-postions of the final guaipyridine products.  The 
configuration at the 8-position can be set through a Sharpless asymmetric dihydroxylation 
(AD), which was named after K. Barry Sharpless who won the Nobel Prize in 2001 for his 
work in asymmetric chemistry.45 The reaction uses a clever mixture of commercial 
compounds (AD mix-α or β) which includes the osmium catalyst, potassium osmate (K2Os4), 
and one of two chiral auxillaries, dihydroquinine phthalazine [(DHQ)2PHAL] or 
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Figure 6. AD mix stereoselectivity mnemonic 
 
dihydroquinidine phthalazine [(DHQD)2PHAL], depending on the desired stereochemistry of 
the product.  A mnemonic is commonly used to decide which of the two forms of AD mix 
should be used to obtain the desired stereochemistry in the product (Figure 6).  By following 
this mnemonic and visualizing our substrate with the largest alkene substituent (RL) in the 
‘SW quadrant’ we should be able to select for either enantiomer by using the appropriate AD 
mix variety.  This in turn should settle the discrepancy of cananodine’s absolute 
stereochemistry debated by Wu and Craig. 
Transition metal-mediated hydrogenation is a likely method of stereoselectivity at the  
5-position and several catalysts were identified as possible reagents to affect the desired 
transformation.   Wilkinson’s catalyst and Crabtree’s catalyst, two well-known 
hydrogenation reagents, were chosen to attempt the terminal alkene reduction.  We were 
especially hopefully that Crabtree’s catalyst could perform the task, as literature precedent 
dictates that ligating groups such as hydroxyl, alkoxyl, ester, and other carbonyl groups  
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attached to an olefinic substrate in a 6-membered ring make effective directors of Crabtree’s 
catalyst and promote the hydrogentation.46 No example of this directing effect has been 
reported on 7-membered rings, however, which is present is our target compounds. 
 
2.2. Previous work by Meyer, Ligon and Yarbrough 
 The first Vyvyan group member to explore these synthetic routes was Jennifer 
Meyer.47 In her research, she first investigated directed ortho-metalation of substituted 
pyridine derivatives with expectations of utilizing the products in palladium-catalyzed 
Negishi cross-coupling.48 A number of pyridine derivatives activated at the 2-position (2.6) 
were synthesized for use in model studies to determine the viability of metalation at the 
desired aromatic carbon (Scheme 5).  Three activating groups at the 2-picolyl positon were 
used in these models studies including methoxymethyl ether (MOM), benzamide (CONHPh)  
and a carboxylic acid.  Three lithium bases were also employed over the course of these 
reactions in hopes of in situ generation of the appropriate aryl lithium intermediate (2.7).  
Several different known trapping agents were used to test if indeed the expected lithium 
intermediate was being formed.  Using iodine or D2O would presumably give the 
corresponding iodo- or deuterated pyridine derivative, while the use of DMF or dry ice 
would be expected to provide the aldehyde and carboxylic acid derivatives respectively.  
Unfortunately, none of the attempts ever resulted in 3-substituted products (2.8), bringing 
into question the formation of 2.7.  In fact, deprotonation at the 6-aryl and picolyl positions 
was often observed and led to a butyl addition derivate 2.9 when n-BuLi was used as the 
base, and the iodo-derivative 2.10 when I2 was used as the trapping agent. 
____________________________________________________ 
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Scheme 5.  
 
 
 Due to the difficulties in functionalizing the 3-position of the pyridine ring, directed 
ortho-metalation and Negishi coupling was deemed an ineffective method of synthesizing 
coupled cananodine intermediates.  Meyer then turned her attention to synthesizing 
intermediates for testing in Suzuki cross-coupling reactions (Scheme 4, Path A).  From 2,6-
lutidine-α-2,3-diol (2.11), several activated pyridyl triflate compounds (2.13-2.15) were 
synthesized to provide a variety of substrates for testing in the coupling reactions (Scheme 
6). Pinacolboronate ester 2.18 was synthesized from 6-methyl-5-hepten-2-one (2.16) via 







and boronate 2.18 were then used in combination under varying conditions to determine the 
most effective coupling method. 
 Her research indicated that the use of pyridyl triflate 2.15, containing a pivaloate ester 
protecting group on the primary alcohol, and an excess of pinacolboronate 2.18 gave the best 
results (79% yield) when using Pd(PPh3)4 and potassium carbonate (K2CO3) in dioxane at 
100 °C.49  This reaction was a noteworthy achievement given the importance of successfully 
synthesizing the coupled intermediate 2.19 to the overall reaction sequence, and the fact that 
no examples of cross-coupling pyridyl triflates and vinyl boronates had previously been 
reported.  Meyer’s next endeavor was to convert the pivaloate group in the newly synthesized 
Suzuki coupling product to the phenyl sulfonate, as well as convert the trisubstituted alkene 
in the side-chain to the corresponding epoxide (Scheme 7).  The Suzuki coupling product 
2.20 containing the derived acetonide side-chain was carried through a series of 
transformations including deprotection and epoxidation procedures to create the side-chain 




 The stage was then set to test sulfone-anion cyclization reactions and attempt to 
produce the cyclized precursor 2.22.  Ten different reaction conditions were devised,  
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including various bases for deprotonation at the picolyl position, as well as several solvents, 
additives, and reaction temperatures.  Despite the extensive experimentation, no cyclized 
material was ever found.  There was, however, clear evidence that sulfone-anion formation 
occurred during the reactions as a drastic color change to yellow/orange upon addition of the 
base to the sulfone-epoxide indicated picolyl anion creation.  It was therefore speculated that 
the sulfone group actually over stabilized the generated anion, reducing its nucleophilicity, 
and dissuading attack on the epoxide to form the seven-membered carbocycle. 
 Learning from Meyer’s work, Toby Ligon continued the epoxide-opening route 
towards the synthesis of cananodine.50 Ligon first pursued construction of a 2.21 analog 
containing a sulfide activating group (as opposed to the sulfone used by Meyer), confident 
that it would be slightly less stabilizing of the picolyl anion, and allow cyclization to proceed. 
Ligon also envisioned significantly shortening the overall number of steps in the sequence by   
performing dihydroxylation of the side-chain double bond after the Suzuki coupling step in 
order to avoid acetonide protection and deprotection procedures.  Literature examples 
indicated that the sulfide would be able to withstand the asymmetric dihydroxylation 
conditions, and not oxidize to the corresponding sulfoxide or sulfone, which was indeed the 
case.51  
 The most pressing issue of course was developing the cyclization reaction conditions.  
To do this, model compound 2.23 was prepared through Suzuki cross-coupling.  This 
compound contains only a monosubstituted terminal alkene in the side-chain and lacks 
functionality at the 2-picolyl position.  The pyridine ring also lacks the methyl substituent at 
the 6-position to suppress competitive deprotonation at a second picolyl site. These 
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simplifications allowed for a reduced number of transformations before the cyclization 
reactions could be attempted, and lessened the complexity of the test substrates.  Although it 
is known that under basic conditions a nucleophile will generally attack the less substituted 
carbon of an epoxide, this approach hinged on the idea that the large negative entropy 
associated with forming the 8-membered ring will outweigh the usual reactivity preferences 
and form the 7-seven membered ring instead.52 After asymmetric dihydroxylation and 
subsequent conversion of the diol to the epoxide, 2.25 was used as the test substrate in 
various new cyclization reactions (Scheme 8).   
 In the first reaction, 2.25 was treated with just the lithium base, lithium 
diisopropylamine (LDA), in THF at a reduced temperature.  These conditions only provided 
the corresponding 8-membered ring derivative, 2.26.  Ligon next employed the Lewis acids 
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hopes of inducing a partial positive charge on the epoxide oxygen and promote cyclization at 
the less substituted carbon.  When the reaction was treated with BF3∙OEt2, Ligon observed 
what appeared to be very strong coordination to the epoxide oxygen, promoting 
isomerization to an aldehyde in situ.  The picolyl anion then apparently attacked the resulting 
aldehyde to give a different 8-member ring in compound 2.27.  Using Et2AlCl did not appear 
to fare any better as the generated chloride ions in solution appeared to add to the epoxide 
and upon work-up with acetic anhydride, the chloroacetate 2.28 was obtained. 
 Clearly, cyclization using monosubstituted epoxides was not a viable option.  These 
results prompted Ligon to test a trisubstituted epoxide substrate to take advantage of the 
inherent preference of the nucleophile to attack the less substituted carbon and yield the 7-
membered ring.  Using test substrate 2.29, standard cyclization conditions were used and 
cyclized compound 2.30 was finally obtained and characterized.  Regardless of the poor 
overall yield, this reaction was monumental to the viability of the overall reaction sequence.  
This reaction also showed that cyclization could be accomplished without the aid of an 
activating group.  In fact, performing the reaction without additional picolyl functionality 
(e.g. sulfone or sulfide) might actually be a necessary condition for cyclization to occur.  
  
Knowing that this cyclization could work on model substrates, Loagan Yarbrough 









the procedures developed by Meyer and Ligon, Yarbrough successfully synthesized the 
epoxide precursor 2.31, and then performed the cyclization reaction to produce cyclized 
material 2.32 (Scheme 9).  The only remaining step was the stereoselective hydrogenation of 
the remaining 1,1-disubstituted alkene.  Yarbrough was only able to attempt one 
hydrogenation, using Pd/C as a catalyst at atmospheric hydrogen pressure.  Unfortunately, 
the reaction did not provide the desired synthetic cananodine, and only a small amount of 
organic material was recovered from the reaction and it hypothesized that the palladium 





2.3. Suzuki-Miyaura cross-coupling and optimization 
2.3.1. Preparation of coupling partners 
 Although much of the epoxide-opening route had been explored by past researchers, 
many reactions still provided unsatisfactory yields and the stereoselective hydrogenation was 
yet to be completed; a significant amount of work was left to be completed.  Using already 
successful procedures for synthesizing the Suzuki coupling partners, aryl triflate 2.35 and 
vinyl boronate ester 2.18, special care was taken to improve the yields of each reaction as 
much as possible (Scheme 1).  From the starting material 6-methyl-5-hepten-2-one (2.16), 
the usually low-yielding triflation reaction using the triflating agent bis-





with yields as high as 57% of triflate 2.17.  The palladium catalyzed borylation reaction, 
using bis(pinacolato)diboron (B2pin2) boron source, was also optimized to give yields as high 
as 92% of boronate ester 2.18.  The synthesis of pyridyl triflate 2.34 is fairly straight forward, 
using NEt3 and triflic anhydride (OTf2) and proceeds in 55-70% yields.  These intermediates 
have all been prepared successfully in gram-scale reactions.  
Scheme 10. 
 
One of the more obviously flawed reactions was the Suzuki coupling stage.  Past 
research had indicated that the use of Pd(PPh3)4 with K3PO4 in dioxane at elevated 
temperatures provided the best results when coupling aryl triflates and vinyl boronates. 
Attempts at reproducing the already successful reaction provided low yields, ranging 
between 15-30% of the coupled product 2.35, although former researchers working on this 
project were only able to achieve yields as high as about 50% when performing coupling 
reactions similar to this one (without the aid of picolyl activating groups).  Given the 
importance of this reaction to the overall sequence, further optimization of the reaction was 







2.3.2. Coupling optimization 
 The poor yields obtained from Suzuki coupling prompted further examination into 
optimizing the reaction conditions.  In order to fully investigate this reaction, a number of 
coupling partners, both nucleophiles and electrophiles (Figure 7), were either prepared or 
purchased to use in a wide variety of coupling conditions.   
 
 
Figure 7. Compounds used in Suzuki coupling optimization 
 
 Three different nucleophilic coupling partners were obtained for use in the coupling 
optimizations.  Pyridyl boronic acid 2.39 was commercially available.  Pinacolboronate ester 
2.18 is the product of already successful reactions (Scheme 10) and is the nucleophilic 
substrate that has been used in previous Suzuki coupling attempts.  Pinacolboronate ester 







dienyl bromide 2.36 is first synthesized through a Grignard coupling of 2,3-dibromopropene 
(2.41) with allylmagnesium chloride, which was isolated and characterized.  The bromide 
was then converted to the boronate ester 2.40 using t-BuLi and isopropoxypinacolboron.  The 
same boronate ester can also be prepared through another known two stage synthesis.54 The 
first stage consists of an identical Grignard reaction in which bromide 2.36 is not purified, 
but rather magnesium turnings, elemental iodine and pinacolborane are subsequently added 
to yield 2.40. 
 The presumed lack of reactivity of pyridyl triflate 2.34 in the Suzuki coupling 
reactions up to this point prompted further examination of different electrophilic coupling 
partners as well and four different compounds were gathered (Figure 7).  Pyridyl triflate 2.34 
and dienyl bromide 2.36 are the products of already successful reaction sequences (Scheme 
10 and 11 respectively).  Pyridyl bromide 2.37 was commercially available and pyridyl 
iodide 2.38 was successfully synthesized through three different methods (Scheme 12).  The 
first method that was used involved a new take on the classical Finkelstein reaction.  This 
reaction, named after the German chemist Hans Finkelstein who discovered the procedure in 
1910, is used for easily replacing one halide with another on alkyl substrates using readily 
available halide salts.55 In 2002, Buchwald and Klapers devised the aromatic Finkelstein 
reaction in which this substitution could be performed on aromatic halides.56 We enjoyed a 
great deal of success using this reaction to synthesize 2.38, achieving yields as high as 85%, 
but quickly realized its limitations.  The reaction itself requires an expensive 
cyclohexyldiamine ligand for activating the copper catalyst.  Together with the relatively  
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high cost of pyridyl bromide rendered this method unfeasible for large scale preparation.  
Another method uses 2,6-lutidine [2,6-dimethylpyridine (2.41)], that is much less expensive 
than the functionalized pyridine derivatives.57 Despite the accessibility of the reagents and the 
ability to perform macro-scale preparations, this reaction employs extremely harsh, acidic 
conditions and a laborious work-up procedure consisting of basification, steam distillation, 
extraction and chromatography to isolate the pure product.  Furthermore, the reaction has 
typically only yielded 10-15% of the expected product while in our hands.  A more balanced 
approach is initiated from moderately priced 3-amino-2,6-dimethylpyridine (2.42) using 
another classical reaction known as the Sandmeyer reaction, after the Swiss chemist that 
discovered it.58 This reaction proceeds through acid-catalyzed diazonium salt formation, 
followed by nucleophilic attack by the desired halide anion, in relatively mild conditions.59  
Using this method, yields between 37-58% have been achieved.  The balance of moderate 
starting material costs, overall ease of performing the reaction and the mass yield has  
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established the Sandmeyer reaction as the preferred method to synthesize 2.38.   
All of the coupling compounds were procured and tested in combination with each 
other under a wide variety of reactions conditions, both novel and from relevant literature 
sources (Table 1).60 Several different variables were tested including the use of three 
different palladium catalysts as well as several different Lewis bases and solvents.  A number 
of different reaction times and temperatures were also experimented with and in some cases 
additives such as exotic phosphine ligands (entries 17 and 18) were used in hopes of inducing 
greater reaction efficiency.  The table clearly demonstrates that the vast majority of 
conditions that were tried resulted in little, if any, of the anticipated coupled product.  Under 
the conditions that were originally used (Scheme 10), pyridyl bromide 2.37 and dienyl 
boronate 2.40 provided slightly increased yields (entry 8) initially leading to the belief that 
using an aryl halide may be more efficient in this particular reaction.  However, when the 
presumably more reactive aryl iodide 2.38 was used under the same conditions, none of the 
corresponding coupled product was observed (entries 10-12) even with varying time lengths 
of the reaction.  In a method described by Falck and co-workers, silver (I) oxide (Ag2O) was 
used as an additive to significantly enhance palladium catalyzed Suzuki-like cross-couplings 
between alkylboronic acids and a variety of alkyl and alkenylhalides and triflates.61  This 
idea was translated to our reaction, first testing pyridyl bromide 2.37 and boronate ester 2.18  
(entry 7).  Under these conditions a modest 38% yield was observed, only a slight 
improvement upon our original conditions.  When both of our original coupling partners, 
triflate 2.34 and boronate 2.18, were used under these conditions (entry 16) a 76% yield was   
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Table 1. Attempted Coupling Reactions 
         
Entry Nuc. Elec. Pd Catalysta Base Solvent Additive Time (h)/Temp. (°C) 
Yield (%)b 
        
 
1 2.39 2.36 Pd(PPh3)4 K3PO4 toluene - 24/100 
8-10 
2 2.39 2.36 Pd(PPh3)4 K3PO4 DMSO - 24/100 
8-13 
3 2.39 2.36 Pd(PPh3)4 NaOH toluene - 24/100 
15 
4 2.40 2.43 Pd(PPh3)4 K3PO4 toluene - 24/100 
29 
5 2.40 2.37 Pd(OAc)2 
K3PO4 
·H2O 
dioxane PPh3 18/100 
15c 
6 2.40 2.37 Pd(OAc)2 
K3PO4 
·H2O 
dioxane PPh3 48/100 
32 
7 2.18 2.37 Pd(dppf)Cl2 K2CO3 THF Ag2O 6/90 
38 
8 2.40 2.37 Pd(PPh3)4 K3PO4 dioxane - 48/100 
37-43 
9 2.40 2.37 Pd(PPh3)4 K3PO4 toluene - 48/100 
32c 
10 2.40 2.38 Pd(PPh3)4 K3PO4 dioxane - 7.5/80 
0 
11 2.40 2.38 Pd(PPh3)4 K3PO4 dioxane - 24/100 
0 
12 2.40 2.38 Pd(PPh3)4 K3PO4 dioxane - 48/100 
0 
13 2.18 2.38 Pd(PPh3)4 K3PO4 dioxane - 24/90 
0 
14 2.18 2.38 Pd(dppf)Cl2 K2CO3 THF Ag2O 6/80 
50-81 
15 2.18 2.34 Pd(dppf)Cl2 K2CO3 THF Ag2O 2/80 
0 
16 2.18 2.34 Pd(dppf)Cl2 K2CO3 THF Ag2O 7/80 
76c 
17 2.40 2.34 Pd(OAc)2 K2CO3 dioxane BrettPhos 22/100 
0d 
18 2.40 2.34 Pd(OAc)2 K2CO3 dioxane XPhos 22/100 
0d 
        
 






observed, although the obtained organic material was identified as an inseparable ~7:1 
mixture of product and starting triflate through proton nuclear magnetic resonance 
spectroscopy (1H NMR) analysis.  Despite the mixture, these results were extremely 
encouraging, and compelled further investigation of these conditions.  It was hoped that the 
pyridyl iodide 2.38 would be reactive enough so that no starting material would remain upon 
isolating the coupled product, or that it could be separated from the product by 
chromatography.  These conditions proved highly successful (entry 14), as the iodide and 
boronate ester 2.18 reacted together to provide the desired coupled product 2.36 in isolated 
yields as high as 81%, while generally ranging from 70-75% yields, and no observed starting 
material remaining.  The success of this reaction can be attributed to the relatively high 
reactivity of the iodopyridine species and the additive Ag2O, which acts as a halide scavenger 
to precipitate iodide as AgI, and in turn drives the equilibrium of the reaction toward the 
product.  These conditions marked a drastic improvement in our ability to efficiently and 
consistently perform the Suzuki coupling reaction and we are now able to prepare larger 
quantities of the coupled precursor 2.35 for continuation through the proposed synthetic 
sequence. 
 
2.4. Synthetic route continuation 
2.4.1. Preparation of the guaipyridine core 
 With optimized cross-coupling conditions in hand, it was concluded that the use of 
pyridyl iodide 2.38 was imperative to achieving high yields and purity in the reaction.  As 
previously discussed, 2.38 was used in the optimized coupling conditions using the Ag2O 





reactions in the synthetic route to produce the bicyclic guaipyridine core (2.39) of the final 
molecule (Scheme 13).  After the Suzuki coupling, dihydroxylation of the trisubstituted 
alkene afforded the 1,2-diol 2.43 by Sharpless asymmetric dihydroxylation.  Depending on 
which of the two AD mix varieties that is used, either stereochemistry can be selected at the 
trisubstituted alkene.  At this stage it was determined that Ligon and Yarbrough had been 
using the incorrect AD mix (β) and thus the stereochemistry at the 8-position (S) was 
opposite of that which was desired.  In the end, we prepared both enantiomers of the 
dihydroxylation reaction, which could ultimately lead us to all four diastereomers of the 
target, cananodine.  AD mix-α would lead to stereochemistry matching the naturally 
occurring cananodine with 5R, 8R configuration by first inducing (S) stereochemistry at the 
sp2 internal alkene carbon of 2.35. 
Scheme 13.  
 
Yields as high as 71% were achieved for this dihydroxylation reaction and the next 
step was epoxidation of the diol.  Past researchers had obtained nearly quantitative yields in 
the subsequent epoxidation reaction, although reproducing these results was difficult.  





yields as high as 71% were achieved, although they have typically been much lower.  
Important to the stereochemistry in sequence is that the epoxidation mechanism involves an 
SN2 like susbstitution to displace a mesylate leaving group.  In doing so, the configuration is 
inverted at the stereocenter of 2.31. Chiral GC of the epoxide products demonstrated 
enantiomeric excess of 96% when selecting (S) configuration with AD mix-α, and 95% when 
selecting for (R) configuration with AD mix-β in the dihydroxylation reaction.  Despite the 
lower yields, the epoxide precursor 2.31 was obtained, purified and successfully cyclized 
through base-promoted picolyl anion epoxide-opening to give guaipyridine 2.32.  Low yields 
are generally observed in this reaction which is attributed the fact that deprotonation can 
occur on both of the methyl groups at the 2- and 6-positions.  Deprotonation of a picolyl 
hydrogen at the 6-position will obviously lead to no epoxide-opening and cyclization, but 
could possibly lead to side product formation although none have been specifically isolated.  
In producing the cyclized guaipyridine core, compound 2.32, only one stereoselective 
hydrogenation reaction remained before the total synthesis of cananodine was completed. 
 
2.4.2. Terminal alkene hydrogenation and reduction reactions 
 The last step in the total synthesis of cananodine is conversion of the remaining 1,1-
disubstituted alkene at the 5-position of the cycloheptane ring to the corresponding methyl 
with (R) stereochemistry.  One hydrogenation reaction was already attempted by Yarbrough 
and it demonstrated that the non-selective hydrogenation catalyst, 10% Pd/C, did not provide 
any recognizable organic product, let alone 1.10.  Two different transition metal 
hydrogenation catalysts were also thought to be able to perform the desired transformation:  






after Sir Geoffrey Wilkinson, is a rhodium complex containing three triphenylphosphine 
ligands and one chloride.  Crabtree’s catalyst, named after the British chemist, Robert 
Crabtree, possesses an iridium central metal ion with tris(cyclohexyl)phosphine, 1,5-
cyclooctadiene, and pyridine ligands. Based on previously reported directed Ir 
hydrogenations it was hypothesized that the hydroxyl substituent would direct the iridium 
metal into position for hydrogenation of the double bond (Figure 8).  We were also, however, 
 
Figure 8. Proposed directed hydrogenation of 2.32 
 
aware that the tertiary hydroxyl substituent at the 8-position on the cycloheptane ring of 1.10 
may be too sterically hindered or too far away from the alkene at the 5-position to direct such 
action. Several distinct conditions were initially attempted in using these hydrogenation  
____________________________________________________ 
62 Wilkinson, G.; Young, J.F.; Osborn, J.A.; Jardine, F.H.; J. Am. Chem. Soc., 1966, 1711-1732. 






catalysts (Scheme 14).  The hydrogenations at one atmosphere were performed using a 
hydrogen balloon, while pressurized hydrogenations reactions were performed using a 
Fischer-Porter apparatus.  The hydrogenation using Crabtree’s catalyst was attempted under 
two different hydrogen pressures, using dichloromethane as the solvent.  To our 
disappointment, reactions at both 1 atmosphere and 50 psi hydrogen pressure yielded no 
product, and the starting material was recovered.  It is speculated that the tertiary hydroxyl 
group is in fact too far away from the alkene to support hydrogenation.  Wilkinson’s catalyst 
proved to be slightly more successful.  Although no product was obtained from reactions 
Scheme 14. 
 
using 1 atmosphere of hydrogen, elevated pressures between 30-50 psi did provide modest 
yields of the pure products.  Both NMR and gas chromatography-mass spectrometry (GC-
MS) analyses indicated that the isolated products were actually a diastereotopic mixtures 





reaction produced a slight diastereomeric excess of one of the two diastereomers.  However, 
noticeable broadening in one of the two peaks prompted further GC-MS analysis, and upon 
changing the thermal conditions a small starting material (2.32) peak with mass-to-charge 
ratio (m/z) of 231 was separated.  It is possible that this peak could also correlate to the 
unreduced internal alkene isomer of 2.32).  The result was a near 1:1 ratio of the two 
cananodine diastereomers (Figure 9), eluting at approximately 21.8 and 24.4 minutes, both 
with m/z = 233.  Hydrogenation of the 2.32 (S) enantiomer afforded at best a ~2:1 mixture of 
diastereomers which allowed for specific NMR chemical shift correlation and thus 
identification of cananodine resonances by comparing to literature values (see 2.4.3, Tables 
2, 3). 
 
Figure 9. Wilkinson’s hydrogenation crude gas chromatogram 
 
Although the lack of reactivity when using Crabtree’s catalyst and the lack of 
























































































































unexpected as largely unhindered, 1,1-disubstituted alkenes have been remarkably under-
studied and few enantioselective hydrogenation methods exist.64  Encouraged to isolate at  
least one of the two pure diastereomers, two additional hydrogenation catalysts were 
obtained and used in similar hydrogenation attempts.  The norbornadiene (nbd) rhodium 
catalyst 2.46, developed by John Kenneth Stille, (well known for the Stille cross-coupling 
using alkyl tin and alkyl halides reagents), has been commonly used in hydrogenations of 
1,1-disubstituted alkenes.65,66 The exotic threonine-derived phosphinite iridium catalyst, 2.47, 
developed by Andreas Pfaltz et al, has also displayed remarkable selectivity in reducing 
activated styrene derivatives.67 Both catalysts are commercially available. 
 
The hydrogenations using 2.46 and 2.47 were run using 50 psi hydrogen pressure in a  
Fischer-Porter tube.  Again, to our disappointment, the Ir catalyst provided a very small 
amount of a diastereotopic mixture by GC-MS analysis, but mostly starting material.  The 
Rh(nbd) catalyst also provided unsatisfactory results as only the starting material was 
recovered by NMR analysis.  GC-MS analysis of the crude reaction product did indicate that  
____________________________________________________ 
64 Burgess, K.; Cui, X.; Chem. Rev., 2005, 105, 3272-3296. 
65 Stille, J. K.; Amma, J. P.; J. Org. Chem. 1982, 47, 468. 
66 (a) Evans, D.A.; Morrissey, M.M.; J. Am. Chem. Soc., 1984, 106, 3866-3868. 
(b) Paquette, L.A.; Long, Y.O.; Yang, J.; J. Am. Chem. Soc., 2003, 125, 1567-1574. 





a small amount of product had been formed, and only a single diastereomer was observed.  
Literature sources for this Rh catalyst indicate that hydrogen pressures between 600-900 psi 
have significantly enhanced overall yields and selectivity, but we lack the appropriate 
equipment and instrumentation necessary to perform reactions with such extreme pressure 
requirements.  Being able to perform this hydrogenation at elevated pressures may result in 
higher selectivity for 1.10. 
As the extent of practical hydrogenation methods had seemingly been reached, our 
attention was turned to alternate alkene reduction procedures.  In 2012, Prabhu et al 
described a novel guanidine salt catalyzed styrene reduction in the presence of aqueous 
hydrazine.68 They believe that the hydrogen bonding capability of guanidine with hydrazine  
forms the reductive catalyst and releases nitrogen gas as a by-product.  Unfortunately, even 
with excessive amounts of both guanidine salt and hydrazine, the reaction was never 
successful in our hands.  Two lithium metal mediated reductions on a compound related to 
2.32 were also were also attempted (see 3.5.) with little success.   
 
All hydrogenation and reduction methods to date have so far been ineffective in 
performing the desired reduction of the terminal alkene to produce a single diastereomer of 
the target compound.  Although standard flash chromatography has proven ineffective in 
separating the mixture of diastereomers that are obtained from Wilkinson’s hydrogenation, 
other separation methods were explored in hopes of isolating the pure stereoisomers. 
____________________________________________________ 





2.4.3. Attempted diastereomer separation 
As the number of hydrogenation/reduction methods available had become virtually  
exhausted and have proven ineffective in providing just a single cananodine diastereomer, we 
turned our attention to high-performance liquid chromatography (HPLC) methods of 
separating the diastereotopic mixtures that are obtained from the Wilkinson’s 
hydrogenations.  It had already been established that the diastereomers 1.10 and 1.10a were 
inseparable by standard flash chromatography on both silica and alumina solid phases.  
Reverse phase thin-layer chromatography (TLC) also indicated no separation, dampening our 
hopes that reverse phase HPLC could achieve the separation.   
Despite this, analytical scale reverse phase HPLC was conducted to attempt the 
separation and determinate the feasibility of performing HPLC on a preparative scale.  The 
crude hydrogenation product displayed a sharp peak with retention time of 15 minutes under  
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the given solvent conditions, indicating no separation of the two stereoisomers (Figure 10).  
Another small peak was observed at approximately 19 minutes in the crude hydrogenation 
sample which corresponded to 2.32, verified by matching peaks in a control chromatogram 
of just the terminal alkene starting material.  Incorporation of 0.1% formic acid into the 
solvent system, as suggested by Aisa et al, did not improve separation of the stereoisomers, 
or even show any broadening the diastereomer peak at 15 minutes.39 These results indicate 
that reverse phase HPLC is not an effective method for separating the cananodine 
diastereomers on an analytical scale with the current solvent system. 
Although exhaustive efforts to obtain just a single cananodine diastereomer through 
multiple hydrogenation and reduction attempts, and HPLC failed to provided just a single 
cananodine diastereomer, it can still be confidently said that the desired cananodine  
stereoisomer was produced through comparison of 1H NMR and 13C NMR chemical shifts 
with previously reported results (Tables 2, 3).   Spectral data from both Wu’s naturally 
occurring 1.10 and the synthetic 1.10 produced by Craig and Henry were used to assess 
chemical shift correlations with our synthetic cananodine.34,43 Resonances from the 5S 
epimer, 1.10a, were also deduced based on the  known chemical shifts for the naturally 
occurring 5R epimer 1.10.  The tables show generally close agreement in chemical shifts 
between our 1.10 and literature values for both proton and carbon NMR spectra.  Some 
incongruities can be seen in 1H NMR coupling constants (J values), but all appear to be 
within instrumental error.  Two curious chemical shift discrepancies are observed at the 8-
position stereocenter as well as the 7β hydrogen when comparing to the natural product 
isolated by Wu.  These chemicals shifts, however, both closely match those reported by 









δH, multiplicity (J in Hz) 
Natural product 
(400 MHz) 
Vyvyan et al 
(500 MHz) 
ΔδH Craig & Henry 
(300 MHz) 
5S Epimer 
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2.89, dd (12.2, 11.7) 
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To our satisfaction, the 13C chemical shifts of our synthetic cananodine match remarkably 
well with the already reported values, all within 1.0 ppm.  It should be noted that Professor 
Craig provided our lab with the actual NMR spectra of their synthetic cananodine as well as 
the natural product for visual comparison.  The unsettled specific rotation of cananodine can 
also be confirmed as the the hydrogenation precursor 2.32 was measured to have [α]20
𝐷
 = 
+16.3°.  In assuming that the sign of the optical rotation does not change after the final 
hydrogenation, this experimental evidence suggests that the naturally occurring guaipyridine 
exists as (+)-cananodine, which agrees with the data reported by Craig and Henry. 
 
2.5. Progress toward the syntheses of rupestines B-D 
 We have demonstrated that the epoxide-opening route is an effective method of 
producing the bicyclic guaipyridine core, although we have yet to perfect the final method of 
reducing the 1,1-disubstituted alkene at the 5-position of the 7-membered carbocycle.  The 
success in this route led us to believe that a similar synthetic sequence (Scheme 15) could be 







could again be achieved through hydrogenation of the terminal alkene in 2.48, which is the 
product of a familiar epoxide-opening reaction on 2.49, demonstrated in the synthesis of 
cananodine.  Compound 2.49 is the likely product of optimized cross-coupling conditions 
between 2.38 and 2.50 followed by dihydroxylation and epoxidation procedures.  Boronate 
ester 2.50 could be prepared from the appropriate heptenone and octenone starting materials.  
Rupestines B-D were chosen as target molecules because they contain methyl and ethyl 
ketone substituents at the 8-position and were thought to be more easily synthesized than 
other rupestine compounds.  Rupestines B (1.20) and C (1.21) possess ethyl ketone 
substituents and are C5 epimers of one another.  Rupestine D (1.22) contains a methyl ketone 
substituent at the 8-position.   
 To synthesize these compounds, additional preparation of the boronate ester Suzuki 
coupling partners is required due to the scarcity of commercial suppliers of the alkenones 
2.57 and 2.58 (Scheme 16).  Inexpensive, commercially available alkynols are first subjected 
to chlorination through an SN2 reaction using thionyl chloride (SOCl2) and pyridine to 
provide chloro-alkynes 2.56 and 2.57 in good yields.  Substitution at the α-position of 2,4-







facile semi-hydrogenation, the usual triflation method using PhNTf2 provided dienyl triflates 
2.62 and 2.63.  It was originally thought that selecting for the (Z) configuration in the internal 
alkene could provide higher reactivity in the eventual epoxide opening stage as rotation about 
the C3 and C4 carbons would bring the epoxide into a closer proximity to the picolyl anion.  
Curiously, after subjecting the newly formed triflates to borylation conditions, none of the 
boronate ester products 2.59 and 2.60 were observed upon extraction of the organic material.  
It is speculated that the palladium catalyst that is used in this reaction strongly coordinates to 
the now less-hindered 1,2-disubstituted alkene, rather than the trisubstituted alkene substrate 
used in the cananodine route.  This steric relief likely causes side product formation rather 
than the expected boronate ester products. 
The unsuccessful borylation reaction caused us to make slight adjustments to the 







double bond of the substrates, Sharpless asymmetric dihydroxylation and protection with an 
acetonide group was performed prior to borylation and coupling attempts (Scheme 17).  The 
dihydroxylation and protection procedures proceeded smoothly to provide protected products 
2.63 and 2.64. From there, the borylation procedure was repeated and this time provided the 
boronate esters 2.65 and 2.66 in moderate to good yields indicating that functionalization and 
protection procedures were necessary for borylation to occur.  The optimized coupling 
conditions using aryl iodide 2.38 again allowed for easy access to the subsequent coupled 
products 2.67 and 2.68, and following deprotection of the diol, compounds 2.69 and 2.70 
were obtained for epoxidation attempts.  The epoxidation procedure using MsCl and NEt3 
followed by K2CO3 and MeOH provided 2.72 (R = Et) in moderate yields, although the small 
amount of product obtained was only enough for characterization, and the cyclization 
reaction could not be attempted.  The same epoxidation procedure was not successful in 
providing 2.71 (R = Me), but rather the corresponding bis-mesylate product was observed.  
These results suggest that the lack of steric hindrance surrounding the 1,2-diol in 2.71 allows 
for fast mesylate bond formation at both hydroxyl sites, and thus the preferential mesylate 
formation, elimination and cyclization does not appear to occur.  Other routes will need to be 
explored for the epoxidation of 2.71.   
 Later investigation of the enantiopurity of the substrates unfortunately revealed that 
the protected diols 2.63 and 2.64 were essentially racemic mixtures by chiral GC analysis and 
therefore all of the isolated products after the dihydroxylation stage were also racemic 
mixtures.  Although disappointing, these results were not entirely unexpected as literature 
references indicate very poor enantioselectivity of cis-olefins in the asymmetric 





especially when designing potential pharmaceuticals is paramount, as selection of the wrong 
stereoisomer commonly leads to limited or no activity, or unwanted side effects.  
Consequently, the rupestine B-D synthetic route required further alteration to achieve 
improved selectivity at the stereocenters. 
The most obvious way to improve the enantioselectivity was to change the geometry 
of the internal double bond of the dihydroxylation substrates 2.62 and 2.63.  trans-Olefins 
have been shown to have a higher degree of selectivity in the dihydroxylation reaction than 
their cis-olefin counterparts, and so construction of the trans-analogs of the compounds in 
Scheme 17 was envisioned as new synthetic targets (Scheme 18). 
 Crotyl chloride (2.77) a widely available commercial compound was chosen as the 







eliminates the thionyl chloride driven chlorination reaction that was previously a part of the 
sequence.  This is balanced by the fact that (E)-1-chloropent-2-ene [2.78 (R = Et)] is 
extremely difficult to find commercially, and so it was necessary to first reduce 2-pentyn-1-ol 
(2.75) with lithium aluminum hydride (LAH) to the analogous trans-alkenol 2.76, and then 
convert to the chloro-derivative by the previously mentioned procedure.  Both routes also 
eliminate down-stream Pd catalyzed hydrogenation of the internal alkyne from the previous 
synthetic route which was used to introduce the cis-alkene.  Unfortunately, initial 
chlorination attempts on substrate 2.76 have only provided the SN2’ product. However, 
familiar carbonylation and triflation procedures have been used on 2.77 to provide triflate, 
2.80 which then allowed for the Sharpless dihydroxylation.  Upon completing the reaction 
chiral GC showed vastly improved enantiomeric excess of 61% for 2.82, however still not at 
a desirable level of enantiopurity.  Despite this, the subsequent three reactions were 
attempted which proceeded smoothly as diol 2.85 was isolated for further epoxidation/ 
cyclization attempts. 
 It was already established that one epoxidation attempt using NEt3, MsCl, K2CO3, 
and MeOH failed to convert the 2.85 substrate to the corresponding product.  Although the 
number of ways to form reactive intermediates (such as epoxides) from diols is limited, other 
methods were attempted in hopes of obtaining a cyclized guaipyridine core (Scheme 19).  An 
epoxidation method described by Sharpless goes through a cyclic intermediate to form a 
halohydrin, and is followed with elimination of the halide by the remaining hydroxyl oxygen 
acting as the nucleophile.  Trimethyl orthoacetate was first used to form the orthoester 
derivative of the starting diol.  Two different halide sources, acetyl bromide and 





Scheme 19.  
 
following the reactions by TLC seemed to clearly indicate formation of the cyclic 
orthoesters, upon addition of the halide sources TLC analysis became inconclusive.  After 
completion and work-up of the reaction, spectral analysis indicated only starting material 
retention in both cases.  Another method to convert diols to more reactive intermediates 
described by Sharpless involves formation of a cyclic sulfate form the starting diol.59  Cyclic 
sulfates are more reactive (for better or worse) than their oxirane analogs, thus it was thought 
if cyclic sulfate 2.88 could be obtained, the efficiency of the subsequent cyclization reaction 
could be improved.  To make this cyclic sulfate, the cyclic sulfite must first be prepared.  The 
reaction to produce cyclic sulfite 2.87 was unsuccessful, the starting material was recovered 










3. Access to the Guaipyridine Core via Intramolecular Heck Reaction 
3.1. The Heck cross-coupling reaction 
 As is common in target oriented synthesis, multiple strategies for producing the same 
compound can often be envisaged by the researcher and can potentially lead to surprising 
discoveries.  A second route to access the guaipyridine core hinges on a late stage 
intramolecular Heck cross-coupling reaction between a side-chain monosubstituted terminal 
alkene and an aryl halide or triflate.  It was hypothesized that this reaction could form the 7-
membered ring of the final molecule and provide the bicyclic core, inherent to all 
guaipyridines.  From there, numerous transformations at the 8-position can be envisioned to 
eventually synthesize a variety of guaipyridine compounds.   
 
3.1.1. History of the Heck coupling reaction 
The Heck reaction itself is a well-established and important tool in organic chemistry 
and natural products synthesis for the formation of carbon-carbon bonds, dating back over 
four decades.  The palladium catalyzed reaction between olefins and aryl halides through 
vinylic hydrogen substitution was first reported by Mizoroki et al in 1971, but independently 
discovered and refined into a more convenient and practical form by Richard F. Heck (for 
whom the reaction is named after) less than a year later.69,70 Palladium catalyzed cross-
coupling reactions in general have since become increasingly ubiquitous as a synthetic tool 
and arguably the most widely recognized and useful method of forming carbon-carbon 
bonds.  The importance of these reactions to organic chemistry was recognized in 2010 
____________________________________________________ 
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when Heck shared the Nobel Prize in chemistry with Akira Suzuki and Ei-ichi Negishi (who 
soon after Heck developed organoboron and organozinc Pd coupling reactions, respectively) 
for their work in developing cross-coupling chemistry. 
Like other coupling reactions, the Heck reaction follows a catalytic cycle mechanism 
in forming the products (Figure 11).71 Both Pd (0) and Pd (II) catalysts have been shown to 
be effective for this transformation, but regardless of the catalyst, it must initially proceed 
through a pre-activation step in which the metal center is ultimately reduced to Pd (0).  
Standard oxidative addition then occurs, in which the palladium inserts itself between the 
alkyl or aryl halide bond, then simultaneously breaks the C-X bond while forming Pd-X and 
 
Figure 11. General Heck reaction catalytic cycle 
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Pd-R bonds.  The olefinic substrate then also coordinates to the palladium and is thought to 
displace the labile halogen or pseudo-halide from the metal center.  The π-electrons from the 
olefinic substrate then donate to the metal center forming a transient carbocation, which 
allows for migratory insertion of the alkyl or aryl group into the positively charged alkene 
substrate and forms the new C-C bond.  The palladium then binds a hydrogen atom from the 
substrate and the resulting PdH species is eliminated to reform the double bond and release 
the product.  A last reductive elimination step (not shown) requires a base to regenerate the 
active Pd (0) catalyst from the hydridopalladium (II) species. 
 As widely used as this process has become, the overwhelming majority of literature 
references cite reactions of the intermolecular variety involving di- and trisubstituted olefins.  
Several years after the initial work by Mizoroki and Heck the first instances of the 
intramolecular version of the reaction were reported by Heck and elaborated on by Shibasaki 
and other researchers when they began to properly explore the potential and utility of this 
transformation.72 Since the late 1980’s and early 1990’s this reaction in general has 
flourished in the fields relating to target-oriented synthesis.  Overman and Dounay have 
reviewed numerous applications of the asymmetric intramolecular Heck reaction from this 
era including the synthesis of a variety of alkaloids, terpenoids, polyketides and many other 
classes of natural products.73   
While the overwhelming majority of cyclizations that the Heck coupling has been 
used for involve the formation of 5- and 6-membered ring systems, relatively few examples 
of 7-membered ring formation exist.  Even fewer publications describe 7-membered  
____________________________________________________ 
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carbocycle formation, although multiple syntheses of 7-membered N-heterocycles have been 
reported.74 One of the few examples of 7-membered carbocycle formation through Heck 
cyclization was demonstrated by Banerjee et al in their synthesis of the analgesics (±)-
komaroviquinone and (±)-faveline methyl ether in 2005.75 The group first synthesized 
intermediate 3.1 and used an intramolecular Heck reaction to perform the 7-exo cyclization in 
forming the tricyclic core (3.2) of the naturally occurring products. 
 
 Our guaipyridine targets share similarities in the fused aryl and carbocycle motif with 
the substrates used by Banerjee et al in their intramolecular Heck cyclization, which gave us 
confidence that the guaipyridine core could be constructed in this manner.  Despite the 
similarities, the subtle differences in structure, including the presence of a pyridine ring 
rather than a benzene ring, made it difficult to say with certainty that a Heck reaction would 
be successful.  Model studies on simple, less-precious substrates were needed in order fully 
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3.1.2. Intramolecular Heck reaction model studies 
 To assess whether the Heck reaction was a viable method for forming our particular 
guaipyridine bicyclic system, a series of model substrates were prepared for intramolecular 
cyclization testing (Scheme 20).  Commercially available 3-bromo-2-methylpyridine (3.3) 
was chosen as the test substrate.  This compound contains both the aryl halide needed for 
Heck cyclization, as well as the 2-methyl functionality needed for constructing alkenyl side-
chains of various lengths.  The lack of a methyl group at the 6-position made this compound 
Scheme 20. 
 
a simpler test substrate.  The compounds 3.4 and 3.6 containing butenyl and hexenyl side-
chains at the 2-position were prepared with relative ease using a strong lithium base to 
deprotonate the picolyl position, and the appropriate alkenyl bromide reagent.  To our 
disappointment, the corresponding pentenyl derivative, 3.5, could never be formed under the 
same conditions and thus no 6-exo Heck cyclization was attempted.  This is likely explained 
by the strong preference of 4-bromo-1-butene to undergo elimination and form the 
conjugated 1,3-butadiene under basic conditions.  Even after synthesis of the butenyl p-
toluenesulfonate, 3.11, containing a more electronically stable leaving group, the addition 





3.6 proved successful.  The 5-exo cyclopentylpyridine compound, 3.7, was obtained as the 
only product from Heck coupling under standard conditions.  The intramolecular coupling of 
3.6 provided a 3:1 mixture of 7-exo and 7-endo cyclization products (3.9) by NMR 
integration of identifiable vinyl resonances.  These results were encouraging as they 
presented evidence that the Heck reaction could be used to form the guaipyridine core. 
 As previously mentioned, the test substrate 3.3 lacked the necessary methyl group at 
the 6-position of the pyridine ring.  The substrates that will be used to construct our target 
molecules contain methyl substituents at both the 2- and 6- positions, and so another model 
study was necessary to indicate whether an activating group (such as a halide or sulfide) was 
needed to selectively alkylate only the 2-picolyl position (Scheme 21).  It was hoped that 
functionalizing the phenol with a MOM protecting group would be enough to dictate the 
needed selectivity by loosely coordinating a lithium ion to produce a reactive organo-lithium 
intermediate in situ.  In this competitive lithiation experiment, the 2,6-dimethylated pyridinol 
3.12 was chosen as the starting material and chloromethyl methyl ether (MOMCl) was used 







agent was used to determine which picolyl site would be deprotonated and subsequently 
alkylated.  The two expected products were compounds 3.14 and 3.15 which could be 
generated by deprotonation at either picolyl site.  What was actually observed after isolation 
of the organic material and NMR analysis was product 3.16, a somewhat surprising result 
stemming presumably from directed ortho metalation (3.13a).76 While neither of the 
expected products were observed in this model study, insightful information was nonetheless 
gathered as the results clearly indicated that some sort of activating group was needed to 
selectively alkylate at the 2-picolyl position.  
 
 3.2. Initial synthetic plan 
The results obtained from the Heck reaction and competitive lithiation model studies 
were encouraging and revealing enough to begin construction of synthetic intermediates.  
Our initial synthetic plan was envisaged to consist of two central reaction steps (Scheme 22).  
In the first, an intermolecular variant of the epoxide-opening demonstrated in the synthesis of 









add to the electrophilic epoxide ring of 3.20.  After halogenation or triflation at the 3-position 
of the pyridine ring, the Heck reaction substrate 3.18 would be obtained.  The important 
intramolecular Heck cyclization would then close the 7-membered ring to provide bicyclic 
3.17 and from there multiple transformations on the 8-position substituent and hydrogenation 
of the terminal alkene can be envisioned to access a variety of different guaipyridine 
compounds.  With our synthetic route in mind, the preparation of the epoxide opening 
partners was commenced (Scheme 23).   
Starting from cheap, commercially available 3-hydroxy-6-methylpyridne (3.21) 
aromatic substitution using formaldehyde afforded pyridyl diol 2.11, previously used by 
Meyer in her Suzuki coupling optimization attempts (See 2.2).  Acid catalyzed substitution 
with 48% hydrobromic acid and thiophenol afforded the pyridyl thioether 3.22.  The 
noticeably poor yields observed in this reaction are thought to stem from the inherent pH 
sensitivity of the product.  In the work-up procedure, a crude aqueous solution that is too 
basic tends to deprotonate the phenol group, while increased acidity protonates the nitrogen 
of the pyridine ring.  Both scenarios result in water soluble compounds which cannot be 







product could not be obtained.  Unfortunately, the phenol group of 2.11 cannot first be 
protected because the extremely acidic conditions of the subsequent thioetherication step 
would likely cleave any protecting group. Despite a poor yield, the large scale reaction 
provided a useable amount of product and the ensuing protection of the phenol group 
provided the first epoxide-opening partner, 3.19. 
 Next was the synthesis of alkenyl epoxide 3.20 [(R = Me) Scheme 24].  The reaction 
sequence first involved synthesis of the appropriate phosphonium bromide salt 3.24. This salt 
was then used as a ylide in the following Wittig reaction (a C-C bond forming reaction 
named after the German chemist, Georg Wittig) with acetone to produce diene 3.25.  
Unfortunately, no pure diene 3.25 product was ever isolated.  Although at least some product 
formation did appear to occur by NMR, the inherent volatility of the compound made 
isolation of the pure product difficult if not impossible.  Distillation of the material was an 
unfeasible purification method due to the relatively small scale of the reactions. 
Scheme 24. 
 
 The difficulties associated with producing either of the initial epoxide opening 
partners 3.19 and 3.20 (R = Me) required us to adjust our synthetic plans and look elsewhere 
for compounds that could be used to construct the Heck coupling precursor.  In doing so, a 
different approach was taken when considering the roles of the alkylation partners that we 
hoped could be used to synthesize the desired Heck coupling precursor (Scheme 25).  Rather 
than using a sulfide activating group, it was hypothesized that the bromide derivative (3.26) 





triflation of the phenol group (3.28) would then serve to both protect the phenol during the 
subsequent nucleophilic alkylation and act as the electrophilic site during Heck cyclization.  
Preparation of ester 3.29 through simple acid catalyzed esterification with MeOH and the 
appropriate carboxylic acid (3.27) would then replace epoxide 3.20 as the second addition 
partner.  Deprotonation of the carbon α-carbonyl would allow 3.29 to act as the nucleophile 
in the reaction as opposed to the electrophilic epoxide.  Heck precursor 3.30 could thus be 




3.3. Preparation of precursors and the bromide elimination reaction 
 Multiple routes for synthesizing pyridyl bromide 3.28 were suggested and initially 
pursued (Scheme 26).  Acid catalyzed bromination was first attempted by refluxing pyridyl 
diol 2.11 in HBr and H2SO4, which resulted in no product formation and isolation of only a 
small amount of organic material.  Bromination using N-bromosuccinimide (NBS) and PPh3 
did not fare any better as very little product was observed in the reaction.  The pH sensitivity 





as was the case in the synthesis sulfide 3.22.  With this is mind, 2.11 was again refluxed with 
HBr and upon concentration and cooling of the reaction mixture thick white crystals formed 
at the bottom of the flask.  These crystals were isolated and identified as the hydrobromo-salt 
of 3.26, compound 3.31, with an observed melting point of 222 °C closely matching the 
literature value of 224 °C.77 Although the hydrobromo-salt was easily synthesized, 
subsequent triflation of the phenol using two equivalents of NEt3 and O(TF)2 did not result in 
any of the desired pyridyl triflate 3.37 and no identifiable NMR resonances were observed. 
Scheme 26. 
 
These results led us to two conclusions.  First, the difficulty in brominating the 
picolyl position indicated that perhaps the phenol group needed to first be protected before 
bromination, as suggested by past researchers in the Vyvyan group.  Also, because we have 
successfully activated phenol groups in the past, activation of both of the hydroxyl groups in 
2.11 with either triflate or mesylate groups seemed to be a reasonable supposition.  The latter 
proposal would also eliminate protection and deprotection procedures in the total synthesis, 
as the aryl triflate or mesylate would be used as a leaving group in the Heck cyclization. 
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Bis-triflation was first attempted by reacting 2.11 with excess NEt3 and Tf2O at a  
reduced temperature (Scheme 27) and mixed results were observed from three separate 
attempts at synthesizing the bis-triflate 3.32.  While the product certainly appeared to have 
been synthesized by NMR analysis, it was isolated after chromatography as viscous red oil, 
indicating significant inseparable impurities which included a large amount of the mono- 
triflate species.  The amount of mono-triflate that was produced and the overall amount of 
organic material that was isolated from the reaction appeared to vary drastically with each 
attempt.  Regardless, the apparent bis-trilfate mixture was used in the ensuing alkylation 




 The mixed results displayed by the bis-triflation route incited experimentation with 
mesylate activating groups.  The expected product in a reaction between 2.11 and excess 





mixture appeared to undergo a substitution reaction at the picolyl position instead, as 
evidenced by GC-MS data (m/z = 236) for the isolated product and only one mesylate singlet 
at 3.30 ppm in the 1H NMR spectrum.  This result, although unexpected, was not 
unwelcomed as the chloride substituent at the picolyl position could still potentially be used 
as the leaving group in the following nucleophilic substitution.  However, when this 
transformation was attempted a disappointing 13% of impure Heck precursor 3.35 was 
obtained. 
 The poor efficiency of the bis-activation routes and the overall impurity of the 
products obtained from them forced us to take a step back and consider protecting the phenol 
group before any further transformations on the substrate (Scheme 28).  After protection of 
2.11 with an allyl group, bromination of the 2-picolyl position became a simple task resulting 







nucleophilic addition reactions, it was also changed to the tert-butyl ester derivative (3.38) in 
hopes that the increased steric bulk would suppress self-condensation of the ester in the 
strongly basic conditions.  Increased reactivity was indeed observed as the bromide 
elimination reaction between 3.37 and 3.38 proceeded smoothly in satisfactory yields to 
synthesize the first important intermediate in the sequence, 3.39.  Subsequent Pd catalyzed 
phenol deprotection was the next course of action.  Initial fears that the Pd(PPh3)4 catalyst 
would interact with the side-chain alkene rather than the allyl protecting group were quickly 
dismissed when the reaction resulted in very good yields of phenol 3.49 as the only product.  
Triflation of the newly formed phenol group was also achieved in good yields, culminating a 
series of highly successful reactions to produce the Heck coupling precursor 3.41. 
 
3.4. Intramolecular Heck reactions 
 After successful synthesis of the Heck precursor 3.41, the stage was set to test 
intramolecular Heck coupling reaction conditions in hopes of constructing the bicyclic 
guaipyridine core 3.42.  Several different conditions were used before successful conversion 
of the starting alkenyl triflate to the corresponding 7-membered ring was observed (Table 3).  
Pd(OAc)2, a Pd (II) species, was the first catalyst that was tried because of the success that 
was achieved when this catalyst was used in the model Heck reaction studies, providing 5- 
and 7-membered carbocycles from intramolecular cyclization.  Despite the earlier success of 
these conditions, two reactions under roughly the same time and temperature conditions, but 
employing different bases, provided no product and starting material was recovered (entries 
1, 2).  Changing the palladium (II) species to Pd(dppf)2Cl2, again  under the same conditions, 





the catalyst that any product was observed (entry 4).  After letting the mixture stir for about 
one day with K2CO3 and PPh3 in acetonitrile at elevated temperatures, the product 3.42 was 
isolated in very good yields after separation from impurities via chromatography.  
  
Table 4. Survey of Heck Pd Catalysts and Bases 
 
       





       
1 Pd(OAc)2 K2CO3 MeCN PPh3 20/90 0c 
2 Pd(OAc)2 K3PO4 MeCN PPh3 22.5/90 0c 
3 Pd(dppf)Cl2 K2CO3 MeCN PPh3 23/90 0 
4 Pd(PPh3)4 K2CO3 MeCN PPh3 23/90-100 75-84 
 
a25 mol% bIsolated yields  cSome starting material recovered. 
 
To our satisfaction 3.42 was the only product that was isolated, even though model 
studies indicated the potential for both 7-exo and 7-endo cyclization mechanisms.  Also of 
note is the fact that while neither of the palladium (II) catalysts provided cyclized products of 
any kind, switching to the Pd (0) catalyst readily gave the desired product and in very 
acceptable yields.  One rationale for this is that the PPh3 that is used to displace the 





the zero oxidation state may not have had the desired effect.  It has yet to be seen in our lab 
whether this reaction would proceed without the use of PPh3 when using a Pd (0) catalyst. 
 
3.5. Attempted hydrogenation and reduction reactions 
 Synthesis of the guaipyridine core compound 3.51 can be accomplished in seven 
steps in a 13% overall yield.  Still, the issue at hand was whether the 1,1-disubstituted alkene 
at the 5-position could be stereoselectively reduced.  It was hoped that the larger ester 
coordinating group would be able to better assist in a hydrogenation using Crabtree’s Ir 
catalyst, and it was yet to been seen what effect the already semi-successful Wilkinson’s 
catalyst would have during hydrogenation.  Subjecting 3.42 to Crabtree’s hydrogenation 
conditions, again, appeared to have no effect and starting material was recovered from the 
reaction.  Wilkinson’s catalyst had essentially the same effect on 3.42 that it did on the 
cananodine precursor 2.32.  NMR and GC-MS analysis, for a second time, revealed a 1:1 
ratio of the diastereomers 3.43 and 3.43a. 
 
Several alternative reduction attempts were also tried on this substrate.  The 
previously attempted guanidine nitrate catalyzed reduction fared no better in reducing the 
alkene in 3.42 than it did in the reaction with 2.32 (See 2.4.2.).  Even with a significant 
excess of the guanidine salt catalyst and hydrazine, no product could be isolated. 
 Two lithium metal mediated reductions were also attempted.  In the first, lithium and  
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dimethylaminonaphthalene (DMAN) were reacted together to form a green radical-anion 
‘LDMAN’ solution (Scheme 29).78 This solution was then added to 3.42 and after a series of 
one-electron and proton donations at the double bond (mediated by the proton donor, t-
BuOH), 3.43 would be the expected product.  Again, this reduction did not appear to have 
reduced the double bond as only a miniscule amount of product was observed by NMR and 
GC-MS analysis.  Distinctive color changes were, however, observed during the course of 
the reaction suggesting that some reaction was in fact occurring.  Upon addition of LDMAN 
to 3.42, the solution turned bright orange.  Then, quenching with the first equivalent of t-
BuOH changed the solution to colorless.  These visual indicators suggested that the radical 
anion of 3.42 was initially generated and that quenching with 1 eq. of t-BuOH provided the 
corresponding methyl radical.  However, any further addition of LDMAN/t-BuOH failed to 
effect noticeable change in the solution, and in the end the starting material was recovered.  




The last reduction attempt was derived from a well-known procedure known as the 
Birch reduction, named after the Australian chemist Arthur Birch who published a series 
articles describing his work with metal mediated reductions from 1944-1949.79 This reaction 
employs liquid ammonia at reduced temperatures along with the lithium metal to generate 
free electrons and ammonia anions, which are powerful reducing agents.  Although this  
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method has traditionally been used for reducing aromatic compounds to their corresponding 
1,4-cyclohexadiene counterparts, we were hopeful it could have the same effect on the 
conjugate alkene of 3.42.  After successful generation of ammonia anions, the solution was 
added to the 3.42 substrate.  Spectroscopic analysis of the crude reaction product again 
indicated only a very small amount of product 3.43 formation.  These results concluded three 
largely unsuccessful alkene reduction attempts as well as three different hydrogenation 
attempts resulting in little to no product formation.  Only the Rh based Wilkinson’s catalyst 
provided products of any kind although, as noted, in ~1:1 diastereotopic mixtures. 
 
 
3.6. Attempted reductive-Heck reactions  
 To try and avoid the hydrogenation and reduction procedures all together, we 
consulted appropriate literature sources to assess whether a reductive-Heck reaction was 
feasible in our system.  This type of reaction would reduce the terminal double bond through 
hydride addition while simultaneously forming the 7-membered ring of the guaipyridine 
core.  Although the first instance of hydride ion capture by a vinylpalladium species was 
reported in 1988 by Grigg et al, very few references are available for this type of reaction and 
no reports of 1,1-disubstututed alkene reduction during Heck coupling could be found.80   
Recent total syntheses have, however, demonstrated precedence for using the reductive Heck  
____________________________________________________ 
80 Grigg, R.; Burns, B.; Sridharan, V.; Worakun, T.; Tetrahedron Lett., 1988, 29, 4329-4332. 







reaction to form both 7-membered carbocycles and heterocycles.  For instance, in 2012 Sinha 
et al used the reductive-Heck reaction to synthesize members of the iboga alkaloid family.81 
By submitting the azabicyclooctene indolamine 3.44 with indolyl iodide to reductive-Heck 
conditions they were able to synthesize the 7-membered N-heterocycle 3.45. 
The conditions for reductive-Heck couplings are generally very similar to those used 
in standard Heck reactions.  In order to induce the desired reductive effects, a hydride ion 
source must be made available within in the reaction system to reduce the vinylpalladium 
intermediate.  Commonly used hydride sources for this reaction are formic acid or sodium 
formate due to their willingness to act as hydride donor and because unreactive carbon 
dioxide is generally the only by-product that is produced.  Nitrogen-containing bases are also 
frequently used in these reactions.  Several different conditions were surveyed in hopes of 
producing the reduced guaipyridine core 3.52 (Table 4).  To our disappointment, standard 
conditions using both formic acid and sodium formate as the hydride source did not provide 
the reduced product (entries 1, 2).  Adding the nitrogen base, piperidine, was also 
unsuccessful under similar conditions (entry 3).  Employing the ammonium salt, 
tetrabutylammonium bromide (Bu4NBr), as the base provided an interesting mixture of  
products (entry 4).  Although 3.52 was still not observed, the standard Heck reaction product 
3.51 as well as the internal alkene isomer 3.53 were initially isolated in a 44% yield as an 





the ratio of either isomer indicating that the isomerization occurred before cyclization.  A 
repeated trial of this reaction demonstrated inconsistent yields, and thus was abandoned. 
Table 5.  Reductive Heck Coupling Conditions 
 
        
Entry Pd cat. 
Hydride 
Source 
Base Additive Solvent 
Time (h)/ 
Temp. (°C)  
Product 
        
        
1 Pd(PPh3)4 HCO2H - PPh3 DMF:MeCN 6/60 - 
2 Pd(PPh3)4 HCO2Na - PPh3 DMF:MeCN 6/60 - 
3 Pd(PPh3)4 HCO2Na piperidine - DMF 5/75 - 
4 Pd(OAc)2 HCO2Na Bu4NBr - DMF 24/r.t. 3.42, 3.46 
        
 
With a second, efficient route for accessing the bicyclic guaipyridine core in hand, 
continued pursuit of an efficient hydrogenation or reduction method for the final terminal 
alkene must be continued.  Despite the inability to effectively perform such a reaction thus 
far, numerous transformations can be envisioned at the 8-position to create many rupestine 








4.  Conclusions 
 Overall, two different methods of accessing the bicyclic guaipyridine core was 
successfully demonstrated and may lead to future guaipyridine syntheses.  The first synthetic 
route employs base-promoted epoxide-opening to form the 7-membered ring of the 
guaipyridine core while the second route makes use of an intramolecular Heck cyclization to 
form the same bicyclic core.  In doing so, many synthetic challenges were overcome and key 
products were isolated, leaving well-defined goals for future synthetic aspirations.   
 Much of the epoxide-opening cyclization route had already been accomplished by 
past researchers, but the remaining terminal alkene hydrogenation and low yields from key 
synthetic steps left much to be desired.  Optimization of the important Suzuki cross-coupling 
reaction led to a much needed improvement of the mass recovery of the coupled 
intermediate, and thus the synthetic route was continued to the final stereoselective 
hydrogenation step.  The best results stemming from exhaustive hydrogenation and reduction 
attempts provided disappointing diastereotopic mixtures of the target compound, cananodine.  
The desired product and the three other cananodine diastereomers were, however, confirmed 
by several characterization techniques including NMR, HRMS and GC-MS analyses. 
 After much initial toil, a second synthetic route was developed to efficiently produce 
the guaipyridine core.  A key reactions in this sequence was alkylation of a pyridyl bromide 
which provided an important intermediate.  After two additional steps, the Heck precursor 
was isolated and employing intramolecular Heck reaction conditions gave the guaipyridine 
bicyclic core.  Although hydrogenation and reduction attempts were also tried on the terminal 
alkene of this compound, no improvement in selectivity was observed.  Future 





guaipyridine compounds.  For instance, treating the ester substituent with excess MeMgBr 
would provide the 2-propyl substituent of cananodine, while conversion of the ester to the 
aldehyde followed by treatment with 1 eq. MeMgBr or EtMgBr and then oxidation of the 
























5.  Experimental Section 
General Experimental Procedures 
 
All reactions were performed following all necessary safety procedures, including the 
use of nitrile gloves and UVEX splash-proof safety goggles.  All reactions involving air- or 
moisture-sensitive materials were carried out in oven and/or flame dried glassware under 
argon.  All reactions were stirred using a magnetic stir bar at room temperature unless 
otherwise noted.  Diethyl ether, THF, CH2Cl2, MeCN, and toluene were dried before use by 
passing through a column of activated alumina using an Innovative Technology Pure Solv™ 
400 Solvent Purification System.  All solutions were concentrated by rotary evaporation 
under reduced pressure.   
All chromatography was performed with mixtures of hexanes and ethyl acetate unless 
otherwise noted.  For materials purified by chromatography, parameters are reported using 
the following format: (column diameter, solvent reservoir volume, solvent mixture ratio).  
Flash chromatography (~10 psi) was carried out with hand-packed columns of silica 
(Silicycle, 230-400 mesh).  All TLC analysis was performed using Sorbent Technologies 200 
µm silica layer fluorescence UV254 TLC plates. 
1H NMR spectroscopy experiments were performed on a Varian Unity Inova 500 
MHz FT-NMR spectrometer and plotted and processed by VnmrJ 3.2 and/or Spinworks 3 
software.  Between eight and 32 scans were performed on each sample and referenced to the 
tetramethylsilane (TMS) peak (0.00 ppm).  Chemical shifts are reported using the following 
format: chemical shift (ppm) [multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, 





 13C NMR spectroscopy experiments were performed on a Varian Unity Inova 500 
MHz FT-NMR Spectrometer and processed by the VnmrJ 3.2 software.  Between 256-1026 
scans were performed on each sample and referenced to the CDCl3 triplet resonace (77.0 
ppm).  Chemical shifts are reported using the following format: chemical shift (ppm). 
 Infrared spectroscopy experiments were performed on a ThermoNicolet Nexus 470 
FT-IR Spectrophotometer (Diamond ATR) and plotted and processed by the OMNIC 
software.  Absorptions are reported using the following format: absorption (cm-1) [intensity 
(s = strong, m = medium, w = weak, br = broad)]. 
 Gas chromatography-mass spectrometry was performed using a Varian CP3800 GC 
with Saturn 2000 Ion Trap MS with the help of Charles Wandler and WWU Scientific 
Technical Services.  Gas chromatograms and mass spectra were processed using Varian MS 
Data Review Version 6.9 and plotted using Microsoft Excel 2010.  High resolution mass 
spectrometry was performed by the Dr. John Greaves lab at the University of California-
Urvine.  Chiral gas chromatography was performed on a Varian 3900 gas chromatograph 
using an Agilent Cyclosil-B 30 m × 0.256 µm ID × 0.25 µm column.  Data was processed 
with the Interactive Graphics 6.9 software and plotted using Microsoft Excel 2010.  High 
performance liquid chromatography was performed using a Varian 240 Prostar HPLC with 
programmable UV/Vis detector with the help of Erin Macri and WWU Scientific Technical 
Services.  HPLC spectra were processed with the Interactive Graphics 6.9 software and 
plotted using Microsoft Excel 2010.  Polarimetry experiments were performed using a 
Rudolph Digital digital polarimeter and calibration was checked with a d-menthol standard 






General Procedure A: Triflation 




Notebook Entry: PSA143, PSB030, PSB130, PSB162, PSB234, PSC032, PSC126, PSC235, 
PSC280, PSD010, PSD017 
 
LHMDS (1.06 M, 30.1 mL, 32.5 mmol) and THF (60 mL) were added to a 250 mL round 
bottom flask under Ar atmosphere brought to -78 ˚C in a dry ice/isopropanol bath.  Alkenone 
2.16 (3.16 g, 25 mmol) was added drop-wise to the reaction flask over the course of 30 min 
in a solution THF (13 mL).  The solution was stirred an additional 15 min before quick 
addition of PhNTf2 (9.38 g, 26.3 mmol) was added via cannula in a solution of THF (23 mL) 
and the mixture warmed to room temperature overnight.  The reaction was quenched with 
sat. NaHCO3 solution (50 mL) and diluted with hexanes (50 mL).  The combined organic 
layers were washed with H2O (2 × 50 mL) and sat. NaCl (1 × 50 mL) and combined organic 
layers were dried over anhydrous MgSO4.  The solution was filtered and concentrated using 
rotary evaporation.  Dienyl triflate 2.17 was isolated via flash chromatography (2¾” diameter 
column, 1 L reservoir, 19:1 hexanes:EtOAc) (3.71 g, 57%) as a yellow oil. 
1H NMR (CDCl3, 500 MHz): δ 5.10 (d, J = 3.4, 1 H, CH2=C), 5.08 (tt, J = 7.3, 1.5, 1 H, 
CH2-CH), 4.93 (dt, J = 3.4, 1.0, 1 H, CH2=C), 2.36 (t, J = 7.4, 2 H, C-CH2), 2.23 (app. q, J = 
6.8, 2 H, C-CH2-CH2), 1.70 (s, 3 H, CH3), 1.62 (s, 3 H, CH3). 
13C NMR (CDCl3, 125 MHz): δ 133.7, 121.5, 104.3, 33.9, 25.63, 25.59, 24.6, 17.7. 
FT-IR (Diamond ATR): 3092 (w), 2961 (w), 1715 (m), 1525 (m), 1350 (s), 1290 (s), 1268 
(s), 1194 (m), 1135 (m), 823 (m), 718 (s). 
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Notebook Entry: PSB034, PSB045, PSB117, PSB133, PSB140, PSB166, PSB270, PSC040, 
PSC236, PSC281, PSD012, PSD019 
 
Bis(pinacolato)diboron (0.917 g, 3.61 mmol), PdCl2(PPh3)2 (0.115 g, 0.164 mmol),  KOPh 
(0.651 g, 4.93 mmol) and PPh3 (0.0516 g, 0.197 mmol) were loaded into 100 mL round 
bottom flask and brought under Ar atmosphere.  Toluene (35 mL) and dienyl triflate 2.17 
(0.848 g, 3.28 mmol) were then added to reaction flask and the mixture was stirred at 60°C 
for 6 h.  DI H2O was added to the flask and the aqueous layer was extracted with hexanes (3 
× 20 mL).  The combined organic layers were washed with sat. NaCl (1× 20 mL) and dried 
over anhydrous MgSO4.  The solution was filtered, concentrated and purified by radial 
chromatography (4 mm plate, 8 mL/min, 6:1 hexanes:EtOAc) to give dienyl boronate ester 
2.18 (0.464 g, 92%). 
1H NMR (CDCl3, 500 MHz): δ 5.77 (d, J = 3.4, 1 H, CH2=C-Bpin), 5.60 (d, J = 3.4, 1 H,  
CH2=C-Bpin), 5.14 (t, J = 7.3, 1 H, CH2CH), 2.17 (m, 2H,), 2.11 (t, J = 7.8, 2 H, CH2-CH2), 
1.61 (s, 3 H, CH3), 2.57 (s, 3 H, CH3), 1.27 (s, 12 H, Bpin). 
13C NMR (CDCl3, 125 MHz): δ 131.4, 129.0, 124.4, 83.3, 35.6, 27.0, 25.7, 24.9, 24.82, 
24.78, 17.7. 












Notebook Entry: PSA135, PSA147 
A two-neck, 100 mL round bottom flask was charged with pyridinol 2.33 (0.839 g, 6.80 
mmol) and equipped with an addition funnel and rubber septum and brought under Ar 
atmosphere.  CH2Cl2 (30 mL) and NEt3 (1.07 mL, 7.70 mmol) were added to the reaction 
vessel and the solution was cooled in an ice/H2O bath.  The solution was allowed to stand for 
30 min before OTf2 (1.23 mL, 7.32 mmol) was added drop-wise to the mixture.  The reaction 
was warmed to room temperature overnight.  The solution was washed with sat. NH4Cl and 
the aqueous layer was extracted with CH2Cl2 (1 × 20 mL).  The combined organic layers 
were dried over Na2SO4, filtered, concentrated and purified by radial chromatography (6 mm 
plate, 1:2 hexanes:EtOAc) to give pyridyl triflate 2.34 (1.22 g, 70%). 
1H NMR (CDCl3, 500 MHz): δ 7.45 (d, J = 8.3, 1H, Ar-H), 7.08 (d, J = 8.3, 1H, Ar-H), 2.58 
(s, 3H, CH3), 2.56 (s, 3H, CH3). 
13C NMR (CDCl3, 125 MHz): δ 158.0, 150.6, 143.5, 129.0, 122.1, 117.3, 24.0, 19.5. 


















Notebook Entry: PSB021, PSB023 
A two-neck, 100 mL round bottom flask was charged with K3PO4 (1.25 g, 5.9 mmol) and 
Pd(PPh3)4 (0.1132 g, 0.098 mmol) and equipped with reflux condenser and septum.  The 
reaction flask was flushed with Ar, then dioxane (25 mL) and pyridyl triflate 2.35 (0.503 g, 
1.96 mmol in 5 mL dioxane) were added to reaction flask with stirring.  The solution allowed 
to stand for 15 min.  Dienyl boronate 2.18 (0.557 g, 2.35 mmol in 10 mL dioxane) was added 
to the reaction flask and the mixture was stirredstirred at 90 °C overnight.  The mixture was 
filtered over Celite®, concentrated under vacuum and purified by flash chromatography (1½” 
column, 500 mL reservoir, 3:1 hexanes:EtOAc) to produce coupled product 2.35 (0.905 g, 
4.45 mmol, 22.5%).    
1H NMR (CDCl3, 500 MHz): δ 7.24 (d, J = 7.6, 1 H, Ar-H), 6.92 d, J = 7.6, 1 H, Ar-H), 5.20 
(d, J = 1.8, 1 H, Ar-C=CH2), 5.07 (t, J = 7.3 1 H, CH2-CH), 4.88 (d, J = 1.8, 1 H, ArC-CH2), 
2.50 (s, 3 H, Ar-CH3), 2.47 (s, 3 H, Ar-CH3), 2.34 (t, J = 7.6, 2 H, CH2-CH2), 2.04 (m, 2 H, 
CH2-CH2), 1.66 (s, 3 H, CH3), 1.52 (s, 3 H, CH3). 
13C NMR (CDCl3, 125 MHz): δ 155.9, 154.6, 148.1, 136.4, 134.8, 132.0, 123.6, 120.1, 
115.0, 37.6, 26.3, 25.7, 24.2, 22.8, 17.7. 
FT-IR (Diamond ATR): 2967 (m), 2925 (m), 2856 (m), 1590 (s), 1465 (s), 1437 (s, br), 1375 







General Procedure C:  Suzuki Coupling58 
 




Notebook Entry: PSB122, PSB125, PSB134, PSB137, PSB148, PSB160, PSB182, PSB241, 
PSB291, PSC152, PSC223, PSC239, PSD016, PSD020 
 
A flame dried, 100 mL round bottom flask was charged with K2CO3 (3.41 g, 24.7 mmol), 
Ag2O (4.77 g, 20.6 mmol) and Pd(dppf)Cl2 (0.672 g, 0.823 mmol) equipped with septum and 
stir bar, and brought under Ar atmosphere.  Aryl iodide 2.38 (1.92 g, 8.23 mmol) and dienyl 
boronate 2.18 (2.04 g, 8.64 mmol) were added to the stirring solution which was then heated 
at 90 °C for 6 h.  The solution was filtered over Celite® and concentrated.  The crude organic 
solution was purified by flash chromatography (1 ½” diameter column, 500 mL reservoir, 3:1 
hexanes:EtOAc) to provide pyridyl diene 2.35 (1.43 g, 81%). 

















Notebook Entry: PSB051, PSB089 
A three-neck, 100 mL round bottom flask was equipped with a reflux condenser, addition 
funnel and septum and brought under Ar atmosphere.  The flask was charged with 
allylmagnesium chloride (2.0 M in THF, 20.0 mL, 40.0 mmol) and brought to rapid reflux.  
After reflux was established, 2,3-dibromopropene 2.41 (85%, 3.25 mL, 30.0 mmol) was 
added over the course of 1 h.  The reaction stirred under reflux for 2.5 h and then let stirred at 
room temperature overnight.  The reaction was quenched with 10% HCl solution slowly 
drop-wise (CAUTION! vigorous reaction) and the aqueous phase was extracted with diethyl 
ether (3 × 30 mL).  The combined organic layers were dried over anhydrous CaCl2.  The 
crude organic solution was filtered, concentrated, and purified by vacuum distillation (bp = 
40-43 °C at 39 mmHg) to provide dienyl bromide 2.36 (2.40 g, 50%). 
1H NMR (CDCl3, 500 MHz): δ 5.79 (ddt, J = 10.0, 6.5, 1.8, 1 H, CH2-CH), 5.58 (d, J = 1.2, 
1 H, CH=CH2), 5.42 (d, J = 1.2, 1 H, CH=CH2), 5.07 (dd, J = 10.6, 1.2, 1 H, C=CH2), 5.01 
(dd, J = 17.0, 1.8, 1 H, C=CH2), 2.51 (t, J = 6.8, 2 H, C-CH2), 2.32 (dt, J = 7.1, 2 H, CH2-
CH2). 














Notebook Entry: PSB074, PSB094 
A two-neck, 50 mL round bottom flask was equipped with a stir bar, thermometer and 
septum and brought under Ar atmosphere.  Dienyl bromide 2.36 (0.805 g, 5.00 mmol) in a 
solution of THF (9 mL) was added to the flask and cooled with a dry ice/isopropanol bath.  
The solution allowed to stir for 0.5 h before drop-wise addition of t-BuLi (1.6 M, 6.25 mL, 
10.0 mmol) followed by an additional 0.5 h of stirring.  pinBi-OPr (1.40 g, 7.50 mmol) was 
added in a solution of THF (6 mL) and the reaction flask was allowed to slowly warm to 
room temperature overnight.  The reaction was quenched with H2O (10 mL), the aqueous 
layer extracted with CH2Cl2 (3 × 15 mL), and combined organics layers were dried over 
anhydrous MgSO4.  The crude organic solution was filtered through a Celite
® plug and 
concentrated.  The product was purified by flash chromatography (1½” diameter column, 500 
mL reservoir, 9:1 hexanes:EtOAc) to provided boronate ester 2.40 (0.589 g, 57%). 
1H NMR (CDCl3, 500 MHz): δ 5.82 (m, 1 H, CH=CH2), 5.79 (d, J = 3.9, 1 H, C=CH2), 5.62 
(s, 1 H, C=CH2), 5.0 (dd, J = 17.1, 2.0, 1 H, CH=CH2), 4.94 (dd, J = 10.3, 1.5, 1 H, 
CH=CH2), 2.22 (m, 4 H, CH2-CH2), 1.27 (s, 12 H, Bpin). 












Notebook Entry: PSB092, PSB105 
A 50 mL round bottom flask was charged with Mg turnings (0.350 g, 14.4 mmol) and 
sublimed I2 (7 crystals) and equipped with a stir bar and septum.  The flask then brought 
under Ar atmosphere at which time THF (20 mL) was added.  The solution stirred until most 
of the original color had disappeared.  HBpin (3.15 g, 24.6 mmol) was then added followed 
by addition of dienyl bromide 2.36 (1.93 g, 12.0 mmol) over 5 min and the mixture stirred 
for 3 h.  The reaction was quenched with 10% HCl (5 mL) and extracted with diethyl ether (2 
x 10 mL).  The combined organic layers washed were with sat. NaCl (1 x 15 mL) and dried 
over MgSO4.  The crude organic solution was then filtered and concentrated under vacuum.  
Purification by radial chromatography (4 mm plate, 8 ml/min, 3:1 hexanes:EtOAc) provided 
boronate 2.40 (0.857 g, 34%). 














Notebook Entry: PSB103, PSB112, PSB129, PSB154 
A 25 mL screw-top culture tube was equipped with stir a bar and septum and brought under 
Ar atmosphere.  The flask was charged with pyridyl bromide 2.37 (1.13 g, 6.00 mmol) and 
dioxane (6 mL).  The septum was briefly removed and copper (I) iodide (0.059 g, 0.300 
mmol), NaI (1.88 g, 12.0 mmol) and N,N-(dimethyl)cyclohexyldiamine (0.084 g, 0.600 
mmol) were quickly added to the stirring solution.  The septum was replaced with a screw 
cap and the reaction was heated at 110 °C for 24 h.  The reaction was allowed to cool to 
room temperature before dilution with sat. NH4Cl (5 mL).  The solution was poured into H2O 
(20 mL), followed by extraction of the aqueous layer with CH2Cl2 (3 × 15 mL).  The 
combined organic layers were dried over anhydrous Na2SO4.  The crude organic solution was 
filtered and concentrated, then purified by radial chromatography (6 mm plate, 10 mL/min 
1:1 hexanes:EtOAc) to provide pyridyl iodide 2.38 (1.19 g, 85%). 
1H NMR (CDCl3, 500 MHz): δ 7.90 (d, J = 7.9, 1 H, Ar-H), 6.70 (d, J = 7.9, 1 H, Ar-H), 
2.70 (s, 3 H, Ar-CH3), 2.48 (s, 3 H, Ar-CH3). 
13C NMR (CDCl3, 125 MHz): δ 159.3, 157.4, 146.5, 122.2, 92.4, 28.9, 23.9. 
FT-IR (Diamond ATR):  2918 (w), 1557 (m), 1420 (s), 1016 (s), 811 (s). 












Notebook Entry: PSB158, PSB163, PSB165, PSB271 
A flame dried, 250 mL, three-neck round bottom flask was equipped thermometer/adapter 
and reflux condenser. Fuming sulfuric acid (oleum; 60%, 35 mL) was added to the flask and 
cooled in an ice/H2O bath.  2,6-Lutidine 2.41 (7.28 mL, 62.5 mmol) was added to the flask in 
portions as to not exceed a solution temperature of 40 °C.  The solution was then heated to 50 
°C at which time sublimed I2 (19.8 g, 78.1 mmol) was added.  The reaction was heated to 
200 °C and stirred for 4 h.  The reaction was cooled to room temperature and poured over 
400 mL crushed ice in a 1 L Erlenmeyer flask.  The flask was cooled in an ice bath followed 
by quenching with NaOH pellets (~50 g, ~10 g/5 min with swirling) (CAUTION: highly 
exothermic reaction).  Steam distillation of the crude mixture was performed and the 
collected distillate was extracted with ether (2 × 100 mL).  The combined organic layers 
dried were over anhydrous MgSO4, filtered and concentrated.  Purification via flash 
chromatography (1½” diameter column, 500 mL reservoir, 3:1 hexanes:EtOAc) provided 
pyridyl iodide 2.38 (2.10 g, 15%). 













Notebook Entry: PSC142, PSC147, PSC170, PSC196, PSC218, PSD014, PSD018 
A two-neck, 100 mL round bottom flask was equipped with a stir bar and thermometer/ 
adapter and charged with p-TsOH∙H2O (4.69 g, 24.6 mmol) and MeCN (35 mL).  The 
solution was cooled in an ice/H2O bath at which time aryl amine 2.42 (1.00 g, 8.18 mmol) 
was added and a suspension of amine salt precipitated.  Meanwhile, a solution of NaNO2 
(1.14 g, 16.4 mmol) and KI (3.96 g, 20.5 mmol) in DI H2O (5.25 mL) was prepared.  This 
solution was added to the amine salt solution drop-wise as to keep the internal temperature 
below 10 °C.  The solution was stirred for 10 min in the ice-bath and stirred at rt  for 1 h. The 
reaction mixture was diluted with DI H2O (50 mL) and diethyl ether (30 mL).  The obtained 
organic layer was washed with sat. NaHCO3 (1 × 30 mL) and sat. Na2S2O3 (2 × 30 mL) 
solutions.  The combined organic layers were dried over anhydrous Na2SO4, then filtered 
and.  The crude material was purified by flash chromatography (1½” diameter column, 500 
mL reservoir, 3:1 hexanes:EtOAc) to give pyridyl iodide 2.38 (1.10 g, 58%) as light yellow 
oil. 

















Notebook Entry: PSD025 
 
A 250 mL round bottom flask containing pyridyl diene 2.35 (1.33 g, 6.16 mmol) was charged 
with AD mix-α (8.63 g, 1.4 g/mmol), MeSO2NH2 (0.762 g, 8.01 mmol), DI H2O (31 mL) 
and t-BuOH (31 mL).  The solution was initially stirred in an ice/H2O bath and allowed to 
warm gradually to rt for 24 h.  The reaction was quenched with Na2SO3 (~8 eq.) and stirred 
for 15 min before removal of t-BuOH by rotary evaporation under vacuum.  The solution was 
diluted with H2O and extracted with EtOAc (2 × 50 mL). The combined organic layers were 
dried over MgSO4, concentrated and purified by flash chromatography (1½” diameter 
column, 500 mL reservoir, 5% EtOH in EtOAc) to provide pyridyl diol 2.43 (0.80 g, 52%).  
1H NMR (CDCl3, 500 MHz): δ 7.25 (d, J = 8.22, 1 H, Ar-H), 6.93 (d, J = 7.6, 1 H, Ar-H), 
5.24 (s, 1 H, C=CH2), 4.92 (s, 1 H, C=CH2), 3.38 (dd, J = 10.6, 2.4, 1 H, CH-OH), 2.65 (m, 
1 H, C-CH2), 2.51 (s, 3 H, Ar-CH3), 2.49 (s, 3 H, Ar-CH3), 2.40 (m, 2 H, C-CH2), 1.87 (s, br, 
1 H, OH), 1.50 (m, 1 H, CH2-CH2), 1.41 (m, 1 H, CH2-CH2), 1.16 (s, 3H, CH3), 1.12 (s, 3H, 
CH3). 
13C NMR (CDCl3, 125 MHz): δ 156.3, 154.8, 148.0, 136.6, 134.8, 120.6, 115.7, 73.2, 34.8, 
29.9, 26.7, 24.3, 23.2, 22.8, 14.2. 
FT-IR (Diamond ATR): 3355 (w, br), 2952 (w), 2668 (w), 1394 (w), 831 (s) 
HRMS (ESI, M+Na) Calculated for C15H23NNaO2: 272.1627. Found: 272.1623. 
[α]𝟐𝟎
𝑫










Notebook Entry: PSB124, PSB126, PSB150, PSB161, PSB188, PSB242, PSB292, PSC153, 
PSC225, PSC240 
 
In accordance with General Procedure D, a 250 mL round bottom flask containing pyridyl 
diene 2.35 (1.07 g, 4.95 mmol) was charged with AD mix-β (4.85 g, 1.0 g/mmol), 
MeSO2NH2 (0.612 g, 6.34 mmol), DI H2O (50 mL) and t-BuOH (50 mL).  The solution was 
stirred at rt for 24 h.  Purification by flash chromatography (1½” diameter column, 500 mL 
reservoir, 5% EtOH in EtOAc) provided pyridyl diol 2.43 (1.22 g, 70%).  

























Notebook Entry: PSD026 
 
Pyridyl diol 2.43 (0.72 g, 2.88 mmol), NEt3 (0.80 mL, 5.76 mmol) and CH2Cl2 (29 mL) were 
charged to a 100 mL round bottom flask and brought under Ar atmosphere.  The solution was 
cooled in an ice/H2O bath before MsCl (0.42 mL, 4.32mmol) was added drop-wise.  The 
mixture was allowed to warm to room temperature while being monitored by TLC.  After 
~30 min, MeOH (29 mL) and K2CO3 (1.59 g, 11.52 mmol) were added and the mixture was 
stirred at rt overnight.  The reaction was then filtered over Celite® and washed with sat. 
NaCl (1 × 100 mL) and extracted with CH2Cl2 (3 × 50 mL).  The combined organic layers 
were dried over anhydrous MgSO4, filtered and concentrated.  Purification by flash 
chromatography (2 ¾” diameter column, 1 L reservoir, 1:1 hexanes:EtOAc) provided 
epoxide 2.31 (0.38 g, 57%). 
1H NMR (CDCl3, 500 MHz): δ 7.28 (d, J = 7.8, 1 H, Ar-H), 6.95 (d, J = 7.8, 1 H, Ar-H), 
5.28 (app. dd, J = 2.7, 1.46, 1 H, C=CH2), 4.94 (d, J = 1.5, 1 H, C=CH2), 2.74 (dd, J = 7.3, 
5.4, 1 H, CH2-CH-C) 2.42 (s, 3 H, Ar-CH3), 2.41 (s, 3 H, Ar-CH3), 2.40 (m, 2 H, C-CH2), 
1.60 (m, 2 H, CH2-CH2), 2.24 (s, 3 H, CH3), 2.21 (s, 3 H, CH3). 
13C NMR (CDCl3, 125 MHz): δ 156.2, 154.5, 147.3, 136.4, 134.4, 120.2, 115.4, 63.8, 58.3, 
34.4, 27.2, 24.8, 24.2, 22.8, 18.7. 
FT-IR (Diamond ATR): 2961 (m), 2925 (m), 1590 (m), 1458 (m), 1174 (m), 839 (s) 
HRMS (CI+) Calculated for C15H22NO: 232.1701. Found: 232.1700. 
[α]𝟐𝟎
𝑫
 = +10.3° (c = 0.32, l = 0.10 dm, CHCl3). 
Chiral GC analysis: Hold at 140 °C for 120 min. Retention times: 63.650 (major 









Notebook Entry: PSB128, PSB142, PSB146, PSB157, PSC157, PSC227, PSC241 
 
In accordance with General Procedure E, pyridyl diol 2.43 (1.08 g, 4.31 mmol), NEt3 (0.84 
mL, 6.03 mmol) and CH2Cl2 (43 mL) were charged to a 25 mL round bottom flask and 
brought under Ar atmosphere.  The solution was cooled in an ice/H2O bath before MsCl 
(0.55 mL, 5.60 mmol) was added drop-wise.  The mixture was allowed to warm to room 
temperature while being monitored by TLC.  After ~1 h, MeOH (43 mL) and K2CO3 (2.38 g, 
17.2 mmol) were added and the mixture was stirred at rt overnight.  Purification by flash 
chromatography (1” diameter column, 250 mL reservoir, 5% EtOH in EtOAc) provided 
epoxide 2.31 (0.707 g, 71%). 
(For spectroscopic characterization data, see page 92) 
 [α]𝟐𝟎
𝑫
 = -6.9° (c = 0.34, l = 0.10 dm, CHCl3). 
Chiral GC analysis: Hold at 140 °C for 120 min.  Retention times: 61.714 (major 




















Notebook Entry: PSD030 
 
A 100 mL round bottom flask was charged with pyridyl epoxide 2.31 (0.28 g, 1.22 mmol) 
and brought under Ar atmosphere.  The epoxide was dissolved in THF (24.5 mL) and the 
solution was cooled in a dry ice/isopropanol bath before n-BuLi (1.6 M, 2.29 mL, 3.67 
mmol) was added drop-wise.  One additional 1.0 eq. aliquot of n-BuLi was added 15 min 
later.  The solution was allowed to gradually warm to room temperature with stirring and 
then quenched with sat. NaHCO3.  The aqueous layer was extracted with diethyl ether (3 x 50 
mL), dried over anhydrous MgSO4, filtered and concentrated.  Purification by flash 
chromatography (1” diameter column, 250 mL reservoir, 5% EtOH in EtOAc) provided the 
cyclized material 2.32 (0.092 g, 33%) as a light yellow oil. 
1H NMR (CDCl3, 500 MHz): δ 7.44 (d, J = 7.8, 1 H, Ar-H), 6.96 (d, J = 7.8, 1 H, Ar-H), 
5.12 (app. s, 1 H, C=CH2), 5.10 (d, J = 2.0, 1 H, C=CH2), 3.19 (app dt, J = 15.1, 2.0, 1 H, 
Ar-CH2), 2.87 (dd, J = 14.7, 9.3, 1 H, Ar-CH2), 2.63 (ddd, J = 13.7, 7.8, 4.9, 1 H, Ar-C-
CH2), 2.51 (s, 3 H, Ar-CH3), 2.40 (ddd, J = 13.2, 8.8, 3.9, 1 H, Ar-C-CH2), 1.87 (s, br, 1 H, 
OH), 1.78 (dddd, J = 11.2 9.3, 3.9, 2.0, 1 H, CH2-CH-CH2), 1.60 (m, 2 H, C-CH2-CH2) 
13C NMR (CDCl3, 125 MHz): δ 158.0, 156.2, 148.6, 135.7, 120.9, 114.2, 110.0, 73.4, 47.2, 
39.4, 34.3, 30.9, 27.8, 26.3, 24.1. 
HRMS (CI+) Calculated for C15H22NO: 232.1701. Found: 232.1709. 
[α]𝟐𝟎
𝑫










Notebook Entry: PSB221, PSB248, PSB250, PSC023, PSC029, PSC161, PSC215 PSC231, 
PSC243 
 
In accordance with General Procedure F, a 50 mL round bottom flask was charged with 
pyridyl epoxide 2.31 (0.108 g, 0.467 mmol) and brought under Ar atmosphere.  The epoxide 
was dissolved in THF (9.3 mL) and the solution was cooled in a dry ice/isopropanol bath 
before n-BuLi (1.6 M, 0.29 mL, 0.467 mmol) was added drop-wise.  Two additional 1.0 eq. 
aliquots of n-BuLi were added at 15 min intervals.  Purification by flash chromatography (1 
½” diameter column, 500 mL reservoir, 5% EtOH in EtOAc) provided the cyclized material 
2.32 (0.037 g, 35%) as a light yellow oil. 
(For spectroscopic characterization data, see page 95) 
[α]𝟐𝟎
𝑫














General Procedure G: Wilkinson’s Hydrogenation 
 
Preparation of 2-((5R,8R)-2,5-dimethyl-6,7,8,9-tetrahydro-5H-





Notebook Entry: PSB231, PSB264, PSC219 
All reagents and equipment were initially brought under nitrogen atmosphere in a glovebox.  
Wilkinson’s catalyst (0.018 g, 0.020 mmol) was charged to a 90 mL Fischer-Porter tube.  
Cananodine precursor 2.32 (0.092 g, 0.40 mmol) was dissolved in a 9:1 THF:EtOH (8 mL) 
solution and added to the Fischer-Porter tube, followed by NEt3 (83 µL, 0.59 mmol).  The 
Fischer-Porter tube pressure regulator and adapter were then assembled, brought outside the 
glovebox, charged with 50 psi H2 gas and allowed to stir overnight.  The pressure was 
released from the vessel and the solution was filtered through a plug of silica and 
concentrated under vacuum to provide a crude mixture of 1.10 and 1.10a (0.045 g, 49%, ~1:1 
mixture). 
1H NMR 1.10 (CDCl3, 500 MHz): δ 7.39 (d, J = 7.8, 1 H, Ar-H), 6.94 (d, J = 7.8, 1 H, Ar-), 
3.22 (dd, J = 13.6, 3.9, 1 H, Ar-CH2), 3.00 (m, 1 H, Ar-CH), 2.92 (dd, J = 12.2, 11.7, 1 H, 
Ar-CH2), 2.51 (s, 3 H, Ar-CH3), 2.14 (m, 1 H, Ar-CH-CH2-CH2), 1.90 (m, 1 H, Ar-CH-
CH2), 1.79 (m, 1 H, Ar-CH-CH2-CH2), 1.61 (qd, J = 12.2, 3.4, 1 H, Ar-CH2-CH), 1.44 (m, 1 






13C NMR 1.10 (CDCl3, 125 MHz): δ 161.0, 154.3, 137.8, 132.3, 120.6, 73.3, 48.0, 39.9, 
36.1, 35.3, 32.5, 27.5, 26.2, 24.0, 20.7. 
1H NMR 1.10a (CDCl3, 500 MHz): δ 7.30 (d, 1 H, Ar-H), 6.95 (d, 1 H, Ar-H), 3.24 (dd, 1 
H, Ar-CH2), 3.00 (m, 1 H, Ar-CH), 2.90 (dd, 1 H, Ar-CH2), 2.50 (s, 3 H, Ar-CH3), 2.02 (m, 
1 H, Ar-CH-CH2-CH2), 1.89 (m, 1 H, Ar-CH-CH2), 1.73 (m, 1 H, Ar-CH-CH2-CH2), 1.61 
(m, 1 H, Ar-CH2-CH), 1.44 (m, 1 H, Ar-CH-CH2), 1.33 (d, 3 H, Ar-CH-CH3), 1.28 (s, 3 H, 
C-(CH3)2(OH)), 1.26 (s, 3 H, C-(CH3)2-OH). 
13C NMR 1.10a (CDCl3, 500 MHz): δ 159.4, 154.6, 133.7, 127.7, 120.9, 73.7, 47.3, 39.5, 
36.5, 36.5, 33.8, 27.4, 26.8, 25.9, 18.6. 






























Notebook Entry: PSB231, PSB264, PSC219 
In accordance with General Procedure G, all reagents and equipment were initially brought 
under nitrogen atmosphere in a glovebox.  Wilkinson’s catalyst (0.0023 g, 0.0025 mmol) was 
charged to a 90 mL Fischer-Porter tube.  Cananodine precursor 2.32 (0.011 g, 0.049 mmol) 
was dissolved in a 9:1 THF:EtOH (1 mL) mixture and added to the Fischer-Porter tube, 
followed by NEt3 (10 µL, 0.074 mmol).  The Fischer-Porter tube pressure regulator and 
adapter were then assembled, brought outside the glovebox, charged with 50 psi H2 gas and 
allowed to stir overnight.  The pressure was released from the vessel and the solution was 
filtered through a plug of silica and concentrated under vacuum to provide a crude mixture of 
1.10b and 1.10c (0.015 g, 23%, ~2:1 mixture). 











General Procedure H: Alkynol Chlorination 
 
Preparation of 1-chlorobut-2-yne84 
 
 
Notebook Entry: PSA011, PSA026, PSA034, PSA044, PSA070, PSA118, PSB061, PSC035, 
PSC177 
 
SOCl2 (10.9 mL, 0.150 mol), pyridine (14 drops), and diethyl ether (50 mL) were added to a 
three neck, 100 mL round bottom flask, equipped with a reflux condenser and addition 
funnel, and brought to reflux.  2-Butyn-1-ol (7.48 mL, 0.100 mol) was added over the course 
of 1 h.  The solution refluxed for 5 h.  The ether was then distilled off and the remaining 
solution transferred to a 25 mL round bottom flask.  The remaining solution was then 
distilled (bp = 101 °C at 760 mmHg) to provide 2.51 as a colorless oil (8.06 g, 91%). 
1H NMR (CDCl3, 500 MHz): δ 4.12 (q, J = 2.9, 2 H, Cl-CH2), 1.85 (t, J = 2.9, 3 H, C-CH3). 




















Notebook Entry: PSA020, PSA035, PSA045, PSA048, PSA051, PSA117, PSB072, PSB267, 
PSC139, PSC178 
 
In accordance with General Procedure H, SOCl2 (10.9 mL, 0.150 mol), pyridine (14 drops), 
and ether (50 mL) were brought reflux with stirring, and 2-pentyn-1-ol (9.19 mL, 0.100 mol) 
was added over the course of 1 h.  After work-up, the product 2.52 was isolated by 
distillation (bp = 121 at 760 mmHg) as a colorless oil (9.14 g, 90%). 
1H NMR (CDCl3, 500 MHz): δ 3.56 (t, J = 7.5, 2 H, Cl-CH2), 2.59 (qt, J = 7.5, 2.3, 2 H, 















General Procedure I: α-Substitution with 2,4-pentanedione85 
Preparation of hept-5-yn-2-one84 
 
Notebook Entry: PSA014, PSA032, PSA036, PSA046, PSA072, PSA120, PSB067, PSC042, 
PSC181 
 
Chloroalkyne 2.51 (4.40 g, 49.0 mmol), K2CO3 (7.45 g, 54.0 mmol), 2,4-pentanedione (5.50 
mL, 54.0 mmol), and EtOH (50 mL) were combined and refluxed for 24 h in a 100 mL round 
bottom flask with stirring.  After reflux the excess EtOH, and formed EtOA were distilled 
off.  The remaining salt solution was dissolved in 60 mL ice H2O, extracted with diethyl 
ether (4 × 10 mL) and the combined organic layers were washed with sat. NaCl (2 × 10 mL).  
The organic solution was then dried over anhydrous K2CO3, filtered and concentrated.  
Alkynone 2.53 was isolated by vacuum distillation (B.P. = 79-82 °C at 30 mmHg) as a clear 
colorless liquid (5.22 g, 64%). 
1H NMR (CDCl3, 500 MHz): δ 2.63 (t, J = 7.0, 2 H, C-CH2), 2.39 (tq, J = 5.1, 2.6, 2 H, CH2-
CH2), 2.17 (s, 3 H, H3C-C=O), 1.76 (t, J = 5.1, 3 H, C≡C-CH3). 
13C NMR (CDCl3, 125 MHz): δ 207.0, 58.3, 42.8, 29.9, 13.4, 3.4. 












Preparation of oct-5-yn-2-one84 
 
 
Notebook Entry: PSA022, PSA038, PSA047, PSA049, PSA052, PSA119, PSB079, PSC144, 
PSC182 
 
In accordance with General Procedure I, chloro-alkyne 2.52 (7.77 g, 0.0770 mol), K2CO3 
(11.6 g, 0.0841 mmol), 2,4-pentanedione (8.63 mL, 0.0841 mol), and EtOH (50 mL) were 
combined and refluxed for 24 h in a 100 mL round bottom flask with stirring.  After work-up 
and distillation (B.P. = 85-94 °C at 36 mmHg), alkynone 2.54 was isolated as a clear, 
colorless oil (6.37 g, 67%). 
1H NMR (CDCl3, 500 MHz): δ 2.64 (t, J = 6.9, 2 H, O=C-CH2), 2.41 (tt, J = 7.7, 2.2, 2 H, 
CH2-CH2), 2.17 (s, 3 H, O=C-CH3), 2.13 (qt, J = 7.7, 2.2, 2 H, CH2-CH3), 1.01 (t, J = 7.7, 3 
H, CH2-CH3). 
13C NMR (CDCl3, 125 MHz): δ 207.1, 82.2, 77.8, 43.0, 29.9, 14.2, 13.4, 12.3. 














General Procedure J: Pd/BaSO4 Semi-Hydrogenation of Alkynes 
Preparation of (Z)-hept-5-en-2-one86 
 
Notebook Entry: PSA042, PSA053, PSA074, PSC048, PSC184 
Alkynone 2.53 (3.22 g, 29.0 mmol), Pd/BaSO4 catalyst (0.643 g, 20 wt%), quinoline (0.294 
mL, 10 wt.%) and EtOAc (100 mL) were combined in a 250 mL round bottom flask with 
stirring.  The flask was fitted with a rubber septum and flushed with Ar for 5 min.  The flask 
was then flushed with H2 gas using a hydrogen balloon.  Another hydrogen balloon attached 
to the flask and the mixture was stirred for 1.5 h.  The flask was then flushed with Ar, and 
filtered over Celite®.  Alkenone 2.55 was obtained after rotary evaporation (3.28 g, 99%).   
1H NMR (CDCl3, 500 MHz): δ 5.48 (dqt, J = 9.9, 6.74, 1.6, 1 H, CH=CH), 5.33 (dtq, J = 
9.9, 7.3, 1.6, 1 H, CH=CH), 2.48 (t, J = 7.3, 2 H, O=C-CH2), 2.32 (app. q, J = 7.3, 2 H CH2-
CH), 2.16 (s, 3 H, CH3-C=O), 1.62 (dd, J = 6.74, 1.0, 3 H, CH-CH3)\ 
13C NMR (CDCl3, 125 MHz): δ 208.6, 128.5, 125.1, 43.4, 29.9, 21.3, 12.6. 














Preparation of (Z)-oct-5-en-2-one87 
 
 
Notebook Entry: PSA054, PSA055, PSA064, PSA139, PSB091, PSC146, PSC185 
In accordance with General Procedure J, alkynone 2.54 (2.39 g, 19.2 mmol), Pd/BaSO4 
catalyst (0.478 g, 20 wt.%), quinoline (0.24 mL, 2.1 mmol, 10 wt.%) and EtOAc (75 mL) 
were combined in a 250 mL round bottom flask with stirring under H2 atmosphere.  
Alkenone 2.56 was obtained after work-up and concentration (2.40 g, 99%).   
1H NMR (CDCl3, 125 MHz): δ 5.40 (dtt, J = 10.7, 7.3, 1.5, 1 H, CH=CH), 5.28 (dtt, 10.7, 
7.3, 1.5, 1 H, CH=CH), 2.48 (t, J = 7.8, 2 H, O=C-CH2), 2.31 (app. q, J = 7.3, 2 H CH2-
CH2), 2.14 (s, 3 H, H3C-C=O), 2.05 (dqd, J = 7.3, 7.3, 1.5, 2 H, CH2-CH3), 0.96 (t, J = 7.3, 3 
H, CH2-CH3). 






















Notebook Entry: PSA060, PSA114, PSB102, PSC053, PSC186 
In accordance with General Procedure A, LHMDS (1.06 M, 33.0 mL, 34.9 mmol) and THF 
(60 mL) were added to a 250 mL round bottom flask under Ar atmosphere and cooled in a 
dry ice/isopropanol bath with stirring for 15 min.  Heptenone 2.55 (3.02 g, 26.9 mmol) was 
added drop-wise to the reaction flask over the course of 0.5 h in a solution THF (15 mL).  
The solution was stirred for an additional 15 min before quick addition of PhNTf2 (10.1 g, 
28.2 mmol) was added via cannula and the mixture warmed to room temperature overnight.  
Dienyl triflate 2.57 (2.92 g, 44%) was isolated via flash chromatography (1½” diameter 
column, 500 mL reservoir, 19:1 hexane:EtOAc) as a yellow oil. 
1H NMR (CDCl3, 500 MHz): δ 5.57 (dqt, J = 10.7, 7.3, 1.5 Hz, 1 H, CH=CH), 5.36 (dtq, J = 
10.7, 7.2, 1.5, 1 H, CH=CH), 5.14 (d, J = 3.4, 1H, CH2=C-OTf), 4.97 (dt, J = 3.4, 1.0, 1 H, 
CH2=C-OTf), 2.42 (t, J = 7.3, 2 H, TfO-C-CH2), 2.33 (app. q, J = 7.3, 2 H, CH2-CH2), 1.66 
(m, 3 H, CH2CH3). 
13C NMR (CDCl3, 125 MHz): δ 156.4, 127.6, 126.2, 120.2, 104.3, 34, 24, 13. 
FT-IR (Diamond ATR): 3020 (w), 2923 (w), 1670 (w), 1416 (m), 1248 (w) 1205 (s), 1140 
(m), 883 (m), 693 (m). 













Notebook Entry: PSA063, PSA073, PSA144, PSB042, PSB102, PSC154, PSC187 
In accordance with General Procedure A, LHMDS (1.06 M, 46.2 mL, 49.0 mmol) and THF 
(90 mL) were added to a 500 mL round bottom flask under Ar atmosphere and stirred while 
cooling in a dry ice/isopropanol bath for 15 min.  Octenone 2.56 (4.76 g, 37.7 mmol) was 
added drop-wise to the reaction flask over the course of 0.5 h in a solution of THF (20 mL).  
The solution stirred an additional 15 min before quick addition of PhNTf2 (14.1 g, 39.6 
mmol) was added via cannula and the mixture warmed to room temperature overnight.  
Dienyl triflate 2.58 (4.04 g, 41%) was isolated via flash chromatography (2¾” diameter 
column, 1 L reservoir, 19:1 hexane:EtOAc) as a yellow oil. 
1H NMR (CDCl3, 500 MHz): δ 5.50 (dtt, J = 7.4, 3.4, 2.0 1 H, CH=CH), 5.30 (dtt, J = 7.3, 
3.4, 2.0, 1 H, CH=CH), 5.14 (d, J = 3.9, 1 H, CH2=C-OTf), 4.95 (dt, J = 3.4, 1.0, 1 H, 
H2C=C-OTf), 2.40 (t, J = 6.8, 2 H, TfO-C-CH2), 2.30 (app. q, J = 7.8, 2 H, CH2-CH2), 2.05 
(m, 2 H, CH2-CH2), 0.97 (t, J = 7.8, 3 H, CH2-CH3). 
13C NMR (CDCl3, 125 MHz): δ 156.3, 133.9, 125.8, 104.5, 33.9, 23.7, 20.5, 14.2. 















Notebook Entry: PSC190 
In accordance with General Procedure D, AD mix-α (4.09 g, 1.00 g/mmol), 
methanesulfonamide (0.506 mg, 5.32 mmol), dienyl triflate 2.57 (1.01 g, 4.09 mmol), DI 
H2O (20 mL) and t-BuOH (20 mL) were added to a 100 mL round bottom flask containing 
2.57, and stirred while cooling in an ice/H2O bath.  The crude organic material was purified 
by flash chromatography (1½” diameter column, 500 mL reservoir, 1:1 hexanes:EtOAc) to 
give diol  2.61 (0.607 mg, 53%) as a viscous, light yellow oil.  
1H NMR (CDCl3, 500 MHz): δ 5.15 (d, J = 3.4, 1 H, C=CH2), 5.02 (d, J = 3.9, 1 H, C=CH2), 
3.86 (m, 1 H, CH-CH), 3.65 (m, 1 H, CH-CH), 2.66 (ddd, J = 15.6, 9.3, 4.9, 1 H, CH2-CH2), 
2.46 (ddd, J = 16.6, 9.3, 7.3, 1 H, CH2-CH2), 1.95 (s, 2 H, OH), 1.72 (m, 1 H, CH2-CH2), 
1.65 (m, 1 H, CH2-CH2), 1.20 (d, J = 6.3, 3 H, CH3). 
13C NMR (CDCl3, 125 MHz): δ 156.5, 118.4, 74.0, 73.4, 70.4, 30.6, 27.8, 17.1. 
FT-IR (Diamond ATR):  3374 (w, br), 2977 (w), 1671 (w), 1411 (m), 1204 (s), 1139 (s), 895 
(s), 611 (s). 















Notebook Entry: PSA133, PSA149, PSB110, PSC160, PSC191 
In accordance with General Procedure D, AD mix-β (2.95 g, 1g/mmol), MeSO2NH2 (0.201 g, 
2.11 mmol) dienyl triflate 2.58 (0.544 g, 2.11 mmol), DI H2O (10 mL) and t-BuOH (10 mL) 
and were combined in a 50 mL round bottom flask.  Light yellow oil, diol 2.62 (0.412 g, 
63%) was obtained after work-up and flash chromatography (1½” diameter column, 500 mL 
reservoir, 1:1 hexanes:EtOAC).  
1H NMR (CDCl3, 500 MHz): δ 5.15 (d, J = 3.9, 1 H, C=CH2), 5.02 (d, J = 3.9, 1 H, C=CH2), 
3.66 (m, 1 H, CH-CH), 3.60 (m, 1 H, CH-CH), 2.66 (ddd, J = 15.6, 9.3, 5.4, 1 H, CH2-CH2), 
2.46 (ddd, J = 16.1, 9.3, 7.3, 1 H,  CH2-CH2), 1.71 (m, 2 H, CH-CH2), 1.52 (m, 2 H, CH2-
CH2), 1.03 (t, J = 7.3, 3 H, CH3). 
13C NMR (CDCl3, 125 MHz): δ 156.6, 118.6, 76.1, 75.8, 72.8, 30.5, 27.4, 24.7, 10.2. 
FT-IR (Diamond ATR):  3382 (w, br), 2969 (w), 1670 (w), 1412 (m), 1204 (s), 1139 (m), 
897 (m), 610 (m). 











General Procedure K: 1,2-Diol Protection 
 





Notebook Entry: PSC194 
Diol 2.61 (0.567 g, 2.04 mmol), R-(-)-camphorsulfonic acid (0.0388 g, 0.204 mmol), 
dimethoxypropane (5.00 mL, 40.8 mmol), and acetone (4 mL) were combined in a 25 mL 
round bottom flask equipped with a stir bar, and the solution was stirred at room temperature 
for 30 min.  The mixture was then concentrated and purified by flash chromatography (2½” 
diameter column, 1 L reservoir, 12:1 hexanes:EtOAc) to give compound 2.63 (0.495 g, 
76%). 
1H NMR (CDCl3, 500 MHz): δ 5.16 (d, J = 3.4, 1 H, C=CH2), 5.02 (d J = 3.9, 1 H, C=CH2), 
4.32 (m, 1 H, CH-CH), 4.05 (m, 1 H, CH-CH), 2.63 (ddd, J = 15.1, 9.8, 5.4, 1 H, CH2-CH2),  
2.42 (ddd J = 16.1, 9.3, 6.3 Hz, 1 H, CH2-CH2), 1.67 (m, 2 H, CH2-CH2), 1.46 (s, 3 H, C-
CH3) 1.36  (s, 3 H, C-CH3), 1.21 (d, J = 6.3, 3 H, CH-CH3). 
13C NMR (CDCl3, 125 MHz): δ 156.3, 118.2, 107.8, 104.6, 76.8, 76.5, 73.4, 30.8, 28.3, 26.8, 
15.2. 
FT-IR (Diamond ATR):  2986 (w), 1670 (w), 1415 (m), 1205 (s), 1139 (m), 897 (m). 
HRMS (ESI, M+Na) Calculated for C11H17F3NaO5S: 341.0646.  Found: 341.0638. 
Chiral GC analysis: 120 °C for 60 min. Retention times: 22.12 (minor enantiomer) and 












Notebook Entry: PSC166, PSC195 
In accordance with General Procedure K, diol 2.62 (1.19 g, 4.06 mmol, R-(-)-CSA acid 
(0.0773 g, 0.406 mmol, 10 mol %), dimethoxypropane (9.95 mL, 81.2 mmol, 20 eq.), and 
acetone (7.75 mL) were combined in a 25 mL round bottom flask.  Purification by flash 
chromatography (1½” diameter column, 500 mL reservoir, 3:1 hexanes:EtOAc) gave 
compound 2.64 (1.22 g, 90%). 
1H NMR (CDCl3, 500 MHz): δ 5.15 (d, J = 3.9, 1 H, C=CH2), 5.01 (d, J = 3.4, 1 H, C=CH2), 
4.05 (m, 2 H, CH-CH), 2.63 (ddd, J = 15.6, 9.8, 4.9, 1 H, CH2-CH2), 2.42 (ddd, J = 16.1, 9.8, 
6.8, 1 H, CH2-CH2) 1.64 (m, 4 H, CH2-CH3 & CH2-CH2), 1.43 (s, 3 H, C-CH3), 1.35 (s, 3 H, 
C-CH3) 1.03 (t, J = 7.3 , 3 H, CH2-CH3). 
13C NMR (CDCl3, 125 MHz): δ 156.1, 118.4, 107.8, 104.6, 79.3, 76.6, 76.3, 30.7, 28.5, 26.6, 
22.4, 10.7. 
FT-IR (Diamond ATR):  2984 (w), 1670 (w), 1416 (m), 1205 (s), 1141(m), 899 (m). 
HRMS (ESI, M+Na) Calculated for C12H19F3NaO5S: 355.0803.  Found: 355.0804. 
Chiral GC analysis: 120 °C for 120 min.  Retention times: 82.5239 (major enantiomer) and 














Notebook Entry: PSC198 
In accordance with General Procedure B, B2pin2 (0.397 g, 1.57 mmol), Pd(PPh3)2Cl2 (0.050 
g, 0.071 mmol), KOPh (0.282 g, 2.14 mmol) and PPh3 (0.224 g, 0.085 mmol) were charged 
to a 25 mL round bottom flask.  An argon atmosphere was established, followed by addition 
of anhydrous toluene (10 mL).  Protected diol 2.63 was added to the mixture which was then 
stirred at ~60 °C for 5.5 hrs.  The crude organic material was purified by flash 
chromatography (1” diameter column, 250 mL reservoir, 6:1 hexanes:EtOAc) to give 
boronate 2.65 (0.256 g, 61%) as a yellow oil. 
1H NMR (CDCl3, 500 MHz): δ 5.82 (d, J = 3.41, 1 H, C=CH2), 5.66 (d, J = 2.93 Hz, 1 H, 
C=CH2), 4.26 (app. dq, J = 13.2, 7.3, 1 H, CH-CH), 4.06 (ddd, J = 10.7, 8.8, 5.4, 1 H, 
C=CH2), 2.36 (ddd, J = 14.7, 10.7, 5.4, 1 H, CH2-CH2), 2.16 (ddd, J = 14.7, 9.8, 5.4, 1 H, 
CH2-CH2), 1.68 (m, 1 H, CH2-CH2), 1.55 (m, 1 H, CH2-CH2), 1.47 (s, 3 H, C-CH3), 1.38 (s, 
3 H, C-CH3), 1.30 (s, 12 H, (CH3)4), 1.18 (d, J = 6.4, 3 H, CH-CH3). 
13C NMR (CDCl3, 125 MHz): δ 142.7, 129.4, 107.3, 84.4, 77.3, 73.8, 31.8, 29.3, 28.5, 26, 
24.8, 22.7, 15.7, 14.1. 
FT-IR (Diamond ATR): 2979 (m), 1369 (s), 1307 (m), 1214 (m), 1141 (s), 1083 (m), 858 
(m). 












Notebook Entry: PSC167, PSC199 
In accordance with General Procedure B protected diol 2.64 (0.597 g, 1.80 mmol), B2pin2 
(0.501 g, 1.98 mmol, 1.1 eq.), Pd(PPh3)2Cl2 (0.068 g, 0.0898 mmol), KOPh (0.363 g, 2.69 
mmol), PPh3  (0.0287 g, .1077 mmol) and toluene (12 mL) were combined in a 25 mL round 
bottom flask and heated at 60 °C under Ar atmosphere.  Flash chromatography purification 
(1” diameter column, 250 mL, 6:1 hexanes:EtOAc) provided boronate 2.66 (0.431 g, 83%) as 
a yellow oil. 
1H NMR (CDCl3, 500 MHz): δ 5.81 (d, J = 2.9, 1 H, C=CH2), 5.66 (d, J = 2.9 Hz, 1 H, 
C=CH2), 4.07 (app. dt, J = 9.8, 5.6, 1 H, CH-CH), 3.98 (app. dt, J = 8.8, 4.9, 1 H, CH-CH), 
2.40 (ddd, J = 14.2, 10.8, 5.4, 1 H, CH2-CH2), 2.16 (ddd, J = 15.1, 9.8, 5.4, 1 H, CH2-CH2), 
1.67 (m, 2 H, CH-CH2), 1.56 (m, 2 H, CH2-CH2), 1.47 (s, 3 H, C-CH3), 1.36 (s, 3 H, C-
CH3), 1.28 (s, 12 H, (CH3)4), 1.00 (t, J = 7.3, 3 H, CH3). 
13C NMR (CDCl3, 125 MHz): δ 143.5, 129.6, 107.7, 83.2, 79.7, 77.8, 32.1, 29.2, 28.5, 26.3, 
24.5, 22.7, 10.4. 
FT-IR (Diamond ATR): 2979 (w), 1367 (m), 1307 (m), 1141 (s), 862 (m). 
HRMS (CI+) Calculated for C17H32BO4: 311.2397.  Found: 311.2391. 
[α]𝟐𝟎
𝑫













Notebook Entry: PSC202 
In accordance with General Procedure C, Pd(dppf)Cl2 (0.073 g, 0.083 mmol), K2CO3 (0.343 
g, 2.48 mmol) and Ag2O (0.481 g, 2.07 mmol) were charged to a 50 mL screw-top culture 
tube was equipped with a stir bar and rubber septum.  The flask was brought under Ar 
atmosphere and THF (16.5 mL) was added.  The solution was stirred for 5 min before 
addition of boronate 2.65 (0.257 g, 0.867 mmol) and pyridyl iodide 2.38 (0.192 g, 0.825 
mmol).  The reaction was stirred at 100 °C 6 h.  Purification via flash chromatography (1” 
diameter column, 250 mL reservoir, 3:1 hexanes:EtOAc) provided coupled product 2.72 
(0.096 g, 42%) as a light yellow oil.  
1H NMR (CDCl3, 500 MHz): δ 7.28 (d, J = 8.8, 1 H, Ar-H), 6.96 (d, J = 7.8, 1 H, Ar-H), 
5.28 (d, J = 1.5, 1 H, Ar-C=CH2), 4.94 (d, J = 1.0, 1 H, Ar-C=CH2), 4.24 (app. quin., J = 6.3, 
1 H, CH-CH), 4.04 (ddd, J = 9.3, 5.4, 4.0, 1 H, CH-CH), 2.59 (ddd, J = 15.1, 10.7, 4.9, 1 H, 
CH2-CH2), 2.53 (s, 3 H, Ar-CH3), 2.52 (s, 3 H, Ar-CH3), 2.36 (ddd, J = 16.1, 11.2, 5.9, 1 H, 
CH2-CH2), 1.60 (m, 1 H, CH2-CH2), 1.47 (m, 1 H, CH2-CH2), 1.42 (s, 3 H, C-CH3), 1.34 (s, 
3 H, C-CH3), 1.13 (d, J = 6.4, 3 H, CH-CH3) 
13C NMR (CDCl3, 125 MHz): δ 156.2, 154.3, 147.8, 136.3, 120.2, 115.2, 110.0, 107.4, 77.5, 
73.6, 34.1, 28.6, 28.1, 25.9, 24.9, 2.8, 15.4. 
FT-IR (Diamond ATR): 2983 (w), 2933 (w), 1590 (w), 1454 (m), 1377 (m), 1245 (m), 1216  
(m), 1082 (s), 858 (m). 










Notebook Entry: PSC172, PSC203 
In accordance with General Procedure C, boronate 2.66 (0.399 g, 1.29 mmol) pyridyl iodide 
2.68 (0.286 g, 1.23 mmol), Pd(dppf)Cl2 (0.100 g, 0.123 mmol), K2CO3 (0.508 g, 3.68 mmol), 
Ag2O (0.710 g, 3.07 mmol) and anhydrous THF (24.5 mL) were combined in a 50 mL screw-
top culture rube and heated at 100 °C for 6 h while stirring.  After work-up, purification via 
flash chromatography (1½” diameter column, 250 mL reservoir, 3:1 hexanes:EtOAc) gave 
coupled product 2.73 (0.254 g, 72%) as a light yellow oil.  
1H NMR (CDCl3, 500 MHz): δ 7.27 (d, J = 7.8, 1 H, Ar-H), 6.96 (d, J = 7.8, 1 H, Ar-H), 
5.27 (d, J = 2.0, 1 H, Ar-C=CH2), 4.94 (d, J = 1.5, 1 H, Ar-C=CH2), (ddd, J = 9.3, 5.4, 3.5, 1 
H, CH-CH), 3.96 (app. quin., J = 4.9, 1 H, CH-CH), 2.61 (ddd, J = 15.1. 10.7, 4.9 , 1 H, 
CH2-CH2), 2.54 (s, 3 H, Ar-CH3), 2.52 (s, 3 H, Ar-CH3), 2.36 (ddd, J = 15.6, 10.3, 5.9, 1 H, 
CH2-CH2), 1.52 (m, 4 H, CH2-CH2 & CH2-CH3), 1.41 (s, 3 H, C-CH3), 1.34 (s, 3 H, C-CH3), 
0.98 (t, J = 7.3, 3 H, CH3). 
13C NMR (CDCl3, 125 MHz): δ 156.1, 154.1, 147.9, 136.3, 134.6, 120.1, 115.2, 107.5, 79.5, 
77.3, 34.1, 28.6, 28.0, 26.0, 24.2, 22.7, 10.6. 
FT-IR (Diamond ATR): 3053 (m), 2937 (m), 1591 (m), 1461 (m), 1378 (m), 1216 (m), 1048 
(m), 692 (m). 
HRMS (ESI+) Calculated for C18H28NO2: 290.2120.  Found: 290.2119. 
[α]𝟐𝟎
𝑫







General Procedure L: Deprotection 
Preparation of (2R,3S)-6-(2,6-dimethylpyridin-3-yl)hept-6-ene-2,3-diol 
 
Notebook Entry: PSC204 
A 25 mL round bottom flask containing coupled product 2.67 (0.0859 g, 0.312 mmol) was 
cooled in an ice/H2O bath.  A second 25 mL round bottom flask was charged with TFA (3 
mL) and DI H2O (3 mL) and cooled in an ice/H2O bath before being added to the reaction 
flask.  The solution was stirred for 1 h in an ice bath.  The reaction was quenched slowly at 
reduced temperature with sat. NaHCO3 solution (10 mL) and extracted with diethyl ether (2 
× 10 mL).  Combined organic layers were dried over anhydrous MgSO4, filtered and 
concentrated to provide diol 2.69 (0.034 g, 46%) as a viscous, colorless oil. 
1H NMR (CDCl3, 500 MHz): δ 7.28 (d, J = 7.8, 1 H, Ar-H), 6.95 (d, J = 7.8, 1 H, Ar-H), 
5.26 (d, J = 1.5, 1 H, Ar-C=CH2), 4.92 (s, 1 H, Ar-C=CH2), 3.79 (m, 1 H, CH-CH), 3.62 (m, 
2 H, CH-CH), 2.62 (s, br, 2 H, OH), 2.60 (m, 2 H, CH2-CH2), 2.52 (s, 3 H, Ar-CH3), 2.49 (s, 
3 H, Ar-CH3), 2.37 (m, 1 H, CH2-CH2), 1.50 (m, 2 H, CH2-CH2), 1.12 (d, J = 6.4, 3 H, CH3). 
13C NMR (CDCl3, 125 MHz): δ 156.0, 154.4, 147.8, 136.6, 134.8, 120.3, 115.4, 74.3, 70.3, 










Preparation of (3S,4R)-7-(2,6-dimethylpyridin-3-yl)oct-7-ene-3,4-diol 
 
Notebook Entry: PSC175, PSC176, PSC205 
In accordance with General Procedure L, coupled product 2.68 (0.240 g, 0.830 mmol), TFA 
(8 mL) and DI H2O (8 mL) were combined in a 50 mL round bottom flask and cooled in an 
ice/H2O bath with stirring for 1 h.  After work-up, concentration of the organic layer 
provided diol 2.70 (0.144 g, 70%). 
1H NMR (CDCl3, 500 MHz): δ 7.30 (d, J = 5.9, 1 H, Ar-H), 6.97 (d, J = 7.8, 1 H, Ar-H), 
5.29 (d, J = 1.0, 1 H, Ar-C=CH2), 4.95 (d, J = 1.0, 1 H, Ar-C=CH2), 3.64 (ddd, J = 10.3, 6.4, 
3.4, 1 H, CH-CH), 3.53 (app. quin., J = 3.9, 1 H, CH-CH), 2.64 (app. quin., J = 7.8, 1 H, 
CH2-CH2), 2.54 (s, 3 H, Ar-CH3), 2.52 (s, 3 H, Ar-CH3), 2.40 (m, 1 H, CH2-CH2), 1.90 (s, 
br, 2 H, OH), 1.55 (ddd, J = 13.7, 8.3, 6.4, 2 H, CH2-CH2), 1.46 (m, 2 H, CH2-CH3), 1.00 (t, 
J = 7.8, 3 H, CH2-CH3). 
13C NMR (CDCl3, 125 MHz): δ 156.1, 154.5, 147.9, 136.5, 134.7, 120.2, 115.4, 76.2, 73.9, 
33.9, 29.3, 24.4, 24.1, 22.8, 10.4. 
FT-IR (Diamond ATR): 3346 (br), 2925 (m), 1591 (m), 1463 (m), 1065 (m), 972 (m), 905 
(m), 831 (m), 702 (s). 















Notebook Entry: PSC183 
In accordance with General Procedure E, diol 2.70 (0.043 g, 0.172 mmol) NEt3 (31 µL, 0.224 
mmol) and CH2Cl2 (3.5 mL) were combined in a 10 mL pointed bottom flask under argon 
atmosphere. The solution was cooled in an ice/H2O bath at which time MsCl (19 µL, 0.190 
mmol) was added drop-wise in 0.5 mL anhydrous CH2Cl2.  The solution warmed to room 
temperature and the reaction progress was monitored by TLC.  After ~30 min, an additional 
0.5 eq. of NEt3 and MsCl were added.  After an additional 30 min the reaction was deemed 
complete by TLC and MeOH (4 mL) and K2CO3 (0.222 g, 1.60 mmol) were added to the 
flask and the reaction was stirred overnight.  After work-up, the organic layer was filtered 
and concentrated to give epoxide 2.72 (0.018 g, 44%). 
1H NMR (CDCl3, 500 MHz): δ 7.28 (d, J = 7.3, 1 H, Ar-H), 6.6 (d, J = 7.8, 1 H, Ar-H), 5.28 
(d, J = 1.5, 1 H, Ar-C=CH2), 4.96 (d, J = 1.5, 1 H, Ar-C=CH2), 2.72 (ddd, J = 6.9, 4.5, 2.4, 1 
H, CH-CH), 2.67 (app. td, J = 5.4, 2.0, 1 H, CH-CH), 2.52 (s, 3 H, Ar-CH3), 2.49 (s, 3 H, 
Ar-CH3), 1.60 (m, 4 H, diastereotopic CH2), 0.99 (t, J = 7.8, 3 H, CH2-CH3). 
13C NMR (CDCl3, 125 MHz): δ156.2, 154.5, 147.3, 136.4, 134.4, 120.2, 115.4, 59.9, 58.1, 
57.9, 33.9, 30.4, 25.1, 24.2, 22.8, 9.9. 
FT-IR (Diamond ATR): 3382 (w, br) 3074 (w), 2967 (m), 1649 (m), 1450 (m), 1328 (m). 







Preparation of (E)-hept-5-en-2-one83 
 
Notebook Entry: PSC206, PSC211. PSC232, PSC238 
In accordance with General Procedure H, crotyl chloride 2.77 (4.77 mL, 50.0 mmol) 2,4-
pentanedione (5.64 mL, 55.0 mmol), K2CO3 (7.60 g, 55.0 mmol) and EtOH (33 mL) were 
combined in a 100 mL round bottom and refluxed for 24 h with stirring.  After work-up, the 
product was purified by vacuum distillation (bp = 54-60 °C at 33 mmHg) to provide 
alkenone 2.79 (3.24 g, 60%) as a clear, colorless liquid. 
1H NMR (CDCl3, 500 MHz): δ 5.45 (m, 2 H, CH=CH), 2.50 (t, J = 7.3, 2 H, CH2-CH2), 
2.28 (dt, J = 13.7, 6.3, 2 H, CH2-CH2), 1.66 (dd, J = 5.9, 1.0, 3 H, CH3). 
13C NMR (CDCl3, 125 MHz): δ 208.6, 129.5, 125.9, 43.5, 29.9, 26.8, 17.9. 



















Notebook Entry: PSC209, PSC214, PSC234, PSC242 
In accordance with General procedure A, a 250 mL, a three-neck round bottom flask was 
equipped with addition funnel and septa and brought under argon atmosphere.  THF (58 mL) 
and LHMDS (1.06 M, 30 mL) were charged to the flask and cooled in a dry ice/isopropanol 
bath.  Alkenone 2.79 (2.62 g, 23.3 mmol) was added to the addition funnel in a solution of 
THF (10 mL) and added drop wise to the solution over 30 min.  After complete addition, the 
solution was stirred for 15 min.  PhNTf2 (8.75 g, 24.5 mmol) was added to a 50 mL flask and 
brought under argon atmosphere.  The solid was dissolved in THF (20 mL) and quickly 
added to the solution via cannula.  After work-up, purification via flash chromatography (2 
¾” column, 1 L reservoir, 19:1 hexanes:EtOAc) provided semi-pure product 2.80 (2.16 g, 
38%) as a yellow oil. 
1H NMR (CDCl3, 500 MHz): δ 5.54 (m, 1 H, CH=CH), 5.40 (m, 1 H, CH=CH), 5.13 (d, J = 
3.9,1 H, C=CH2), 4.96 (d, J = 3.4, 1 H, C=CH2), 2.42 (t, J = 7.3, 2 H, CH2-CH2), 2.25 (app. 
q, J = 6.8, CH2-CH2), 1.69 (dd, J = 6.4, 1.0, 3 H, CH3). 
 13C NMR (CDCl3, 125 MHz): δ 156.4, 128.2, 127.1, 120.3, 104.5, 33.9, 28.9, 17.9. 
FT-IR (Diamond ATR): 3027 (w), 2923 (w), 1669 (w), 1415 (m), 1204 (s), 1140 (s), 914 
(m) 609 (m). 













Notebook Entry: PSC210, PSC220, PSC237, PSC244 
In accordance with General Procedure D, AD mix-α (3.97 g, 1g/mmol), MeSO2NH2 (0.768 g, 
5.16 mmol), DI H2O (31 mL) and t-BuOH (31 mL) were added to a 100 mL round bottom 
flask.  The solution was cooled in an ice/H2O bath at which time triflate 2.80 (1.52 g, 6.21 
mmol) was added.  After work up, the product was purified by flash chromatography (2 ¾” 
column, 1 L reservoir, 1:1 hexanes:EtOAc) to provide diol 2.81  (0.115 g, 66%) as a viscous, 
light brown oil. 
1H NMR (CDCl3, 500 MHz): δ 5.16 (d, J = 3.9, 1 H, C=CH2), 5.10 (d, J = 3.4, 1 H, C=CH2), 
3.66 (app. quin., J = 6.3, 1 H, CH-CH), 3.41 (ddd, J = 9.3, 5.9, 2.9, 1 H CH-CH), 2.63 (ddd, 
J = 14.6, 9.3, 4.9, 1 H, CH2-CH2), 2.50 (ddd, J = 16.1, 9.3, 6.8, 1 H, CH2-CH2), 2.00 (s, br, 
OH), 1.78 (m, 1 H, CH2-CH2), 1.67 (m, 1 H, CH2-CH2), 1.26 (d, J = 6.4, 3 H, CH3). 
13C NMR (CDCl3, 125 MHz): δ 156.4, 118.3, 104.6, 74.8, 70.8, 30.2, 29.8, 19.7. 
FT-IR (Diamond ATR): 3364 (w, br), 2976 (w), 1670 (w), 1412 (m), 1203 (s), 1138 (s), 894 
(s), 605 (m). 
HRMS (ESI, M+Na) Calculated for C8H13F3NaO5S: 301.0334.  Found: 301.0320. 
[α]𝟐𝟎
𝑫















Notebook Entry: PSC212, PSC221 
In accordance with General Procedure J, diol 2.81 (0.578 g, 2.08 mmol), R-(-)-CSA (0.040 g, 
0.208 mmol), dimethoxypropane (5.10 mL, 41.6 mmol) and acetone (4 mL) were combined 
in a 25 mL round bottom flask and stirred for 1 h.  After work-up, purification via flash 
chromatography (1½” diameter column, 500 mL reservoir, 12:1 hexanes:EtAOc) provided 
2.82 (0.566 g, 86%). 
1H NMR (CDCl3, 500 MHz): δ 5.16 (d, J = 3.4, 1 H, CH2=C), 5.02 (d, J = 3.9, 1 H, CH2=C), 
3.76 (m, 1 H, CH-CH), 3.55 (app. td, J = 8.3, 3.0, 1 H, CH-CH), 2.61 (ddd, J = 15.6, 9.8, 4.9, 
1 H CH2-CH2), 2.48 (ddd, J = 16.1, 9.8, 6.3, 1 H, CH2-CH2), 1.82 (dddd, J = 13.2, 9.3, 6.4, 
3.0, 1 H, CH2-CH2), 1.71 (dddd, J = 13.7, 9.8, 8.8, 4.9, 1 H, CH2-CH2), 1.41 (s, 3 H, C-
(CH3)2), 1.40 (s, 3 H, C-(CH3)2), 1.29 (d, J = 5.9, 3 H, CH-CH3). 
13C NMR (CDCl3, 125 MHz): δ 156.2, 117.4, 108.2, 104.6, 80.8, 76.5, 30.7, 28.5, 23.3, 23.2, 
17.3. 
FT-IR (Diamond ATR): 2918 (w), 1415 (m), 1206 (s), 899 (m). 
HRMS (ESI, M+Na) Calculated for C11H17F3NaO5S: 341.0646.  Found: 341.0640. 
[α]𝟐𝟎
𝑫
 = -4.9° (c = 5.4, l = 0.10 dm, CHCl3). 
Chiral GC analysis: 120 °C for 60 min.  Retention times: 16.0917 (minor enantiomer) and 














Notebook Entry: PSC213, PSC222 
In accordance with General Procedure B, B2pin2 (0.860 g, 3.39 mmol), Pd(PPh3)2Cl2 (0.107 
g, 0.152 mmol), KOPh (0.610 g, 4.62 mmol) and PPh3 (0.048 g, 0.185 mmol) were charged 
to a 100 mL round bottom flask and brought under Ar atmosphere.  Toluene (21 mL) and 
2.82 (0.967, 3.08 mmol) were then added to the flask and stirred at ~60 °C for 6 h.  After 
work-up, purification via flash chromatography (1½” diameter column, 500 mL column, 6:1 
hexanes:EtOAc) provided 2.83 (0.561, 62%). 
1H NMR (CDCl3, 500 MHz): δ 5.82 (d, J = 3.4, 1 H, CH2=C), 5.67 (d, J = 3.4, 1 H, CH2=C), 
3.76 (m, 1 H, CH-CH), 3.56 (m, 1 H, CH-CH), 2.38 (app. quin., J = 8.3, 1 H, CH2-CH2), 
2.23 (app. quin., J = 8.3, 1 H, CH2-CH2), 1.68 (m, 2 H, CH2-CH2), 1.41 (s, 6 H, C-(CH3)2), 
1.29 (s, 12 H, Bpin), 1.28 (s, 3 H, CH-CH3). 
13C NMR (CDCl3, 125 MHz): δ 140.5, 129.4, 107.8, 83.4, 82.0, 31.7, 27.3, 24.8, 17.7.  
FT-IR (Diamond ATR): 2979 (m), 1412 (m), 1307 (m), 1141 (s), 1089 (m), 859 (m). 
HRMS (ESI+) Calculated for C16H30BO4: 319.2060.  Found: 319.2056. 
[α]𝟐𝟎
𝑫
















Notebook Entry: PSC217, PSC224 
In accordance with General Procedure C, Pd(dppf)Cl2 (0.147 g, 0.180 mmol), K2CO3 (0.746 
g, 5.39, mmol) and Ag2O (1.04 g, 4.50 mmol) were charged to a 100 mL round bottom flask 
and brought under Ar atmosphere.  THF (38 mL) was added, followed by 2.83 (0.559 g, 1.89 
mmol), and 2.38 (0.419 g, 1.80 mmol) and the solution was stirred at 90 °C for 6 h.  After 
work-up, purification via flash chromatography (1½” diameter column, 500 mL reservoir, 
3:1 hexanes:EtOAc) provided 2.84 (0.415 g, 84%). 
1H NMR (CDCl3, 500 MHz): δ 7.28 (d, J = 7.8, 1 H, Ar-H), 6.96 (d, J = 7.8, 1 H, Ar-H), 
5.28 (d, J = 1.5, 1 H, CH2=C), 4.95 (s, 1 H, CH2=C), 3.71 (m, 1 H, CH-CH), 3.54 (m, 1 H, 
CH-CH), 2.57 (m, 1 H, CH2-CH2), 2.54 (s, 3 H, Ar-CH3), 2.52 (s, 3 H, Ar-CH3), 2.43 (m, 1 
H, CH2-CH2), 1.62 (m, 2 H, CH2-CH2), 1.40 (s, 3 H, C-(CH3)2), 1.38 (s, 3 H, C-(CH3)2), 1.24 
(d, J = 5.9, 3 H, CH-CH3). 
 13C NMR (CDCl3, 125 MHz): δ 156.2, 154.5, 147.6, 136.4, 120.2, 115.3, 107.8, 81.8, 76.7, 
33.9, 30.4, 27.3, 24.2, 22.8, 17.6. 
FT-IR (Diamond ATR): 2983, (m), 2931 (m), 1590 (m), 1455 (m), 1377 (m), 1238 (m), 
1091 (s), 857 (m). 
HRMS (ESI+) Calculated for C17H26NO2: 276.1964.  Found: 276.1955. 
[α]𝟐𝟎
𝑫












Notebook Entry: PSC226 
In accordance with General Procedure K, 2.84 (0.539, 1.96 mmol), TFA (12 mL) and H2O 
(12 mL) were combined in a 50 mL round bottom flask and stirred for 1 h.  After work-up, 
concentration of the organic layer provided 2.85 (0.246 g, 53%). 
1H NMR (CDCl3, 500 MHz): δ 7.30 (d, J = 7.8, 1 H, Ar-H), 6.98 (d, J = 7.8, 1 H, Ar-H), 
5.28 (d, J = 1.5, 1 H, C=CH2), 4.96 (s, 1 H, C=CH2), 3.62 (app. quin., J = 6.4, 2 H, CH-CH), 
3.38 (m, 2 H, CH-CH), 2.60 (ddd, J = 15.1, 10.3, 5.9, 1 H, CH2-CH2), 2.54 (s, 3 H, Ar-CH3), 
2.52 (Ar-CH3), 2.45 (m, 1 H, CH2-CH2), 1.73 (s, br, 2 H, OH), 1.59 (dddd, J = 13.7, 9.8, 6.4, 
3.4, 1 H, CH2-CH2), 1.52 (m, 1 H, CH2-CH2), 1.19 (d, J = 6.4, 3 H, Ch-CH3). 
13C NMR (CDCl3, 125 MHz): δ 156.1, 154.4, 147.7, 136.6, 136.7, 120.3, 115.5, 75.6, 70.8, 
33.5, 31.5, 24.1, 22.7, 19.7. 















General Procedure M: Picolyl Alkylation 




Notebook Entry: PSB169 
A two-neck 25 mL round bottom flask was brought under Ar atmosphere and charged with 
3.3 (0.344 g, 2.00 mmol) and THF (7 mL).  The solution was cooled in a dry ice/isopropanol 
bath at which time LHMDS (1.06 M, 2.36 mL, 2.50 mmol) was added drop-wise stirred for 
45 min.  Allyl bromide (0.303 g, 2.50 mmol) was added in a solution of THF (1 mL) drop-
wise and stirred at reduced temperature for an additional 1.5 h.  The solution warmed to room 
temperature overnight before being quenched with sat. NaHCO3 (10 mL).  The solution was 
diluted with diethyl ether (10 mL) and the aqueous phase was further extracted with diethyl 
ether (1 × 10 mL).  The combined organic phases were dried over anhydrous MgSO4, filtered 
and concentrated before purification via flash chromatography (½” column, 100 mL 
reservoir, 3:1 hexanes:EtOAc) to provide 3.4 (0.197 g, 46%). 
1H NMR (CDCl3, 500 MHz): δ 8.48 (dd, J = 4.4, 1.4, 1 H, Ar-H), 7.82 (dd, J = 7.8, 1.5, 1 H, 
Ar-H), 7.02 (dd, J = 7.8, 4.4, 1 H, Ar-H), 5.93 (ddt, J = 13.2, 10.3, 6.8, 1 H, CH=CH2), 5.08 
(dd, J = 17.1, 1.5, 1 H, CH=CH2) 5.00 (dd, 10.3, 2.0, 1 H, CH=CH2), 3.06 (t, J = 7.8, 2 H, 
Ar-CH2), 2.52 (m, 2 H, CH2-CH2). 














Notebook Entry: PSB175 
In accordance with General Procedure M, 3.3 (0.344 g, 2.0 mmol) and THF (8 mL) were 
cooled in a dry ice/isopropanol bath before drop-wise addition of LHMDS (1.06 M, 2.36 mL, 
2.50 mmol).  5-Bromo-1-pentene (0.373 g, 2.50 mmol) was then added drop-wise. After 
work-up, purification via flash chromatography (½” column, 100 mL reservoir, 3:1 
hexanes:EtOAc) provided 3.6 (0.200 mg, 42%). 
1H NMR (CDCl3, 500 MHz): δ 8.43 (dd, J  = 4.9, 1.5, 1 H, Ar-H), 7.80 (dd, J  = 8.3, 1.5, 1 
H, Ar-H), 7.00 (dd, J  = 7.8, 4.4, 1 H, Ar-H), (ddt, J = 13.2, 10.3, 6.8, 1 H, CH=CH2), 5.02 
(dd J = 17.1, 2.0, 1 H, CH=CH2), 4.95 (dd, J = 9.3, 2.0, 1 H, CH=CH2), 2.97 (t, J = 7.8, 2 H, 
Ar-CH2), 2.12 (q, J = 7.3, 2 H, Ar-CH2-CH2) 1.76 (m, 2 H, CH2-CH2-CH), 1.52 (m, 2 H, 
CH2-CH2-CH). 














General Procedure N: Model Intramolecular Heck Cyclization 
 




Notebook Entry: PSB178, PSB185 
A 25 mL screw-top culture tube was equipped with a stir bar and charged with MeCN (22 
mL), PPh3 (0.072 g, 0.280 mmol), K2CO3 (0.550 g, 3.98 mmol) and 3.4 (0.116 g, 0.549 
mmol).  The culture tube was degassed in a sonicator for 30 min before addition of Pd(OAc)2 
(0.031 mg, 0.14 mmol).  The culture tube was fitted with a septum and flushed with Ar gas 
before replacing septum with screw-cap.  The solution was stirred at room temperature for 1 
h then at 90 °C for 24 h.  The culture tube was allowed to cool to rt before filtering the 
solution over Celite®.  The solution was concentrated and purified by flash chromatography 
(½” column, 100 mL, 3:1 hexanes:EtOAc) to provide cyclized product 3.7 (0.047 g, 65%). 
1H NMR (CDCl3, 500 MHz): δ 8.42 (dd, J = 4.9, 1.5, 1 H, Ar-H), 7.73 (dd, J = 7.8, 2.0, 1 H, 
Ar-H), 7.11 (dd, J = 7.8, 4.9, 1 H, Ar-H), (dd, J = 2.9, 2 H, Ar-C=CH2), 5.15 (dd, J = 2.4, 2 
H, Ar-C=CH2), 3.10 (m, 2 H, Ar-CH2), 2.84 (m, 2 H, Ar-CH2-CH2). 
















Notebook Entry: PSB179, PSB184 
In accordance with General Procedure N, MeCN (20.5 mL), PPh3 (0.067 g, 0.260 mmol), 
K2CO3 (0.513 g, 3.71 mmol) and 3.6 (0.123 g, 0.510 mmol), and Pd(OAc)2 (0.029 g, 0.130 
mmol) combined in a screw-top culture tube.  After work-up, purification by flash 
chromatography (½” column, 100 mL, 3:1 hexanes:EtOAc) provided the cyclized isomeric 
mixture of 3.9 and 3.9a (0.035 g, 43%, ~3:1 mixture). 
1H NMR 3.9 (CDCl3, 500 MHz): δ 8.36 (dd, J = 4.9, 2.0, 1 H, Ar-H), 7.48 (dd, J = 7.8, 1.96, 
1 H, Ar-H), 7.08 (dd, J = 7.8, 4.9, 1 H, Ar-H), 5.18 (d, J = 2.0, 1 H, Ar-C=CH2), 5.03 (d, J = 
2.0, 1 H, Ar-C=CH2), 3.02 (app.t, J = 5.4, 2 H, Ar-CH2), 2.42 (app. t, J = 5.9, Ar-C-CH2), 
1.89 (m, 2 H, 1.8, Ar-CH2-CH2), 1.82 (quin, J = 5.4, 2 H, Ar-C-CH2-CH2). 
1H NMR 3.9a (CDCl3, 500 MHz): δ 8.37 (dd, J = 4.9, 1.5, 1 H, Ar-H), 7.54 (dd, J = 7.8, 1.5, 
1 H, Ar-H), 7.17 (dd, J = 7.8, 4.9, 1 H, Ar-H), 6.05 (tq, J = 6.8, 1.5, 1 H, Ar-C=CH), 2.83 (t, 
J = 6.8, 2 H, Ar-CH2), 2.22 (quin., J = 7.3, 2 H, Ar-CH2-CH2), 2.10 (s, 3 H, Ar-C-CH3), 1.95 
















Notebook Entry: PSB198 
A two-neck 50 mL round-bottom flask was equipped with addition funnel and brought under 
Ar atmosphere.  The flask was charged with 3.10 (0.721 g, 10.0 mmol) and pyridine (8 mL) 
and cooled to 0 °C in an ice/H2O bath.  TsCl (2.29 g, 12.0 mmol) was added in a solution of 
pyridine (4 mL) drop-wise via addition funnel.  The reaction mixture was stirred at 0 °C for 
4.5 h.  The reaction was quenched with sat. NH4Cl (20 mL) and the aqueous phase extracted 
with diethyl ether (2 × 20 mL).  Combined organic phases were dried over MgSO4, filtered 
and concentrated.  The crude organic material was purified by flash chromatography (1” 
column, 1:2 hexanes:EtOAc) to provide butenyl tosylate 3.11 (1.01 g, 45%). 
1H NMR (CDCl3, 500 MHz): δ 7.80 (d, J = 7.82, 1.47, 2 H, Ar-H), 7.36 80 (d, J = 7.82, 
1.47, 2 H, Ar-H), 5.68 (ddt, J = 13.2, 10.3, 6.35, 1 H, CH2=CH) 5.09 (dd, J = 9.27, 1.46, 
CH2=CH), 5.07 (dd, J = 8.79, 1.47, 1 H, CH2=CH), 4.07 (t, J = 6.84, 2 H, CH2-CH2), 2.41 
(dt, J = 6.84, 1.47, 2 H, CH2-CH2). 
FT-IR (Diamond ATR): 2983 (w), 1735 (w), 1598 (w), 1356 (m), 1174 (s), 954 (m), 901 












General Procedure O:  MOM Phenol Protection 
 




Notebook Entry: PSB167 
A 250 mL recovery flask was charged with 3.12 (1.00 g, 8.12 mmol) and NaH in mineral oil 
suspension (60%, 0.546 g, 22.7 mmol).  The flask was brought under Ar atmosphere and 
charged with THF (80 mL) and MOMCl (0.719 g, 8.93 mmol).  The reaction mixture was 
stirred at rt for 48 h.  The solution was diluted with EtOAc (30 mL), washed with sat. NaCl 
(2 × 40 mL) and the combined organic phase was dried over anhydrous Na2SO4.  The 
solution was filtered, concentrated and purified via flash chromatography (1½” column, 500 
mL, 1:2 hexanes:EtOAc) to provide 3.13 (0.889 g, 65%). 
1H NMR (CDCl3, 500 MHz): δ 7.24 (d, J = 8.3, 1 H, Ar-H), 6.91 (d, J = 8.3, 1 H, Ar-H), 
5.17 (s, 2 H O-CH2-O), 4.61, 3.48 (s, 3 H, O-CH3), 2.47 (s, 3 H, Ar-CH3), 2.46 (s, 3 H, Ar-
CH3). 
















Notebook Entry: PSB176 
A 25 mL round-bottom flask was equipped with a stir bar brought under inert atmosphere.  
Compound 3.13 (0.200 g, 1.20 mmol) and THF (10 mL) were charged to the flask.   The 
solution was cooled in a dry ice/isopropanol bath and n-BuLi (~1.28 M, 0.82 mL, 1.32 
mmol) was added drop-wise.  The solution stirred for 15 min at which time allyl bromide 
(0.217 g, 1.79 mmol) was added all at once.  The solution stirred at rt for 48 h before being 
quenched with sat. NaHCO3 (10 mL).  The aqueous phase was extracted with diethyl ether (2 
× 10 mL) and the combined organic phases were dried over anhydrous Na2SO4.  The crude 
material was filtered, concentrated, and then purified by flash chromatography (1” column, 
250 mL reservoir, 1:1 hexanes:EtOAc) to provide 3.16 (0.093 mg, 38%). 
1H NMR (CDCl3, 500 MHz): δ 6.83 (s, 1 H, Ar-H), 5.93 (ddt, J = 17.1, 10.3, 1.5, 1 H, 
CH=CH2), 5.14 (dd, J = 10.3, 1.5, 1 H, CH=CH2), 5.11 (dd, J = 17.1, 1.5, 1 H, CH=CH2), 
















Notebook Entry: PSB220, PSC265 
A 1 L flat bottom flask equipped with stir bar was charged with 3.21 (54.5 g, 0.50 mol) DI 
H2O, NEt3 (69.7 mL, 0.50 mol) and formaldehyde (37%, 37.5 mL, 0.50 mol).  The solution 
was refluxed for 6 h.  The solution was concentrated give a crude solid which was 
subsequently recrystallized from 95% ethanol to provide 2.11 (35 g, 50%). 
1H NMR (DMSO-d6, 500 MHz): δ 7.80 (d, J = 7.8, 1 H, Ar-H), 6.98 (d, J = 8.3, 1 H, Ar-H), 
5.0 (s, 2 H, Ar-CH2), 2.42 (s, 3 H, Ar-CH3). 
13C NMR (DMSO-d6, 125 MHz): δ 149.3, 147.0, 146.4, 123.2, 122.8, 60.4, 23.3. 





















Notebook Entry: PSB217 
A 50 mL round bottom flask was equipped with a stir bar and charged with 2.11 (1.44 g, 10.4 
mmol), HBr (48%, 13.3 mL) and the mixture stirred for 10 min.  PhSH (1.26 g, 11.4 mmol) 
was added to flask and the solution was heated at reflux 18 h before cooling to room 
temperature.  The solution was transferred to a 125 mL Erlenmeyer flask containing sat. 
Na2CO3 (25 mL) and made basic with sat. Na2CO3 (pH = 11).  The solution was extracted 
with diethyl ether (2 × 20 mL) and the combined organic layers were dried over anhydrous 
Na2SO4, filtered and concentrated to give 3.22 (0.108 g, >1%).
* 
* the crude aqueous solution was again extracted at ~pH’s 7-10), but no additional product was isolated. 
1H NMR (CDCl3, 500 MHz): δ 7.39 (m, 1.5, 2 H, Ar-H), 7.24 (m, 3 H, Ar-H), 7.06 (d, J = 




















Notebook Entry: PSB223 
In accordance with General Procedure O, 3.22 (0.099 g, 0.46 mmol), NaH (60% in mineral 
oil, 0.022 g, 0.922 mmol), MOMCl (0.941 mg, 0.507 mmol) and THF (8 mL) were charged 
to a 25 mL round bottom flask.  After work-up, purification via flash chromatography (½” 
diameter column, 100 mL reservoir, 1:1 hexanes:EtOAc) provided 3.19 (0.067 g, 55%). 
1H NMR (CDCl3, 500 MHz): δ 7.43 (dd, J = 6.8, 1.5, 2 H, Ar-H), 7.30 (d, J = 8.3, 1 H, Ar-
H), 7.26 (m, 2 H, Ar-H), 7.17 (tt, J = 7.3, 1.0, 1 H, Ar-H), 6.98 (d, J = 8.3, 1 H, Ar-H), 5.12 





















Notebook Entry: PSB233, PSB244, PSC034 
PPh3 (1.06 g, 4.03 mmol) was dissolved in toluene (6.5 mL) in a 25 mL round bottom flask. 
3.23 (0.500 g, 3.36 mmol) was added all at once and the solution was refluxed for 18 h.  The 
solution was cooled to room temperature at which point a solid precipitated.  The solid was 
filtered under vacuum, rinsed with hot toluene, and dried in a desiccator to provide 3.24 
(0.560 g, 41%). 
1H NMR (acetone-d6, 500 MHz): δ 7.90 (m, 15 H, PPh3), 5.83 (ddt, J = 13.7, 10.3, 6.8, 1 H, 
CH2=CH), 5.07, (dd, J = 17.1, 2.0, 1 H, CH2=CH), 5.00 (dd, J = 10.3, 2.0, 1 H, CH2=CH), 
























Notebook Entry: PSB265 
Diol 2.11 (0.309 g, 2.10 mmol) was dissolved in 48% HBr (25 mL) and stirred at reflux for 
20 min.  The solution was concentrated under vacuum to approximately 5 mL and then 
cooled.  The white crystals formed were filtered and washed with acetone and hexanes to 
provide the pyridinium salt 3.31 (0.409 g, 65%). 





















Notebook Entry: PSB279, PSB283, PSB286 
A 50 mL two-neck round bottom flask was charged with diol 2.11 (0.500 g, 3.59 mmol) and 
equipped with stir bar and addition funnel.  The flask was brought under Ar atmosphere and 
charged with CH2Cl2 (16 mL) and NEt3 (1.25 mL, 8.98 mmol).  The solution was cooled in a 
dry ice/isopropanol bath at which time Tf2O (1.26 mL, 7.54 mmol) was added drop-wise in a 
solution of CH2Cl2 (2 mL).  The solution was warmed to room temperature overnight.  The 
reaction was quenched with sat. NaHCO3 and the aqueous layer was extracted with CH2Cl2 
(2 × 20 mL).  The combined organic layers were washed with sat. NaCl and dried over 
anhydrous MgSO4.  The solution was filtered, concentrated, and purified via flash 
chromatography (1½” diameter column, 10% acetone in EtOAc) to provide impure bis-
triflate 3.32. 
1H NMR (CDCl3, 125 MHz): δ 7.68 (d, J = 8.8, 1 H, Ar-H), 7.44 (d, J = 8.8, 1 H, Ar-H), 















Notebook Entry: PSB257 
A 25 mL recovery flask was charged with hexenoic acid (1.00 g, 8.76 mL), MeOH (1.06 mL, 
26.3 mmol) and sulfuric acid (2 drops).  The solution was stirred at reflux for 1 h before 
dilution with diethyl ether and sat. NaCl (10 mL each).  The solution was then extracted with 
diethyl ether (2 × 10 mL) and the combined organic layers were dried over anhydrous 
Na2SO4.  The solution was then filtered and concentrated under vacuum to provide methyl 
hex-5-enoate 3.29 (0.690 g, 61%). 
1H NMR (CDCl3, 500 MHz): δ 5.78 (ddt, J = 13.2, 9.8, 6.4, 1 H, CH=CH2), 5.15 (dd, J = 
17.1, 1.5, 1 H, CH=CH2), 4.95 (dd, J = 10.3, 1.0, 1 H, CH=CH2), 3.67 (s, 3 H, O-CH3), 2.33 





















Notebook Entry: PSB281 
A 25 mL recovery flask was brought under Ar atmosphere.  LHMDS (1.06 M, 3.20 mL, 2.39 
mmol) and THF (5 mL) were charged to the flask and cooled in a dry ice/isopropanol bath.  
Methyl hex-5-enoate (0.334 g, 2.61 mmol) was added to solution drop-wise and stirred for 15 
min before quick addition of bis-triflate 3.32 (1.16 g, 2.82 mmol) in THF (5 mL).  The 
reaction warmed to rt overnight and quenched with sat. NaHCO3 followed by extraction with 
diethyl ether (2 × 10 mL).  The combined organic layers were dried over anhydrous MgSO4, 
filtered, concentrated and purified by flash chromatography (1½” diameter column, 500 mL 
reservoir, 6:1 hexanes:EtOAc) to provid impure product 3.30 (0.071 g, 7%). 
1H NMR (CDCl3, 500 MHz): δ 7.45 (d, J = 8.8, 1 H, Ar-H), 7.40 (d, J = 8.8, 1 H, Ar-H), 
5.79 (ddt, J = 13.2, 9.8 ,6.4, 1 H, CH=CH2), 5.03 (dd, J = 17.1, 2.0, 1 H, CH=CH2), 4.98 (m, 
1 H, CH=CH2), 2.68 (m, 2 H, Ar-CH2), 2.44 (s, 3 H, Ar-CH3), 2.08 (app. q, J = 6.8, 2 H, 











Preparation of 2-(hydroxymethyl)-6-methylpyridin-3-yl methanesulfonate 
 
Notebook Entry: PSC045 
A 100 mL round bottom flask was charged with diol 3.43 (0.500 g, 3.59 mmol).  The flask 
was brought under Ar atmosphere and charged with CH2Cl2 (35 mL) and NEt3 (2.00 mL, 
14.4 mmol) and cooled in a dry ice/isopropanol bath.  MsCl (1.11 mL, 14.4 mmol) was 
added drop wise via syringe and the solution warmed to room temperature before it was 
concentrated via rotary evaporation.  The crude product was purified by flash 
chromatography (1” diameter column, 250 mL reservoir, 1:1 hexanes:EtOAc) to provide 
compound 3.34 (0.587 g, 62%) as a light yellow oil. 
1H NMR (CDCl3, 500 MHz): δ 7.67 (d, J = 8.3, 1 H, Ar-H), 7.20 (d, J = 8.3, 1 H, Ar-H), 
4.75 (s, 2 H, Ar-CH2-Cl), 3.30 (s, 3 H, SO2-CH3), 2.60 (s, 3H, Ar-CH3). 


















Notebook Entry: PSC046, PSC082, PSC099, PSC138, PSC193, PSC271 
A 500 mL round bottom flask was charged with diol 2.11 (5.00 g, 735.9mmol) and acetone 
(240 mL) and equipped with stir bar.  K2CO3 (9.93 g, 71.9 mmol) was with stirring followed 
by quick, drop-wise addition of allyl bromide (3.89 mL, 44.9 mmol).  The mixture was 
refluxed for 3 h and monitored by TLC.  The reaction mixture was then filtered under 
vacuum and concentrated via rotary evaporation to provide a crude yellow solid.  The solid 
was dissolved in EtOAc, washed with sat. NaHCO3 (2 × 20 mL), water (1 × 20 mL) and the 
organic layer was dried over anhydrous Na2SO4.  The solution was filtered and concentrated 
to provide compound 3.36 (6.44 g, 99%) as a yellow solid. 
mp = 53-55 °C 
1H NMR (CDCl3, 500 MHz): δ 7.04 (d, J = 8.3, 2 H, Ar-H), 7.00 (d, J = 8.3, 2 H, Ar-H), 
6.02 (ddt, J = 15.6, 10.3, 5.4, 1 H, CH=CH2), 5.39 (dd, J = 17.6, 1.5, 1 H, CH=CH2), 5.30 
(dd, J = 10.7, 1.5, 1 H, CH=CH2), 4.74 (d, J = 4.4, 2 H, Ar-CH2-OH), 4.55 (app. dt, J = 4.9, 
2.0, 2 H, O-CH2-CH), 2.50 (s, 3 H, Ar-CH3). 
13C NMR (CDCl3, 125 MHz): δ 149.1, 148.2, 147.3, 132.6, 121.6, 118.7, 117.9, 68.8, 59.8, 
23.1. 
FT-IR (Diamond ATR): 3093 (m), 2823 (m), 1652(w), 1581 (w), 1478 (m), 1458 (m), 1271 
(s), 1012 (s), 993 (s), 927 (s). 







Preparation of 3-(allyloxy)-2-(bromomethyl)-6-methylpyridine 
 
Notebook Entry: PSC050, PSC085, PSC105, PSC145, PSC164, PSC168, PSC192 
A two-neck, 100 mL round bottom flask was charged with alcohol 3.36 (1.09 g, 6.07 mmol) 
and PPh3 (1.67 g, 6.37 mmol) and equipped with a solid addition funnel.  NBS (1.11 g, 6.25 
mmol) was added to addition funnel and the apparatus was brought under Ar atmosphere.  
CH2Cl2 (40 mL) was charged to the flask and the solution was cooled in a dry ice/MeCN 
bath.  NBS was added to solution in portions over ~15 min.  The solution warmed to room 
temperature overnight.  The reaction was diluted with diethyl ether (40 mL) and washed with 
sat. NaHSO3 and sat. NaHCO3 (2 × 20 mL each) and dried over anhydrous CaCl2.  The 
solution was filtered, concentrated and purified by flash chromatography (2¾” diameter 
column, 1 L reservoir, 3:1 hexanes:EtOAc) to give pyridyl bromide 3.37 (1.07 g, 73%) as a 
bright pink solid. 
mp = 43-44 °C 
1H NMR (CDCl3, 500 MHz): δ 7.09 (d, J = 8.3, 1 H, Ar-H), 7.04 (d, J = 8.3, 1 H, Ar-H), 
6.05 (ddt, J = 15.5, 10.3, 4.9, 1 H,CH=CH2), 5.43 (dd, J = 17.1, 1.5, CH=CH2), 5.31 (dd, J = 
10.7, 1.5, 1 H, CH=CH2), 4.64 (s, 2 H, Ar-CH2-Br), 4.61 (app. q, J = 4.9, 2 H, O-CH2-CH), 
2.50 (s, 3 H, Ar-CH3). 
13C NMR (CDCl3, 125 MHz): δ 150.7, 149.8, 145.4, 132.5, 123.9, 120.4, 117.9, 69.1, 39.7, 
23.4. 
FT-IR (Diamond ATR): 3097 (w), 2887 (w), 1650 (w), 1573 (m), 1470 (s), 1442 (s), 1279 
(s), 1153 (s), 987 (s), 820 (s), 589 (m). 






Preparation of tert-butyl hex-5-enoate 
 
Notebook Entry: PSC068, PSC070, PSC079, PSC109 
A 10 mL round bottom flask was charged with 5-hexenoic acid (0.981 g, 8.59 mmol), DMAP 
(0.210 g, 1.72 mmol), t-BuOH (4.93 mL, 51.5 mmol), and DIC (2.02 mL, 12.9 mmol).  The 
solution was stirred at room temperature overnight.  The solution was poured over DI H2O (5 
mL) and extracted with CH2Cl2 (3 × 10 mL) and the combined organic layers were dried over 
anhydrous MgSO4.  The solution was filtered, concentrated and purified via flash 
chromatography (1½” diameter column, 500 mL, 30:1 hexanes:EtOAc) to provide ester 3.38 
(0.890 g, 61%) as a clear, colorless oil. 
1H NMR (CDCl3, 500 MHz): δ 5.79 (ddt, J = 17.1, 10.3, 3.4, 1 H, CH=CH2), 5.03 (dd, J = 
17.1, 2.0, 1 H, CH=CH2), 4.98 (dd, J =10.3, 1.0, 1 H, CH=CH2), 2.23 (t, J = 7.8, 2 H, C-
CH2), 2.09 (dt, J = 14.2, 6.3, 2 H, C-CH2-CH2-CH2), (quin., J = 7.8, 2 H, C-CH2-CH2), 1.43 
(s, 9 H, C-(CH3)3). 
13C NMR (CDCl3, 125 MHz): δ 173.0, 137.9, 115.2, 80.0, 34.8, 33.0, 28.1, 24.3. 
IR (Diamond ATR): 3079 (w), 2978 (m), 2116 (m), 1729 (s), 1366 (m), 1149 (s), 912 (m). 











Preparation of tert-butyl 2-((3-(allyloxy)-6-methylpyridin-2-yl)methyl) 
hex-5-enoate 
 
Notebook Entry: PSC071, PSC086, PSC110, PSC155 
A 25 mL recovery flask was equipped with a stir bar and septum and brought under Ar 
atmosphere.  THF (1 mL) and LHMDS (1.06 M, 1.25 mL, 1.32 mmol) were charged to flask 
and cooled in a dry ice/isopropanol bath.  Ester 3.38 (0.150 g, 0.881 mmol) was added drop-
wise to the flask in a solution of THF (1 mL).  The solution was stirred for ~15 min at 
reduced temperature followed by quick addition of pyridyl bromide 3.37 (0.235 g, 0.969 
mmol) in a solution of THF (1 mL).  The solution gradually warmed to rt.  The reaction was 
quenched with sat. NaHCO3 and the aqueous layer was extracted with diethyl ether (3 × 10 
mL).  The combined organic layers were dried over anhydrous MgSO4, filtered, concentrated 
Purification via flash chromatography (1” diameter column, 250 mL reservoir, 6:1 
hexanes:EtOAc) provided compound 3.39 (0.158 g, 54%) as a yellow oil. 
1H NMR (CDCl3, 500 MHz): δ 6.98 (d, J =  8.3, 1 H, Ar-H), 6.91 (d, J =  8.3, 1 H, Ar-H), 
6.04 (ddt, J =  17.1, 9.9, 4.9, 1 H, O-CH2-CH), 5.79 (ddt, J = 13.2, 10.3, 6.8,  1 H, CH2-CH2-
CH), 5.43 (dd, J = 17.1, 1.5, 1 H, O-CH2-CH=CH2), 5.29 (dd, J =  10.8, 1.5, 1 H, O-CH2-
CH=CH2), 5.00 (dd, J = 17.1, 2.0, 1 H, CH2-CH2-CH=CH2), 4.94 (dd, 10.3, 2.0, 1 H, CH2-
CH2-CH=CH2), 4.51 (d, 2 H, O-CH2), 3.03 (dd, J = 14.2, 8.3, 1 H, Ar-CH2), 2.99 (dd, J = 
14.2, 6.7, 1 H, Ar-CH2), 2.92 (dddd, J = 13.7, 8.8, 5.8, 4.4, 1 H, Ar-CH2-CH), 2.43 (s, 3 H, 






13C NMR (CDCl3, 125 MHz): δ 174.9, 150.7, 148.8, 138.5, 133.0, 120.8, 118.5, 117.8, 
114.9, 79.8, 69.0, 44.3, 34.6, 31.7, 28.1, 23.5. 
FT-IR (Diamond ATR):  2983 (m), 1705 (s), 1605 (m), 1229 (m), 1029 (m), 854 (s), 825 (s). 

























Preparation of tert-butyl 2-((3-hydroxy-6-methylpyridin-2-yl)methyl) 
hex-5-enoate 
 
Notebook Entry: PSC073, PSC087, PSC114, PSC156 
A 25 mL round bottom flask was charged with pyridyl ester 3.39 (0.743 mg, 0.224 mmol) 
and Pd(PPh3)4 0 (0.129 g, 0.112 mmol).  The flask was brought under Ar atmosphere before 
addition of absolute EtOH (22 mL).  The solution was stirred for 5 min before quick addition 
of K2CO3 (0.929 mg, 6.72 mmol).  The solution stirred for 3 h before it was poured over DI 
H2O (20 mL).  The aqueous layer was extracted with CH2Cl2 (3 × 20 mL).  The combined 
organic layers were dried over anhydrous Na2SO4, filtered, concentrated and purified by flash 
chromatography (1” diameter column, 250 mL reservoir, 2:1 hexanes:EtOAc) to provide 
compound 3.40 (0.602  g, 92%). 
1H NMR (CDCl3, 300 MHz): δ 7.55 (s, br, 1 H, Ar-OH), 7.06 (d, J = 8.2, 1 H, Ar-H), 6.87 
(d, J = 8.2, 1 H, Ar-H), 5.8 (ddt, J = 12.9, 10.0, 6.5, 1 H, CH=CH2), 5.04 (dd, J = 17.0, 1.8, 1 
H, CH=CH2), 4.8 (app. d, J = 11.7, 1 H, CH=CH2), 3.20 (dd, J = 13.5, 11.1, 1 H, Ar-CH2), 
2.88 (m, 1 H, Ar-CH2-CH), 2.68 (dd, J = 14.1, 3.5, 1 H, Ar-CH2), 2.42 (s, 3 H, Ar-CH3), 
2.16 (m, 2 H, CH2-CH2), 1.78 (m, 2 H, CH2-CH2), 1.40 (s, 9 H, C-(CH3)3). 
13C NMR (CDCl3, 125 MHz): δ 177.7, 149.3, 148.8, 146.5, 137.9, 125.0, 122.3, 115.2, 81.7, 
45.8, 34.1, 32.7, 31.0, 28.0, 23.3. 












Notebook Entry: PSC074, PSC094, PSC115 
A 10 mL round bottom flask was brought under Ar atmosphere.  CH2Cl2 (13.5 mL), pyridyl 
ester 3.40 (0.784 mg, 2.69 mmol) and NEt3 (0.49 mL, 3.50 mmol) were charged to the flask 
and cooled in a dry ice/isopropanol bath.  Tf2O (0.50 mL, 2.960 mmol) was added drop-wise 
to the solution which then warmed gradually to rt.  The reaction was quenched with sat. 
NaHCO3 and the aqueous layer was extracted with diethyl ether (2 × 10 mL).  The combined 
organic layers were washed with sat. NaCl and dried over anhydrous MgSO4.  The solution 
was filtered, concentrated, and purified by flash chromatography (1” diameter column, 250 
mL reservoir, 3:1 hexanes:EtOAc) to provide pyridyl triflate 3.41 (0.972 g, 88%). 
 1H NMR (CDCl3, 500 MHz): δ 7.44 (d, J = 8.3, 1 H, Ar-H), 7.06 (d, J = 8.3, 1 H, Ar-H), 
5.82 (ddt, J = 13.2, 9.8, 6.3, 1 H, CH=CH2), 5.04 (dd, J = 17.1, 2.0, 1 H, CH=CH2), 4.97 (dd, 
J = 10.3, 2.0, 1 H, CH=CH2), 3.18 (dd, J = 14.2, 7.8, 1 H, Ar-CH2), 2.96 (m, 2 H, Ar-CH2-
CH), 2.55 (s, 3 H, Ar-CH3), 2.13 (m, 2 H, CH2-CH2), 1.80 (m, 1 H, CH2-CH2), 1.61 (m, 1 H, 
CH2-CH2), 1.40 (s, 9 H, C-(CH3)3). 













Notebook Entry: PSC080, PSC095, PSC119 
A 10 mL screw-top culture tube was charged with PPh3 (0.057 g, 0.0.218 mmol), K2CO3 
(0.437 g, 3.16 mmol), MeCN (17 mL), and pyridyl triflate 3.41 (0.178 g, 0.436 mmol) and 
degassed in a sonicator for 15 min.  The reaction vessel was fitted with a septum and flushed 
with Ar.  Pd(PPh3)4 (0.126 g, 0.109 mmol) was then quickly added and the septum was 
replaced with a screw-cap.  The solution was heated at 90 °C for ~20 h.  The culture tube was 
allowed to cool to room temperature and solution was then filtered over Celite® and 
concentrated.  The residue was filtered over an alumina plug with EtOAc to remove 
remaining impurities.  Concentration of the sample provided compound 3.42 (0.100 g, 84%) 
as a clear, colorless oil. 
1H NMR (CDCl3, 500 MHz): δ 7.40 (d, J = 7.8, 1 H, Ar-H), 6.97 (d, J = 7.8, 1 H, Ar-H), 
5.17 (s, 1 H, C=CH2), 5.05 (s, 1 H, C=CH2), 3.21 (dd, J = 14.7, 2.4, 1 H, Ar-CH2), 3.14 (dd, 
J = 14.7, 10.7, 1 H, Ar-CH2), 2.65 (m, 2 H, CH2-CH2), 2.52 (s, 3 H, Ar-CH3), 2.33 (ddd, J = 
13.8, 9.8, 3.9, 1 H, Ar-CH2-CH), 2.11 (m, 1 H, CH2-CH2), 1.97 (m, 1 H, CH2-CH2), 1.41 (s, 
9 H, C-(CH3)3). 
13C NMR (CDCl3, 125 MHz): δ 174.6, 156.4, 148.7, 136.0, 135.3, 121.2, 115.3, 80.3, 42.8, 
40.7, 33.9, 33.2, 28.0, 24.1. 
FT-IR (Diamond ATR):  2976 (w), 1723 (s), 1366 (m), 1146 (m). 






Preparation of tert-butyl (5R)-2,5-dimethyl-6,7,8,9-tetrahydro-5H-




Notebook Entry: PSC107 
In accordance with General Procedure G, pyridyl ester 3.42 (0.028 g, 0.103 mmol), 
Wilkinson’s catalyst (0.005 g, 0.005 mmol), NEt3 (19 µL, 0.105 mmol), THF (1.8 mL) and 
EtOH (0.2 mL) were combined in a Fischer-Porter tube in a glovebox.  The reaction vessel 
was assembled and brought outside the glovebox and charged with 50 psi H2 gas and the 
solution was stirred overnight.  The solution was filtered through an alumina plug with 
EtOAc, yielding a crude mixture of 3.43 and 3.43a (0.29 g, 100%, ~1:1 mixture) upon 
concentration. 
1H NMR 3.43 (CDCl3, 500 MHz): δ 7.38 (d, J = 7.8, 1 H, Ar-H), 6.99 (7.8, 1 H, Ar-H), 3.34 
(dd, J = 14.5, 10.0, 1 H, Ar-CH2), 3.26 (dd, J = 14.5, 3.0, 1 H, Ar-CH2), 3.00 (m, 1 H, Ar-
CH), 2.50 (s, 3 H, Ar-CH3), 2.36 (dt, J = 10.9, 2.9, 1 H, Ar-CH2-CH), 2.14 (m, 1 H, Ar-CH2-
CH-CH2), 1.96 (m, 1 H, Ar-CH2-CH-CH2), 1.87 (m, 1 H, Ar-CH-CH2), 1.77 (m, 1 H, Ar-
CH-CH2), 1.47 (s, 9 H, O-C-(CH3)3), 1.35 (d, J = 6.8, 3 H, Ar-CH-CH3). 
1H NMR 3.43a (CDCl3, 500 MHz): δ 7.32 (d, J = 7.8, 1 H, Ar-H), 6.94 (d, J = 7.8, 1 H, Ar-
H), 3.28 (dd, 13.6, 10.0, 1 H, Ar-CH2), 3.26 (dt, J = 13.6, 2.0, 1 H, Ar-CH2), 3.00 (m, 1 H, 
Ar-CH), 2.50 (s, 3 H, Ar-CH3), 2.56 (m, J = 10.7, 2.4, 1 H, Ar-CH2-CH),  2.14 (m, 1 H, Ar-
CH2-CH-CH2), 1.96 (m, 1 H, Ar-CH2-CH-CH2), 1.87 (m, 1 H, Ar-CH-CH2), 1.77 (m, 1 H, 








Preparation of tert-butyl 2-methyl-5-methylene-6,7,8,9-tetrahydro-5H-




Notebook Entry: PSC123 
A 10 mL round bottom flask equipped with a stir bar was charged with 3.41 (0.065 g, 0.159 
mmol) and DMF (2.5 mL) followed by addition of Bu4NBr (0.154 g, 0.478 mmol), HCO2Na 
(0.014 g, 0.191 mmol, 1.2 eq.) and Pd(OAc)2 (0.005 g, 0.159 mmol).  The flask was brought 
under Ar atmosphere and stirred at rt.  After 24 h, TLC analysis indicated consumption of the 
starting material.  The solution was washed with sat. LiCl (1 × 10 mL) and extracted with 
ether (2 × 10 mL).  The combined organic layers were dried over anhydrous MgSO4, filtered 
and concentrated.  The crude product was purified via flash chromatography (½” diameter 
column, 100 mL reservoir, 2:1 hexanes:EtOAc) to provide a mixture of products 3.42 and 
3.46 (0.020 g, 45%, ~1:3 mixture). 
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